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Drosophila Protein Inhibitor of Activated STAT (PIAS) is required for chromatin 
organisation. PIAS proteins are SUMO E3 ligases that provide target specificity for 
the addition of small ubiquitin like modifiers (SUMO) to proteins to alter their 
function.  
 
Previous experiments in the Heun laboratory, which used a PIAS overexpression 
system, identified a relationship between PIAS and XNP (X-linked nuclear protein). 
Both proteins play a role in silencing transposable elements and likely interact. XNP 
and ADD1 (ADD (ATRX-DNMT3-DNMT3L) domain-containing protein 1) together 
make up the two halves of their mammalian homologue, the chromatin remodeller 
ATRX. XNP and ADD1 have been shown by us and others to be SUMOylated. We 
hypothesise that the SUMOylation of XNP by PIAS could be essential for its role in 
chromatin organisation and aimed to study this interaction within a Drosophila model 
using S2 tissue culture cells and embryos.  
 
In this thesis, I defined the interactomes of PIAS, ADD1 and XNP using 
immunoprecipitation-mass spectrometry (IP-MS) in the presence and absence of 
SUMOylation. Using CRISPR/Cas9 epitope tagged PIAS in S2 cell lines and primary 
antibodies against endogenous PIAS, I could confirm an interaction between PIAS 
and XNP in a SUMO dependent manner. Interestingly, I found PIAS interacts with 
ADD1 and heterochromatin protein 1 (HP1) in a SUMO independent manner. These 
interactomes support the hypothesis that SUMOylation of XNP by PIAS is involved 















The genome is made of DNA and contains all the instructions necessary to create 
an entire organism. These instructions are encoded in the form of genes and when 
read, control how a cell behaves. A copy of the genome is stored in every cell. 
However, if all the DNA in a single cell were to be stretched out, it would be two 
meters long; therefore, DNA is packaged. This packaging also serves a role in 
regulating the reading of the genes. Loose packaging is proposed to promote 
reading, while tight packaging leads to silencing of genes. In some cancers and 
diseases the packaging can go wrong, meaning that genes that should be silent are 
left on, allowing cells to grow uncontrollably. Through understanding the way DNA 
packaging is regulated further cancer treatments may be developed.  
 
Many proteins regulate DNA packaging. My research has looked at PIAS, which is a 
protein that has the ability to modify other proteins by attaching an additional small 
protein called SUMO. In this thesis I describe my work to see which proteins interact 
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SUMOylation, similarly to ubiquitination, is involved in all stages of a cell’s biology 
and regulation. Although this thesis in large part aims to investigate the interactome 
of the SUMO E3 ligase PIAS, it will focus on the role of PIAS SUMOylation in 
heterochromatin formation and maintenance. Therefore this thesis takes the aim of 
identifying potential mechanisms of PIAS’s role through these four pathways which 
have been identified to interact with PIAS:  
1. the chromatin remodeller ATRX (ADD1 and XNP in Drosophila) 
2. heterochromatin- euchromatin boundary regulators BEAF-32 and other 
insulator proteins 
3. heterochromatin establishment through the piRNA pathway 
4. heterochromatin establishment through the histone methyltransferase 
Eggless.  
Due to the many and varied roles of SUMOylation this thesis will begin by reviewing 
large areas of biology and the role of SUMOylation. It will then continue onto results, 
which will specifically investigate the interactome of PIAS, before attempting to tie 
together biological theory and data within the conclusions and perspectives, 
finishing with hypothetical models.  
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Chapter 1 General Introduction 
 
1.1 Genome Definition and Content  
The genome comprises the total genetic information of an organism, in the form of 
DNA, and is packaged into the cell nucleus. The size of the genome varies 
depending on the organism, with a general trend that eukaryotic genomes are larger 
than prokaryotic genomes and vertebrate genomes are larger than invertebrate 
genomes. The human genome consists of 3.1 giga-bases (gb) of DNA packaged 
into 23 chromosomes. For comparison, the Drosophila melanogaster genome 
contains 180 mega-bases (mb) in 4 chromosomes.  
 
1.2 Central Dogma of Molecular Biology 
The genome is split into non-coding and coding regions. Coding regions of DNA are 
known as genes which are transcribed and translated into functional units in the 
form of RNA and proteins. Proteins are the main structural, functional and regulatory 
units in the cell. The proteins in a cell at any one time make up the proteome of the 
cell and this is dynamically regulated through control at the DNA, RNA and protein 
level.  
 
1.3 Transcription and Processing of mRNAs 
In eukaryotes, RNA Polymerase II (RNAPol II) is responsible for transcribing 
messenger RNA (mRNA) that codes for proteins, for this the TATA binding protein 
(TBP) must recognise the DNA upstream of gene start sites, signified by the DNA 
sequence TATA. This recognition within the highly packaged genome is aided by 
transcription associated factors (Tafs)1. 
 
After gene transcription, precursor mRNA (pre-mRNA) contains exons (coding 
directly for protein) and introns (not coding for protein). Introns are removed and 
exons are spliced together to generate a mature mRNA, which is capped and poly-
adenylated. Post processing, mRNA is exported from the nucleus and translated 
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1.4 Genome Organisation  
DNA is packaged inside the cell nucleus in the form of chromatin. The basic 
repeating unit of chromatin is the nucleosome, which is made up of 147bp of DNA 
wrapped around eight histone proteins (two histone 3 (H3) and two histone 4 (H4) 
dimers flanked by two heterodimers of histone 2A (H2A) and histone 2B (H2B))2,3,4. 
This structure is referred to as “beads-on-a-string”. Nucleosomes are further 
packaged in a series of folding steps regulated by protein-DNA interactions (Figure 
1–1).  
 
Chromatin attaches to an underlying structure in the nucleus. Biochemical extraction 
methods first defined a filamentous ribo-proteinaceous nuclear matrix5 which 
provides a site for DNA replication6, transcription7, splicing8 and chromatin 
remodelling9. More recently an idea of a more dynamic “nuclear mesh” has emerged 
(reviewed in Nozawa 201910). Chromatin-associated RNAs form ‘RNA clouds’ over 
specific clusters of active gene promoters and their distal enhancers which loop into 
proximity (reviewed in Li, 2019)11.  
 
3D genome organisation (genome structure) has emerged as an area of great 
interest with relation to gene transcription (genome function). Spatially certain 
regions of the genome are in greater contact with each other than with other regions 
and form distinct subcompartments, known as topologically associated domains 
(TADs)12. However, the functional significance of these domains across evolutionally 
divergent organisms is under review with increased resolution providing new 
insights into chromatin interactions within TADs, favouring a model13 based on 
chromatin states14. These chromatin states may change with transcriptional 
changes15, RNA Pol II occupancy and an increase in DNA accessibility at boundary 
regions. These boundary regions are enriched for architectural proteins, which bind 
specific DNA sequences such as CCCTC-binding factor (CTCF) which has insulator 
activity16,17.  
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Principles of protein clustering into “factories” containing high local concentrations of 
factors required for specific cellular process is not a new concept18,19. However, new 
interest in chromatin self-organisation based on its biophysical properties has given 
rise to concepts of phase-separated subcompartments. Soluble proteins can bind to  
chromatin scaffolds and each other, oligomerising, bridging or cross-linking to 
organise chromatin domains with particular properties	.	Homotypic attraction 
between similar chromatin states can aid enhancer-promoter contacts (reviewed in 
Robson et al., 201920). 	Alternatively, multivalent interactions can drive the assembly 
of liquid-like dynamic nuclear bodies around their chromatin binding sites. These 
can coalesce and are in constant and rapid exchange with the surrounding 
nucleoplasm. In addition, in vitro intrinsically disordered regions of proteins interact 
with RNA and form liquid droplets. The size, density, and stability of chromatin 
bodies depends on the concentration and interactions of the molecules involved21. 
Sequence-specific interactions may define nucleation sites, but feedback-based 
mechanisms may be required to reinforce a given chromatin state.  
General Background 




Figure 1–1 DNA organisation within the cell nucleus 
DNA is packaged into nucleosomes that are organised into “beads on a string” chromatin 
structures. Chromatin is dynamically packaged inside the cell nucleus, with increasing levels 
of compaction. Figure adapted from Hansen, 201822. 
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1.5 Chromatin Modifications 
Chromatin can be defined by its state. Histone N-terminal tails can be modified by 
the addition of post-translational modifications (PTMs) to provide a “histone code”. 
Specific PTMs or combinations of PTMs are “read” by proteins that have specific 
chromatin binding domains23 24 and as a consequence, chromatin may be modified 
or remodelled to promote or restrict access to the underlying genes.  
 
Two well characterised histone PTMs are acetylation (which is generally associated 
with active chromatin) and methylation (which is generally associated with 
repressive chromatin) of lysine residues, which can be mono-, di- or tri-methylated25. 
Addition and removal of histone PTMs is regulated through enzymes and protein 
complexes that act as “writers” and “erasers” of chromatin marks. For acetylation, 
histone acetyltransferases (HATs) deposits acetyl groups, and histone deacetylases 
(HDACs) catalyse their removal. For methylation, lysine methyltransferases (KMTs) 
and lysine demethylases (KDMs) add and remove methyl groups respectively. 
PTMs can alter the interaction between histones and DNA26, which influences 
chromatin structure and gene expression either by blocking or activating protein 
recruitment or enhancing or inhibiting interactions. The addition of modifications that 
are “above the DNA” and can be stably inherited over generations are called 
epigenetic. 
 
1.6 DNA Modifications 
DNA can be modified by de novo methylation of its bases; this is carried out by two 
DNA methyltransferases (DNMTs): DNMT3a and DNMT3b27. Both are active during 
gametogenesis and re-implantation28, acting to silence regions of the genome29. The 
most prominent DNA modification is the addition of a methyl group at the C5 
position of the pyrimidine ring of the cytosine residue (5meC) in the context of CG 
dinucleotides. In vertebrate genomes ~70% of CG dinucleotides are methylated30 
and unmethylated CG dinucleotides (CpG islands) are typically found within gene 
promoters31. 5meC may exert a repressive effect on transcription by blocking 
association of transcription factors with promoters or blocking access to chromatin 
remodelling complexes and/or histone modifying enzymes. Proteins with a methyl 
binding domain (MBD) such as methyl CpG binding protein 2 (MeCP2)32 bind 
General Background 
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methylated DNA and recruit other proteins that act as chromatin regulators, 
including SIN3, HDAC133, ATRX34 which act in a transcriptional repressor complex35. 
Gene silencing is established through a cross-talk between DNA methylation and 
histone modification. Another example of this is with the DMNT proteins. In addition 
to their role as de novo methyl transferases, the ATRX-DNMT3-DNMT3L (ADD) 
domain of DMNT3 binds histone deacetylation complex 1 (HDAC1)36, MeCP237 and 
polycomb repressive complex 2 (Pc2)38,39, forming part of a larger repressive 
complex. 
 
Drosophila melanogaster have low levels of DNA methylation 40,41, with only one de 
novo DMNT homolog42 which is non-essential43. Histone modifications however, 
play a key role in early embryonic epigenetic reprogramming44, perhaps indicative of 
different underlying mechanisms of regulation of gene expression between 
vertebrates and invertebrates. 
 
1.7 Histone Variants 
Although most nucleosomes consist of the canonical histones: H2A, H2B, H3 and 
H4; histone proteins can differ in their amino acid sequence. H2A and H3 histone 
variants alter the biophysical properties of the nucleosome45 altering the structure 
and function of chromatin, which influences chromatin interaction partners. H3 
histone variants have been well-characterised, one of which is H3.3. Histone H3.3 
differs from canonical H3 by five amino acid residues. H3.3 is found at telomeric46 
and pericentric heterochromatin repeats47, intergenic regions and introns48 and plays 
an essential role in chromatin stability49.  
 
1.8 Histone 3.3 
In Drosophila, H3 variants can compensate for each other in euchromatic regions.  
At highly transcribed genes, in euchromatin, H3.3 is deposited into nucleosomes in 
a replication-independent manner by the histone regulator A (HIRA) complex to 
maintain genome accessibility. H3.3 could account for the epigenetic memory of an 
activated state50. In Caenorhabditis elegans, H3.3 is non-essential yet under heat 
shock, in H3.3 knockout animals, expression of heat shock genes is reduced and 
fewer animals survive49. 
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H3.3 is also enriched at telomeres and the endogenous retrovirus IAP element51, 
with incorporation at these sites mediated by DAXX/ATRX (see sections 1.12 and 
2.4.3)47. In mouse embryonic stem cells H3.3 is essential, with its absence causing 
developmental retardation and embryonic lethality52 and dense chromatin 
packaging53.  
 
1.9 Types of Chromatin  
Chromatin was first described by its appearance under light microscopy54 and at first 
was separated into two subtypes. Loosely packaged ‘open’ euchromatin was 
observed in the central region of the cell nucleus, whereas more densely packaged 
‘closed’ heterochromatin was observed at the periphery, underlying the nuclear 
membrane and attached to the nuclear matrix surrounding the nucleolus55. Our 
current understanding of chromatin is more complex. Chromatin type is defined by 
combinations of histone variants, chromatin modifications, and association with 
chromatin binding proteins that lead to differential packaging/gene expression. In 
Drosophila, chromatin has been categorised into four56, five57, nine or even 30 
different types58,59.  
 
1.10 Constitutive Heterochromatin Definition, Function and Importance 
This thesis will focus on constitutive heterochromatin. Constitutive heterochromatin 
is enriched at centromeric, pericentromeric and subtelomeric regions of the genome 
that contain repetitive DNA sequences60. The histone methylation mark H3K9me361 
and heterochromatin protein 1 (HP1)62 define constitutive heterochromatin at the 
molecular level. Constitutive heterochromatin has essential roles in nuclear 
architecture, chromosome segregation, genome stability via stabilising 
recombination, and repression of gene expression and silencing of transposable 
elements (reviewed in Janssen et al, 201863). Histone variants can also be modified 
by histone methyltransferases, with the introduction of H3.3K9me3 being important 
for heterochromatin formation at mouse telomeres64. In Drosophila, H3.3K9R mutants 
are sterile65, demonstrating that H3.3K9 is essential for propagation of offspring. 
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1.11 Constitutive Heterochromatin Structure, Establishment and Maintenance  
Heterochromatin establishment involves multiple cellular machineries including 
complexes involved in: transcription of DNA; RNA interference (RNAi); protein-
protein interactions; protein-RNA interactions and PTMs which can act singularly or 
in a combinatorial and complementary manner66,67(reviewed in Allshire and Madhani 
201768). In Schizosaccharomyces pombe, heterochromatin is formed through the 
action of the RNA-induced transcriptional silencing complex (RITS), which is 
targeted to endogenous RNA transcripts by small interfering RNAs (siRNAs) 
generated from the cleavage products of transcribed repeats69,70,71. The RITS 
associates with the SUV39 histone H3K9 methyltransferase to deposit H3K9me3 
and recruit HP1 to establish heterochromatin domains. The mechanism of RITS 




Figure 1–2 RNA-dependent and RNA-independent feedback loops for establishing and 
locally spreading heterochromatin in Schizosaccharomyces pombe 
Fission yeast view of heterochromatin spreading. Figure taken from Li and Fu 201911 RNA is 
transcribed from RNA polymerase II (Pol II) and processed by RNA dependent RNA 
polymerase (RdRP) to form double stranded RNA (dsRNA). This dsRNA is then cleaved by 
Dicer 1 to form small interfering RNAs (siRNA). These siRNAs when bound to the RNA-
induced transcriptional silencing complex (RITS) are targeted to complementary regions of 
the genome. Once targeted, the siRNA-RITS complex interacts with the methyltransferase 
enzyme (SUV39) to deposit H3K9me3 and recruit heterochromatin protein 1 (HP1), which 
through a positive feedback loop establishes a heterochromatin domain (red shadow).   
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Another RNAi pathway, the Piwi/piRNA pathway, acts to silence regions of the 
genome72,73. This pathway is conserved in metazoans74 and is responsible for 
silencing transposable elements to prevent their mobilisation in germ cells75,76,77 . 
This is an essential pathway in early embryos78 and stem cells79 (reviewed in Ozata 
et al., 201980). Piwi and piRNAs are imported into the nucleus to direct DNA 
methylation81 of complementary repetitive elements to silence the endogenous retro-
elements LINE 1 and IAP in mouse fetal testes82 in pachytene sperm cells. Piwi and 
piRNAs are involved in epigenetic transcriptional silencing at imprinted genes83 and 
initiate heterochromatin formation72,84. However, the molecular mechanisms of Piwi 
mediated repression, involving downstream proteins remains to be resolved. Piwi 
itself may interact with chromatin modifier proteins which deposit methyl marks at 
chromatin to repress transposable elements. The mechanism of Piwi mediated 
repression in Drosophila melanogaster is shown in Figure 1–3. In Drosophila, most 
primary piRNAs are generated in germline cells from pericentric and telomeric 
heterochromatic genomic loci (piRNA clusters) containing damaged repeated 
transposable element sequences. These primary piRNAs are amplified in a “Ping-
Pong” cycle to generate secondary piRNAs. HP1 recruitment depends on the 
presence of small RNAs85 and HP1 can also interact directly with Piwi86,87.   
 
It has been proposed that ATP-dependent RNA helicases, such as Rm62 and bel, 
may be involved in the production of de novo piRNAs and endogenous small 
interfering RNAs (endo-siRNAs) from euchromatic transposon insertion sites, 
provoking the activation of related small RNA pathways88,89. One of the other RNAi 
pathways in Drosophila involves a complex containing: AGO2 (an Argonaute family 
protein); Tudor-SN (a putative endonuclease (TSN)); VIG (the product of vasa 
intronic gene); fragile X mental retardation protein (Fmr1)90,91; and Rm62. Su(var)3-9 
(histone methyltransferase)(SUV39 in Figure 1-3) was also found to act in this 
pathway92. Fmr1 and Tudor-SN also function as part of the Piwi/piRNA pathway, 
interacting with Piwi93, demonstrating that proteins can be involved in multiple 
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The molecular details of the mechanisms of heterochromatin establishment and/or 
maintenance at pericentromeric and centromeric repeats in Drosophila remains 
unknown. By understanding mechanisms from multiple organisms it may be 
possible to unify concepts. Heterochromatin establishment is possibly aided by the 
siRNA pathway generating siRNA from major satellite repeats in complex with 
Argonaute proteins. In human cell lines, AGO2 interacts with the histone 
methyltransferase SETDB1 to aid heterochromatin spreading94. AGO2 mutant 
Drosophila embryos have defects in chromosome condensation, nuclear kinesis and 
spindle assembly, possibly correlated with defects in the formation of centromeric 
heterochromatin95. Therefore, regulation of AGO2 as part of the siRNA pathway 
plays an important role in heterochromatin assembly at these sites.  
 
RNAs at the pericentromeres and telomeres act locally in cis and associate with 
histone lysine methyltransferases (KMTs)67,96-98 99 to tri-methylate (me3) H3K9 
introducing the repressive H3K9me3 mark100. HP1 is recruited to H3K9me3 through 
its “reader” N-terminal chromo domain101,102. HP1 self-associates through its C-
terminal chromo shadow domain and recruits more KMT proteins in a positive 
feedback loop, causing heterochromatin spreading. HP1a proteins phase-separate 
in response to DNA binding or phosphorylation of their N-terminus to establish 
domain like structures103. In mammals HP1 also recruits HDACs and DNMTs, 
resulting in histone de-acetylation and DNA methylation104-106. Heterochromatin is 
maintained by different mechanisms to those used to establish it. HP1 acts as a 
platform to recruit factors to form silenced chromatin domains107 and may serve as a 
maintenance factor for the heterochromatic state. The heterochromatin state is 
heritable through cell divisions and is maintained through epigenetic mechanisms 
involving “reader” and “writer” proteins108.  
 
In Drosophila, telomeres are maintained by successive transpositions of the 
retroelements: HeT-A and TART. This requires Spindle-E (an RNA helicase) and 
aub (an Argonaute protein)109, both of which act in RNAi based mechanisms to 
maintain telomere elongation.   
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Figure 1–3 RNA-dependent and RNA-independent feedback loops for establishing and 
locally spreading heterochromatin in Drosophila melanogaster 
Taken from Li and Fu 201911. Transposon mRNA (top) is processed by the P-element 
Induced WImpy testis/Aubergine/ RNA-induced silencing complex (Piwi/Aub RISC) complex 
into Piwi-interacting RNAs (piRNAs). The “Ping-Pong” pathway of piRNA–directed 
RNA cleavage is proposed to amplify the piRNA population. It is catalyzed by the 
endonuclease (or “Slicer”) activities of the Piwi proteins Aubergine (Aub) and Argonaute3 
(AGO3) to generate responder piRNAs. These responder piRNAs target nascent RNA 
transcribed from RNA polymerase II (PolII) to recruit the methyltransferase enzyme (SUV39) 
to deposit H3K9me3 and recruit heterochromatin protein 1 (HP1) to establish and spread, 
forming a heterochromatin domain (red shadow) resulting in gene silencing.  
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1.12 Chromatin Accessibility- Assembly and Remodelling 
Chromatin remodellers can expose DNA through nucleosome sliding, nucleosome 
eviction or nucleosome unwrapping (by hydrolysis of ATP) to modulate histone-DNA 
contacts. This allows access of replication, transcription and repair machinery to the 
DNA110. Eukaryotes possess at least four ATP-dependent chromatin remodelling 
families: SWItching defective/Sucrose Non-Fermenting (SWI/SNF), Imitation SWItch 
(ISWI), Chromodomain-Helicase-DNA binding (NuRD/Mi-2/CHD), INOsitol requiring 
80 (INO80) and SWRI111. The SWI/SNF family makes DNA accessible for 
transcription machinery and is important for regulation of gene expression111,112. The 
SNF2 family can be further divided into subfamilies as defined by phylogenetic 
comparison of the SNF2 ATPase region113. All SNF family chromatin remodellers 
contain a DNA/nucleosome binding domain and an ATP binding/ hydrolysis/ DNA 
translocation domain. One member of the SWI/SNF family is the ATRX protein.  
 
Some chromatin remodellers have affinity for specific histone variants114 and interact 
with histone chaperone proteins that are responsible for assembly of histone 
variants into nucleosomes. An example is the ATRX-DAXX-H3.3 complex. The 
histone chaperone death-domain-associated protein (DAXX) stabilises H3.3115 and 
interacts with the chromatin remodeller ATRX to target DAXX to telomeres and 
pericentromeres where it deposits H3.3-containing nucleosomes116. DAXX can be 
post-translationally modified to aid interactions and complex formation with other 
repressive complexes. Disruption of the H3.3 pathway results in reduced levels of 
H3K9me3, ATRX and HP1α. This disruption in heterochromatin formation elevates 
chromosome instability at centromeres117 and telomeres64 resulting in detrimental 
effects on cell survival. See section 2.4.3 for further discussion of ATRX/DAXX/H3.3.  
 
1.13 Chromatin States Define Cell Identity 
The accessibility of the DNA to transcription factors is achieved through the interplay 
of chromatin modifications, chromatin remodellers and histone variants. This 
accessibility is influenced by the 3D organisation of the genome within the cell 
nucleus. This plays a key role in defining chromatin states that maintain cellular 
identity.  
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Chapter 2 Introduction 
 
2.1 Heterochromatin 
2.1.1 Heterochromatin Establishment and Maintenance in Drosophila  
In Drosophila, early embryonic development is directed exclusively by maternal 
products (mRNA and proteins) deposited in the female gamete during oogenesis. 
Drosophila embryos undergo rapid cell division cycles, where only the nuclei divide 
and early cleavages take place without cytokinesis, these are therefore known as 
nuclear cycles (NC).  
 
Drosophila lay eggs that can be collected and studied. A fertilised egg develops into 
an embryo. The progress of early Drosophila embryo development from NC1-14 is 
shown in Figure 2–1A. Separation of heterochromatin from euchromatin is initiated 
around NC10 and is completed by NC14118. This is visible by staining of the DNA 
(Figure 2-1B). The euchromatic state is defined by histone acetylation of H3K9 
(H3K9ac) and is detectable in NC12119 (Figure 2-1C). By NC13, nuclei adopt a Rabl 
configuration, heterochromatin is at the apical pole of the nuclei and is separated 
from euchromatin in the basal pole85,120. This configuration is thought to coincide 
with heterochromatinization121, activation of widespread transcription from the 
zygotic genome122, and cellularisation to enclose nuclei in the syncytial blastoderm 
marking the end of the nuclear cycle stages in development. 
 
Heterochromatinization requires H3K4 demethylation by lysine-specific histone 
demethylase 1A (LSD1)44; H3K9 deacetylation by RPD3 (HDAC1)44; and 
methylation of H3K9 by the KMT Eggless123. Methylation of H3K9 is established in 
NC12, and increases which successive nuclear cycles to form stable chromatin 
domains by NC1485,123. HP1a is detectable in NC11123 and by NC14 is stably 
associated with chromatin124. 
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Seller et al., 2019123 show the histone methyltransferase Eggless, which is required 
in early embryos, is recruited to pericentric satellite DNA in NC10. However, the 
mechanism that recruits Eggless to chromatin remains unknown123,125. Seller et al., 
2019123 hypothesise that maternally deposited small RNAs (including the 359bp 
satellite repeat, derived from sequences on the X-chromosome) could guide 
Eggless to transcripts. The initiation of heterochromatin formation could be triggered 
through an RNAi mediated mechanism as  both the 359bp satellite repeat and 
Eggless are essential85,123. Eggless also plays a role in the piRNA pathway 
(discussed in section 1.11).  
 
The Aravin lab has proposed that Su(var)2-10/PIAS, a SUMO E3 ligase, links the 
Piwi/piRNA pathway to the piRITS and that SUMOylation of the histone 
methyltransferase Eggless is required for its function in heterochromatin formation, 
as they demonstrate that gene repression by Eggless is dependent on Su(var)2-
10126. It is possible that SUMOylation is required to “seed” heterochromatin 
formation as discussed in section 2.3.13 for HP1α targeting to pericentric 
heterochromatin. Seller et al., 2019123 suggest an alternative hypothesis that 
Eggless could bind a DNA binding protein to specify its localisation to specific 
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Figure 2–1 Visualisation of nucleic acid staining in Drosophila melanogaster embryos 
during development and formation of distinct euchromatin/heterochromatin domains 
within nuclear cycle 13/14 embryos distinguished by histone modifications and 
histone binding proteins. 
(A) Images of DAPI stained embryos during the first 14 rounds of nuclear division (nuclear 
cycles 1-14) in a Drosophila embryo. Figure modified from Kotadia 2001127. (B) A Drosophila 
embryo in nuclear cycle 14 (NC 14), inset shows pre-blastoderm cells with the separation of 
heterochromatin and euchromatin in discrete domains by DAPI staining (C) Pre-
blastoderm cells of a nuclear cycle 14 (NC14) wild-type Drosophila embryo, modified from 
Rudolph, 200744, immunostained with α-H2K9Ac and α-HP1 showing discrete staining in the 
basal and apical domain respectively. (D) Staining for histone modifications in pre-
blastoderm cells of a NC14 Drosophila embryo, showing enrichment of H3K9 methylation at 
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2.1.2 Identification of Heterochromatin Proteins by Position-Effect 
Variegation Assays 
Position-effect variegation (PEV) is an epigenetic phenomenon first described in 
Drosophila in 1930128. This was utilised to assay heterochromatin dynamics, for 
example in the ln(1)wm4 Drosophila line, whereby a chromosome inversion has 
placed the euchromatic white gene, that controls eye colour, adjacent to pericentric 
heterochromatin. Heterochromatin spreading into the white locus in some cells 
results in a shutdown of expression of the white gene, resulting in a white eye, 
whereas in other cells this silencing does not occur, leading to a red eye. This 
mosaic expression and clonal inheritance of the silenced state presents as a 
variegated phenotype in Drosophila eyes129. Combination of this with genetic 
knockouts can identify genes or DNA regions required for regulating 
heterochromatin dynamics through interpreting eye colour as an indicator of either 
spreading or recession of the heterochromatin boundary130. 
 
Around 150 proteins, most of which are structural or chromatin related, have been 
identified in this assay through introducing mutations in gene regions which give rise 
to altered chromatin composition130. Proteins encoded by these gene regions are 
classified as either suppressors or enhancers of variegation, Su(var)s or E(var)s 
respectively131. Su(var) proteins play a role in both heterochromatin establishment 
and maintenance.  
 
The histone variant H3.3132, histone deacetylases (e.g. Rpd35/HDAC1133), histone 
methyltransferases134, phosphatases135, components of the SUMOylation 
machinery, components of the RNAi machinery70 (AGO295, Piwi86,118, aubergine118, 
Rm62136 and vig137, Fmr1138) and chromatin remodellers such as XNP139 are all 
encoded by Su(var) genes. This thesis will focus on Su(var)205 - more commonly 
known as heterochromatin protein 1 (HP1)140 and Su(var)2-10 which encodes 
Su(var)2-10 also known as dPIAS or PIAS. 
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2.2 PIAS  
2.2.1 The Su(var)2-10 Gene Locus Encodes PIAS Proteins 
The Su(var)2-10 gene locus on chromosome 2R in Drosophila encodes Su(var)2-10 
protein isoforms131. These isoforms share homology to vertebrate Protein Inhibitor of 
Activated STAT (PIAS) proteins141, therefore Su(var)2-10 protein isoforms are also 
referred to in the literature as dPIAS proteins or just PIAS. 
 
2.2.2 PIAS Expression and Conservation 
PIAS is expressed ubiquitously in Drosophila with the highest levels of expression in 
the embryo142. In adults, expression is highest in the CNS and gonads143. At the 
cellular level, during Drosophila embryogenesis, PIAS localises to heterochromatin 
in nuclear cycles 10-14 coinciding with heterochromatin establishment144. However, 
in interphase nuclei, larval neuroblasts and S2 cells, PIAS does not co-localise with 
heterochromatin and is found near the nuclear periphery, in intranuclear foci, 
proximal to telomeres and at euchromatin57.  
 
PIAS proteins are highly conserved across phyla, with homologs in yeasts, worms 
and plants (Figure 2–2)145. In Drosophila melanogaster PIAS isoforms share 
between 36-44% identity with vertebrate PIAS proteins, 29% identity to Gei-17 
isoforms in C. elegans and 20% identity to Siz proteins in Arabidopsis thaliana and 
Saccharomyces cerevisiae (Figure 2–2). In vertebrates, there are 4 PIAS paralogs: 
PIAS1, PIAS2 (PIAS x), PIAS 3 and PIAS 4 (PIASg) resulting from a gene 
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Figure 2–2 PIAS is conserved 
(A) Multiple sequence alignment (MSA) of PIAS proteins from different organisms. The 
protein architecture of PIAS family members is conserved. The position of four conserved 
functional domains are shown. Conserved amino acids are shown as purple bars. Black 
lines show the aligned amino acid sequence. Gaps in the sequence occur as a result of 
alignment.  
(B) Phylogenetic tree showing the evolutionary relationships among organisms. Highlighted 
in yellow is the Drosophila PIAS protein where it splits from vertebrates. For Drosophila 
melanogaster PIAS isoform I was used as it is the longest isoform. 
The MSA and phylogenetic tree were generated by ClustalOmega, exported into Jalview and 
exported as SVGs. Protein sequences were downloaded from UniProt in January 2019. 
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2.2.3 The Structure of PIAS Proteins 
PIAS proteins have four conserved functional domains: scaffold attachment factor-
A/B/acinus/PIAS (SAP); PINIT; Ring-like domain (RLD); and SUMO interacting motif 
(SIM). The SAP domain binds AT-rich DNA146 and associates with the nuclear 
matrix147. The PINIT domain is involved in nuclear retention148 and substrate 
recognition by Ubc9149. The RLD binds Ubc9 to aid SUMOylation149,150 of target 
proteins. The SIM domain can interact with SUMO and SUMOylated proteins151.  
 
2.2.4 Drosophila PIAS Isoforms  
14 isoforms of dPIAS have been identified. Different isoforms have different N- and 
C- termini generated through alternative splicing. A schematic of the mRNA and 
protein products derived from the Su(var)2-10 locus is depicted in Figure 2–3. The 
C-terminal region has intrinsically disordered regions with polar amino acids that 
allow post-translational modifications and provide platforms for interactions. The 
isoforms are differentially expressed at different stages in development and in 
specific tissues144. The role of specific isoforms is currently unknown. Exons 2-8 are 
present in all dPIAS isoforms and contain the functional domains: SAP, PINIT, RLD 
and AD/SIM. This is referred to as PIAS-CORE. PIAS-CORE is partially sufficient to 
rescue lethality of Su(var)2-101/Su(var)2-102 trans-heterozygous Drosophila 
mutants, but results in infertility144.  
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Figure 2–3 Graphic of the Su(var)2-10 gene locus and its mRNA and protein products 
mRNA is transcribed from the Su(var)2-10 gene locus and is processed, removing 
intervening regions of DNA (introns), to leave alternatively spliced exons. Black boxes depict 
mRNA coding regions and exons, which are spliced together in different combinations, 
giving rise to 14 different transcripts (RA-RN). The protein coding regions (CDS) give rise to 
14 PIAS isoforms (A-N). Each dPIAS isoform includes the core region, termed PIAS-CORE, 
which contains the functional domains: scaffold attachment factor-A/B/acinus/PIAS (SAP); 
PINIT; Ring-like domain (RLD); and the SUMO interacting motif (SIM). The graphic was 
generated by aligning all of the PIAS coding sequences (CDS) and mRNA transcripts 
downloaded from FlyBase (http://flybase.org) in January 2019.  
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2.2.5 Drosophila PIAS Mutant Phenotype  
Several Drosophila lines generated by Reuter and Wolff131 have aided the study of 
the function of dPIAS. The Su(var)2-101 Drosophila line contains an EMS-induced 
point mutation in a conserved region of the Su(var)2-10 locus in the RLD. In 
Saccharomyces cerevisiae, mutation of the equivalent residue in the PIAS 
homologue Siz abolishes Siz ligase activity149. A second Drosophila line, Su(var)2-
102 has a point mutation changing a tryptophan-to-STOP in amino acid 260, inside 
the PINIT domain, that results in a truncated version of dPIAS. Trans-heterozygous 
Su(var)2-101/Su(var)2-102 mutants die as third instar larvae displaying melanotic 
tumours152, which are also observed in the absence of components of the 
SUMOylation machinery153. These tumours display haematopoietic progenitor 
states153 and SUMOylation is disrupted in several types of haematopoietic 
malignancies154. All supporting a hypothesis that PIAS’ SUMOylation function is 
important. Trans-heterozygous Su(var)2-101/Su(var)2-102 mutant Drosophila also 
have aberrantly condensed metaphase chromosomes and telomere defects, with 
telomeres not associating with the nuclear-lamina141 indicating a failure in chromatin 
organisation. 
 
2.2.6 The Function of PIAS  
PIAS1 and PIAS3 were originally identified in mice as binding partners of the 
transcription factors STAT1 and STAT3 respectively. PIAS proteins inhibit STAT 
binding to DNA, preventing transcription of STAT target genes155-157. PIAS proteins 
have SUMO E3 ligase activity, aiding SUMO conjugation to target proteins 
(discussed in section 2.3.2)150. In mice only PIAS1 knockout is embryonic lethal158. 
PIAS1 is critical for cardiac development during embryogenesis, possibly through 
SUMOylation of the transcription factor GATA4159-162 which is essential, although 
further research is required to elucidate the exact mechanisms involved. Deletion of 
all four PIAS genes has not been attempted.  
 
Drosophila PIAS plays a role in transcription141, the mitotic cell cycle141, chromatin 
structure141 and has recently been linked to the piRNA pathway163, after it was 
identified in 2013164 in a genome-wide screen in Drosophila ovarian somatic sheet 
cells as necessary for transposon silencing.  
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2.2.7 The Localisation of Drosophila PIAS  
In the syncytial embryo, where no cell membranes have formed, nuclei divide 
rapidly and synchronously. PIAS is maternally deposited and during interphase 
localises to the cytoplasm and intranuclear spots (Figure 2-4A). During synchronous 
mitosis, PIAS does not localise to metaphase chromosomes but form foci outside 
the nucleus (Figure 2-4B-C).  
 
 
Figure 2–4 Anti-SU(VAR)2-10 staining with exsanguinate sera reveals a dynamic 
localization pattern for SU(VAR)2-10 proteins in early embryos 
In all panels, blue represents DAPI-stained DNA, and green exsanguinate sera staining 
patterns. (A) In interphase/early prophase, spots of staining are found in the nuclear interior.  
During prometaphase (B), the staining appears to collect into discrete structures, the nature 
of which is unknown. (C) By metaphase, the concentrated staining dissipates. Bar, 5μm. 
Data from Kumar Hari’s thesis, page 81 Figure 4-4143. 
 
 
Polytene chromosomes are traditionally used for high-resolution mapping of 
chromatin proteins. They allow visualisation of inter band patterns of euchromatin 
and heterochromatin. Kumar Hari showed that PIAS localises to euchromatic bands 
(Figure 2–5A), telomeric regions (Figure 2–5B) and the heterochromatic 
chromocenter (Figure 2–5C) 143. At telomeric regions PIAS is proximal to HP1a and 
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Figure 2–5 SU(VAR)2-10 is generally associated with squashed polytene 
chromosomes and does not colocalize with HP1 at telomeres 
Indirect immunofluorescence showing SU(VAR)2-10 (green) on squashed polytene 
chromosomes (DAPI stained DNA is blue in all panels). (A) SU(VAR)2-10 associates with 
polytene chromosomes in a general punctate pattern.  The chromocenter is labeled (arrow), 
as are some euchromatic bands (arrowheads), and the tips of chromosome 2L (B) and 4 (C) 
Bar in A, 15 μm (B) Magnified view of area boxed in A showing that SU(VAR)2-10 (green) 
does not colocalize with HP1 (red) at the tip of chromosome 2L. (C) HP1 (red) densely stains 
the chromocenter, and chromosome 4, and SU(VAR)2-10 (green) is found near the tip of 
chromosome 4. Bar, 10μm. 
Data from Kumar Hari’s thesis, page 83 Figure 4-5143. 
 
 
Subsequently PIAS’s genomic binding profile was identified, as one of 35 proteins 
profiled by DamID, to determine different types of chromatin in Drosophila Kc167 
cells57. This found that PIAS is bound to actively transcribed euchromatin in a similar 
localisation pattern to the insulator protein BEAF-3257. PIAS localisation at 
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2.3 Small Ubiquitin-like Modifiers (SUMO) 
2.3.1 Ubiquitin-Like Modifiers (UBLs) 
Ubiquitin and ubiquitin-like modifiers (UBLs), including the small ubiquitin-like 
modifier (SUMO), are a conserved family of proteins with similar three-dimensional 
structures165. SUMO was first identified in 1995, as a suppressor of MIF Two Nr. 3 
(SMT3) in S. cerevisiae167,168. An excess of SMT3 was able to compensate for the 
phenotypes associated with knockout of MIF Two/Centromeric protein- C (Cenp-C) 
in S. cerevisiae. Cenp-C has since been shown to be SUMOylated169,170, but the 
functional relevance remains unknown. UBLs are conjugated to proteins to regulate 
function. Whereas ubiquitin targets proteins for degradation, SUMO can be 
reversibly added to substrate proteins to play multiple roles (discussed below)166. 
 
2.3.2 SUMOylation Pathway 
SUMO has to undergo modification itself before it can be conjugated to a target 
substrate. Since there is high conservation between the machinery of the 
SUMOylation pathway in Drosophila and mammals171 (e.g Human SUMO-2 shares 
68% identity with SMT3, Figure 2–6A), here, I describe the SUMOylation pathway in 
mammals with the Drosophila names in brackets. The process is shown in Figure 2–
6B. Firstly, SUMO (SMT3) is made competent for conjugation by cleavage of a C-
terminal dipeptide by a SUMO-specific protease (SENP) (ULP) thereby exposing a 
C-terminal di-Glycine motif (GG). Conjugation competent SUMO (SMT3) is then 
activated by the E1 heterodimer SAE1/SAE2 (Aos1/Uba2) in an ATP-dependent 
manner. Next, the E2 conjugating enzyme UBC9 (lesswright) binds SUMO (SMT3) 
via a cysteine residue and catalyses a transesterification reaction resulting in a 
highly reactive species. UBC9 (lesswright) catalyses the covalent attachment of 
SUMO (SMT3) to target proteins at lysine residues. Although not essential for the 
addition of SUMO (SMT3) to substrates, E3 ligases facilitate conjugation, by 
providing substrate specificity to UBC9172, by bringing UBC9 and the substrate 
within close proximity, which enhances SUMOylation173. Substrates can be modified 
at multiple sites by SUMO (multi-SUMOylation). SUMO can form chains with 
multiple moieties on one site (poly-SUMOylation) and can form chains with 
alternative PTMs. This allows the build-up of more complex interaction networks 
within the cell. 
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Figure 2–6 The SUMOylation cycle  
(A) The amino acid sequence of Drosophila melanogaster (D.m) SMT3 aligned to human (H) 
SUMO2. (B) The process of SUMOylation and poly- multi- and SUMO-ubiquitin chain 
formation (for details of the process see text). SUMO modification on substrate proteins is 
dynamic and reversible.  
The two amino acids at the C-terminus of SUMO/SMT3 that are cleaved to activate it are 
underlined in red.   
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2.3.3 SUMO Turnover and use of N-ethylmaleimide (NEM) to Inhibit 
deSUMOylation 
UBLs have limited pools available for conjugation to substrate proteins. SENPs can 
cleave and release SUMO from substrates to enable conjugation to different 
subsets of substrates. Under non-stress conditions, for many proteins, only a small 
fraction of substrate is SUMOylated at any one time, suggesting SUMOylation is 
controlled dynamically to modulate protein function. 
 
UBLs are constantly turned over in vivo and this continues in vitro following cell 
lysis; therefore modified forms of a protein often go undetected when analysed by 
western blot. The small-molecule inhibitor NEM, is commonly used in lysis buffers to 
inhibit protein deSUMOylation. NEM is a cysteine peptidase inhibitor which acts by 
covalently modifying the thiol groups of cysteine residues in their active site (Figure 
2–7). SENPs/ULPs are cysteine peptidase which are inhibited by NEM, thus 
preventing their enzymatic activity to remove UBLs. 
 
 
Figure 2–7 The general reaction scheme for N-ethylmaleimide on biological thiols 
Image taken from Sasidharan et al., 2012174. 
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2.3.4 SUMO Conjugation Sites 
The consensus sequence for SUMO conjugation on a substrate protein is the lysine 
residue contained within the amino acid sequence ΨKxE/D, with Ψ being a 
hydrophobic residue and x being any amino acid175. However, it is estimated that 
40% of SUMOylation does not happen at this site173, with the E3 ligase aiding 
SUMOylation at non-consensus sites176. Tools have been developed to predict 
SUMOylation sites on proteins by comparison to consensus sequences for SUMO 
conjugation and experimental data mined from databases177,178. 
 
2.3.5 Interactions of the SUMO-interacting motif (SIM) with SUMO 
In addition to forming covalent interactions, SUMO forms non-covalent interactions 
with proteins179. The best characterised interaction of SUMO with a substrate protein 
is through a SUMO interaction motif (SIM)180. SIMs are characterised by a 
hydrophobic core of three to four aliphatic amino acids (isoleucine, leucine or valine) 
flanked by a stretch of acidic amino acids. This promotes an electrostatic SUMO-
SIM interaction181. Some SIMs are phosphorylation-dependent, with phosphorylation 
preventing or enhancing binding to SUMO182.  
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2.3.6 Biophysical Effects of SUMOylation  
When conjugated to a substrate, SUMO alters the biological activity of that substrate 
by changing the substrate’s interaction surfaces. For example, for HP1a, which is a 
26kDa protein, the conjugation of a 10kDa SMT3 protein increases its size 
substantially. Moreover, SUMO chains increase the mass and surface area of small 
targets. These modifications either prevent or enhance interactions between 
proteins or between proteins and DNA or RNA. The four main mechanisms through 
which SUMO can alter a protein’s function are shown in Figure 2–8 and described 
below: 
 
(A) Direct binding of SUMO to a single protein can facilitate interactions, allowing 
binding of SIM-containing proteins to SUMOylated substrates (Ai); or blocking 
interactions by preventing recognition of interaction surfaces (Aii); or both can 
modulate DNA-binding activity. 
 
(B) SUMOylation can modulate or crosstalk with other post-translational 
modifications (PTMs). Some PTMs target the same amino acid residue on the same 
protein leading to competition for modification of that site. For example, lysine 
residues can be modified by: SUMOylation, methylation, phosphorylation and 
ubiquitination. Therefore SUMOylation can influence the activity of a protein by 
shifting the balance between its other modifications. Other PTMs are 
complementary or antagonistic, for example, recognition of SUMO sites within some 
substrates requires prior phosphorylation of nearby residues183. 
 
(C) SUMOylation can either recruit ubiquitin (Ub) or prevent it from being added. 
Ubiquitin-SUMO chain interaction with SUMO-Targeted Ubiquitin Ligases (STubls) 
results in an altered stability of the protein, resulting in protein degradation by the 
ubiquitin-proteasome system (UPS)184. 
 
(D) SUMOylation can have an indirect effect through interactions mediated through 
SUMO-SIM domains. This can be achieved by sequestering proteins in distinct 
subcellular structures, altering subcellular localisation (Di), forming complex multi-
protein complexes (Dii) and recruiting protein complexes (Diii). 
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Figure 2–8 SUMOylated proteins and/or proteins with SIM domains act through 
different mechanisms to modulate protein function  
Adapted from Garcia-Dominguez Mario, 2013185 and Hannoun, 2010186. 
Introduction 
30   
 
2.3.7 SUMO Plays Essential Roles at a Cell/Organisms Level 
Vertebrates have three SUMO paralogs, SUMO-1, SUMO-2 and SUMO-3. SUMO-2 
and SUMO-3 share 95% identity but only share 50% identity with SUMO-1187. Loss 
of SUMO2 is embryonic lethal whilst SUMO3 KO mice are viable188 and SUMO2/3 
compensates for loss of SUMO1189. In mice, Ubc9-deficient embryos die early post 
implantation190.  
 
Invertebrates and yeasts have a single gene encoding SUMO, Smt3. 
Drosophila SMT3 is 68% identical to SUMO2 (Figure 2–6). Disregulation of the 
SUMOylation pathway by reducing lesswright191, SMT3171,192, the E1 activating 
enzyme192, or an E3 SUMO ligase152 all yield developmental defects (reviewed in 
Smith et al. 2012193). Conjugation of SUMO to target proteins is essential in all 
model organisms tested194 except for S. pombe, where smt3 deletion alters the 
pattern of histone modifications in heterochromatic regions and causes defects in 
heterochromatic silencing195. 
 
SUMOylation is involved in: cell cycle regulation; maintenance of genome stability 
by influencing DNA recombination and repair; transcriptional regulation; mRNA 
metabolism196,197, specifically splicing of pre-mRNAs198; nuclear transport; and cell 
signalling. SUMOylation of substrates increases during stress response, viral 
infection and cellular senescence. SUMO modification of a specific subset of 
proteins also acts to stabilise cell fate decisions.  
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2.3.8 Use of Proteomics to Identify SUMO targets 
Approximately 60% of all nuclear proteins have been identified as SUMO substrates 
with SUMO conjugated on average to 18% of all lysine residues in SUMO target 
proteins. In human cells over 30,000 proteins were found to be SUMOylated when 
assayed by mass spectrometry199. In a recent proteomics study involving SUMO-2/3 
immunoprecipitation to enrich for endogenously SUMOylated proteins from HEK, 
HeLa, and U2OS cells under heat shock and proteasome inhibition conditions, 67% 
of the proteins identified were previously reported SUMO targets200, showing little 
overlap between experiments performed in different conditions. SUMOylated 
proteins have been identified in proteomics studies from human169,201,202, 
mouse200,203-205, C.elegans194,206, Drosophila171,207 and yeasts208. The effect of protein 
SUMOylation has been addressed by mutating SUMO sites and assaying the loss of 
SUMO conjugation phenotype.  
 
Hendriks et al., 2018200 identified differences in SUMOylation substrates in different 
cell types and tissues of wild-type mice. The lowest levels of SUMO conjugation 
were found in the heart and brain and the highest levels in the liver, testis, kidney 
and spleen. In the brain 78% of SUMO2/3 exists in its unbound state, roughly 10% 
was found to be conjugated to E1 and E2 enzymes, or integrated into SUMO-chains 
and the remaining 10% was conjugated to substrate proteins200. Henricks et al., 
2018200 suggest that the SUMOylation system exists in a primed state, able to 
respond to neurological stress, for neuroprotection, as in the case for mice with 
brain ischemia which have increased levels of conjugated SUMO209. In HEK293 
cells, they found 93% of SUMO2/3 conjugated to target substrates whereas on 
average, only 52% of SUMO2/3 was conjugated across all organs. Global 
remodelling of the SUMO proteome in response to stresses, such as ischemia, salt 
stress, heat stress or oxidative stress should also be modelled in vivo in the targets 
to be studied to understand the relevance of that SUMOylation; otherwise it is 
possible that SUMO mediated regulation is possible but does not occurr in a 
physiological system.  
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2.3.8.1 Strategy to Identify SUMO targets using Proteomics  
Although the role of SUMOylation has in part been studied by detecting which 
proteins are SUMOylated, proteomics experiments typically relied on the 
overexpression of transgenes containing modified versions of SUMO210. To allow 
recognition and isolation of SUMO-associated complexes, a standard approach is to 
add a 6-HIS tag at the N-terminus and modify the C-terminal sequence, exchanging 
threonine to lysine (T86K), to insert a site for tryptic digest210. Modified SUMO 
immunoprecipitated from cell lysate using  Ni2+-NTA affinity resin enabled detection 
of SUMO substrates by mass spectrometry, detecting a -KGG motif at sites of 
SUMO conjugation on substrate proteins (Figure 2–9). Algorithms have been 
developed to detect SUMO binding motifs on peptides. The requirements for 
detection of SUMOylation sites using the Andromeda peptide search engine are in 
Appendix 5.  
 
 
Figure 2–9 Multiple sequence alignment of the amino acid sequences of Drosophila 
SMT3 (O97102), Human SUMO2 (P61956) and Drosophila ubiquitin (Q7JPZ2) 
Multiple sequence alignment of Drosophila (D.m) SMT3 (O97102), Human (H) SUMO2 
(P61956) and Drosophila (D.m) ubiquitin (Q7JPZ2). Red line marks the C-terminal di-peptide 
that is cleaved to activate SMT3/SUMO and the box marks the exposed C-terminal regions 
of these proteins. Lysine (K) and arginine (R) residues are marked by *. SUMO modification 
can be added at K residues. K and R sites are recognised by trypsin for cleaving the proteins 
into peptides.  
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2.3.9 SUMOylation of Transcription Factors  
Transcription factors (TFs) are among the most frequently detected targets of 
SUMOylation, with proteomics experiments estimating that 50% of RNA Pol II TFs 
are SUMOylated and so are subject to regulation by SUMO169. The effects of TF 
SUMOylation have been studied for about 200 individual TFs (reviewed in Rosonina 
2017211). With some exceptions, SUMO is generally associated with reduced 
transcription by a variety of mechanisms (Figure 2–8). A model has been proposed 
whereby SUMOylation of TFs enhances their DNA binding and protein-protein 
interactions to control binding site selection and retention212. Interesting examples 
are the transcription factors involved in cellular reprogramming, where 
hypoSUMOylation enhances pluripotency while increased SUMOylation results in 
lineage differentiation213.  
 
Drosophila STAT (STAT92E) acts as a general transcription factor binding zygotic 
genes at the onset of zygotic genome activation214. STAT92E SUMOylation by 
PIAS144 inhibits STAT92E binding to promoters, thus inhibiting the JAK/STAT 
signalling pathway215. 
 
2.3.10 SUMOylation in RNA processing 
SUMO regulates mechanisms involved in RNA processing and stability through 
modifying the actions of the protein regulators of these pathways. SUMOylated 
polyadenylation factors disrupt pre-mRNA 3′ processing216,217 and SUMOylated 
heterogeneous nuclear ribonucleoproteins (hnRNP) proteins have altered RNA 
binding properties218. SUMO-1 modification of methyltransferase like 3 (METTL3), a 
component of the RNA N6-adenosine-methyltransferase complex responsible for 
N6- methyladenosine (m6A), results in repression of its activity219. 
 
PIAS1, TFs and Tafs co-purify with the mammalian spliceosome220, suggesting that 
SUMO conjugation to factors involved in mRNA processing aided by PIAS may 
influence pre-mRNA processing. PIAS1 is also found in nuclear speckles221 which 
are sites in the nucleus enriched for pre-mRNA splicing factors222. 
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2.3.11 SUMO “Spray”  
SUMO can be conjugated on multiple proteins at multiple sites, resulting in the term 
''SUMO spray''223, where SUMO restricted to a local area attaches to substrates to 
“glue” proteins together and stabilise complexes224. Alternatively, “SUMO spray” 
within a local environment may be ligated to target proteins by E3 ligases, models 
have been proposed for group SUMOylation212,223. Most proteins have multiple 
SUMOylation sites which leads to redundancy and has created problems in studying 
and interpreting phenotypes of SUMOylation mutants225.   
 
2.3.12 SUMOylation in 3D Genome Organisation  
The Corces lab has studied the epigenetic regulator protein Modifier of mdg4 
(Mod(mdg4)) in the context of its interaction with DNA-binding insulator proteins to 
regulate transcription of the retrotransposon MDG4 (gypsy) in Drosophila 
melanogaster. SUMOylation of Mod(mdg4) inhibits insulator complex formation 
which is responsible for the formation of chromatin loops226,227 which determine 
nuclear architecture. Topoisomerase I-binding arginine/serine rich (Topors) protein 
physically interacts with components of gypsy chromatin insulators and has both E3 
SUMO ligase228 and E3 ubiquitin ligase229 activity. Ubiquitin modified Mod(mdg4) is 
required for lamina associations of the gypsy insulator and negative regulation of 
SUMOylation of insulator components. However Topors is unnecessary for gypsy 
chromatin insulator function230, suggesting functional redundancy amongst 
mechanisms of SUMOylation and ubiquitination. 
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2.3.13 SUMOylation as an Initiator in Heterochromatin Formation in 
Mammals? 
SUMOylation of chromatin has been associated with reduced transcription231,232. 
Proteomic studies identified lysine 12 on histone 4 (H4K12) as a specific site of 
SUMOylation in vivo233. Studies of this, via chemical SUMO ligation onto histone 4, 
forces an open chromatin structure234,235 which can recruit repressive complexes. A 
SIM in co-repressor of neuron-restrictive silencer element (NRSE)/REI silencing 
transcription factor (CoREST) binds SUMOylated histone H4 and stimulates lysine-
specific histone demethylase1(LSD1)-mediated demethylation of histones234,235. 
CoREST interacts with a PIAS protein (PIASγ) resulting in SUMOylation of CoREST 
and thereby stabilisation of the CoREST co-repressor complex236. In Drosophila, the 
Su(var)3-3 gene encodes a homolog of LSD1 which acts as an H3K4 demethylase 
in early embryonic development. This restricts H3K4me2 at heterochromatin 
through interaction with SU(VAR)3-9, HP1a and RPD3 (HDAC1 in mammals) which 
removes acetyl marks from N-terminal histone tails44.  
 
PIAS proteins play a role in mediating SUMO conjugation to chromatin-associated 
proteins in mammalian cells. One example is SUMOylation of HDAC1237,238 which 
aids239 or inhibits240 its binding to interaction partners. A second example is 
SUMOylation of methyl-binding-domain protein 1 (MBD1), which modulates its 
interaction with CAF-1 and SETDB1 (KMT), controlling cross-talk between DNA and 
histone methylation. Interestingly, SUMO-1 modified MBD1 cannot form a 
repressive complex at the promoter of one of its target genes, causing aberrant 
gene expression241. However, the opposite effect was observed in an in vitro system 
with SUMO2/3 modified MBD1 which was able to interact with MCAF-1 and recruit 
SETDB1242 to form a repressive complex. The difference in experimental set-up was 
suggested for the differences in observations. A third example involves AGO2 
SUMOylation by PIAS3. This may regulate AGO2’s role in RNA interference, with 
SUMO and phosphorylation possibly cross-talking under hypoxic conditions, to 
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In mouse cells, HP1α SUMOylation is proposed as a “seeding” step for de novo 
targeting of HP1α to pericentric heterochromatin244. The hinge region of HP1α is 
required for pericentromeric binding245. When SUMOylated in the hinge region, 
HP1α is targeted to pericentric regions in the absence of Suv39h-dependent 
H3K9me3244. SUMOylated HP1α binds chromatin-associated major satellite RNA, 
which is transcribed from DNA repeats, acting locally in cis. SUMOylation of the 
hinge domain of HP1α allows a more open conformation that allows HP1α to 
interact with pericentric RNAs and other heterochromatin proteins, allowing the 
recruitment of Suv39h1246 which methylates adjacent H3K9. This leads to the 
recruitment, stabilisation and spreading of HP1α along chromatin, forming larger 
heterochromatin domains, which silence DNA.  
 
The Suv39h1/2 (SETDB1/2) histone lysine methyltransferase complex (KMT) has 
two roles at chromatin. In addition to depositing methyl marks at chromatin by tri-
methylation of H3K9, these proteins can also enhance SUMO conjugation to 
substrate proteins, potentially acting as an novel class of E3 SUMO ligases99,231,247. 
SETDB1 proteins have SUMO conjugation and SIM domains248. Different chromatin 
remodelling proteins that confer the same enzymatic activity act to silence different 
regions of the genome. Association of complexes required for heterochromatin 
formation and maintenance are likely to be cell cycle, cell type or cell stage 
dependent. 
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Krüppel associated box (KRAB)-associated protein-1 (KAP1), also known as 
Tripartite motif-containing 28 (TRIM28) or Transcription Intermediary Factor 1 β 
(TIF1β), is another well-characterised E3 SUMO ligase. This acts as a scaffolding 
protein for the recruitment of chromatin remodelling and repressor complexes that 
mediate local heterochromatin formation249. KAP1 is regulated by post-translational 
modifications, with phosphorylation aiding its association with DNA replication 
factors during S-phase of the cell cycle, and KAP1 forms a complex with Suv39h to 
re-establish methyl marks at heterochromatin after DNA replication250.  
 
Figure 2–10 Conceptual framework for the establishment and maintenance of 
constitutive heterochromatin 
This model is based on the mammalian KAP1 E3 ligase (E3) binding to recognition elements 
(RE) through interaction with KRAB zinc finger proteins (ZF). The KAP1 E3 ligase recruits 
histone deacetylase 1 (HDAC1) and histone lysine methyltransferase (KMT) (SETDB1) for 
deposition of H3K9me3 and recruitment of heterochromatin protein (HP1). SUMO (S) is 
required for KAP1 interactions at chromatin. PHD and bromo domains in KAP1 aid 
chromatin recognition (adapted from Peng 2008251) through binding to a combination of post-
translational modifications on histone tails.   
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2.4 The Chromatin Remodeller ATRX 
In vertebrates, Alpha thalassemia mental retardation X-linked (ATRX) is a 
heterochromatic protein encoded on the X-chromosome belonging to the 
SWI2/SNF2 subfamily of ATP-dependent chromatin remodelling proteins252,253.  
 
2.4.1 ATRX Domain Structure and Interactions 
The ATRX protein has two main functional domains: an ATRX-DNMT3-DNMT3L 
(ADD), and a SNF alpha-helical domain (Figure 2–11). There is also a third 
conserved region, the helicase C domain. 
 
The ADD1 domain shares homology with the DNMT3 family of DNA 
methyltransferases171. The ADD domain contains a C2-2 GATA-like zinc finger 
domain and a plant homeodomain (PHD)254. The PHD domain contains an atypical 
zinc finger which specifically recognises H3K9me3 (but cannot bind H3K4me3 or 
H3K4me2255,256) targeting ATRX to heterochromatin257,258. The ADD domain also 
binds DNA directly at G-quadruplex (G4) DNA structures259, a feature shared with 
DMNTs260. Binding to both DNA and histones may enhance ADD1 recruitment to 
specific regions of the genome. 
 
ATRX interacts with HP1261. This interaction or ATRX’s interaction with methyl-
binding protein MECP2262 may stabilise ATRX at heterochromatin (Figure 2–11).  
 
 
Figure 2–11 Domain structure of vertebrate ATRX protein 
The ADD domain is in the N-terminal region and the SNF/helicase C is in the C-terminal 
region. Interaction sites for HP1, DAXX and MeCP2 are marked. In purple are the zinc finger 
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2.4.2 ATRX Mutations 
In vertebrates ATRX is essential; null mutations in mice are embryonic lethal263. 
Mutation in ATRX can result in a range of mental retardation syndromes264-268 which 
vary between individuals and may also include: altered facial features; genital 
abnormalities; and alpha thalassemia. The mutations cluster over two functional 
domains; 50% of mutations are located in the N-terminal ADD domain and 30% in 
the C-terminal SNF (Helicase/ATPase) domain258. 
 
2.4.3 ATRX Function and Mechanisms at Chromatin 
ATRX is required for transcription at satellite repeats, G-rich sequences269, G4-DNA 
structures270, RNA-DNA hybrids (R-loops)271, pericentric heterochromatin repeats 
and sub-telomeric heterochromatin repeats272. ATRX is also is involved in the 
formation of heterochromatin structures to silence endogenous retroviruses273,274, 
imprinted genes262 and tandem repeats275. Knockdown of ATRX results in mitotic 
spindle defects, chromosome misalignment, segregation problems276, an alternative 
lengthening of telomeres phenotype277 and impaired transposon silencing274. 
 
Once recruited to its target sites, ATRX targets the histone chaperone death-
domain-associated protein (DAXX) to facilitate incorporation of the histone variant 
H3.3 into nucleosomes, which may maintain DNA in the B-form conformation to 
maintain an open chromatin structure278,279 for replication through these regions 
(Figure 2–12).  
 
ATRX functions as part of several repressive complexes. In human cells, ATRX 
recruits Chromobox protein homolog 5 (CBX5) (the human homolog of Drosophila 
HP1a) to telomeric regions, which acts with zinc finger protein ZNF274, TRIM28 and 
SETDB1 to deposit and maintain H3K9me3 at telomeres at the 3’ regions of zinc 
finger genes280,281,282. Mutations in ATRX disrupt the organisation of pericentromeric 
heterochromatin46 by altering the pattern of DNA methylation283. Absence of ATRX 
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In mammals, telomeric repeat-containing RNAs (TERRA) transcribed from sub-
telomeric regions of the genome285 compete with ATRX for binding to telomeric 
DNA286. TERRA forms R-loops that promote the formation and stabilisation of G4 
structures at telomeric repeats. RNA-G4 structures formed by TERRA bind to lysine-
specific histone demethylase1 (LSD1), which catalyses the removal of methyl 
groups from H3K4 and H3K9287. This aids telomere recombination288 to maintain 
telomere length in the alternative-lengthening of telomeres (ALT) pathway. ALT is 
activated in many cancers and is critical for cell survival. ATRX supresses the ALT 
pathway. In the absence of ATRX, TERRA transcription increases and telomeres 
are derepressed64. Therefore ATRX plays a critical role at telomeres.  
 
 
Figure 2–12 Model of ATRX-DAXX dependent targeting of H3.3 to pericentric 
heterochromatin, interstitial heterochromatin and telomeres 
ATRX is recruited to chromatin through its ADD domain which recognises a combination of 
H3K4me0 and H3K9me3 on histone H3 tails. ATRX interacts with DAXX to aid deposition of 
the histone variant H3.3 into nucleosomes to maintain an open DNA conformation to allow 
gene expression.  
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2.4.4 ATRX Conservation 
Functional homologs of ATRX, with a conserved SNF domain structure, have been 
identified in both vertebrate and non-vertebrate species (Figure 2–13), with a 
conserved function in the deposition of H3.3 into chromatin in Drosophila289 and 
Arabidopsis290 and a role in chromatin remodelling in C.elegans291. Rad54-like 
homologs of ATRX exist in yeasts292. 
 
 
Figure 2–13 Multiple sequence alignment of ATRX proteins from different organisms 
and the phylogenetic tree derived from it 
(A) Multiple sequence alignment (MSA) of ATRX proteins from different organisms. The 
position of three conserved functional domains is shown. Conserved amino acids are shown 
as purple bars. Black bars show the aligned amino acid sequence, gaps in sequence occur 
as a result of alignment. (B) Phylogenetic tree showing the evolutionary relationships among 
organisms. The MSA and phylogenetic tree were generated by ClustalOmega and exported 
into Jalview to visualise conserved amino acids in purple, then exported as a scalable vector 
graphic to generate the figure in Adobe Illustrator. Protein sequences were downloaded from 
UniProt in January 2019. 
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2.5 XNP, the C-terminal Homolog of ATRX in Drosophila  
XNP was identified as the functional homolog of ATRX in Drosophila, aligning to the 
C-terminal SNF and helicase C/ATPase domains139(Figure 2–13). XNP is expressed 
throughout development as a long and a short isoform139. The longer isoform forms 
a complex with HP1a, is enriched at heterochromatin and facilitates HP1a 
deposition into pericentric beta-heterochromatin in the X chromosome293,294. Knock-
out of the long isoform of XNP does not affect the viability of Drosophila, whereas 
loss of both isoforms is semi-lethal (with ATRX pupa emerging at sub-Mendelian 
ratios) and results in infertility294.  
 
XNP localises to sites of active transcription in regions of rapid nucleosome 
turnover289, at pericentric heterochromatin139 and telomeres295. Interestingly, XNP 
concentrates at a satellite block adjacent to pericentric heterochromatin on the X-
chromosome289. This region is highly decondensed and made up from a 4-base pair 
TAGA DNA repeat. The TAGA repeat is only present in Drosophila melanogaster, is 
adjacent to the chromocenter and is formed of pericentric beta heterochromatin289.  
 
PIAS144 and SMT3144 also localise to the TAGA repeat in Drosophila melanogaster. 
However, ADD1293 and HP1a289 do not localise here. HP1a296, ADD1296 and XNP294 
all localise to the chromocenter, which is formed from a cluster of pericentric 
heterochromatin regions and the forth chromosome. It has been suggested that the 
TAGA repeat is a genome-wide regulator of genome silencing289. Tools to visualise 
repetitive regions in Drosophila297 have shown that pericentric satellite DNA is able 
to aid DNA packaging298 and are the subject of much study. 
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2.6 ADD1, the N-terminal Homolog of ATRX in Drosophila  
A phylogenetic analysis performed on ATRX homologs suggested that the ATRX 
gene split in insects296 resulting in two proteins in Drosophila, ADD1 and XNP 
(Figure 2–14). A protein sharing homology with the N-terminal ADD domain of 
vertebrate ATRX was discovered299 sharing the zinc finger and PHD domains 




Figure 2–14 Protein multiple sequence alignment of Drosophila ADD1 and XNP with 
human ATRX  
The position of conserved functional domains are marked. Also shown is the percent identity 
over conserved regions of ADD1 to ATRX and XNP to ATRX. MSA was generated by 
ClustalOmega, exported into Jalview for visualising conserved amino acids as purple bars. 
Black lines show the aligned amino acid sequence, gaps in sequence occur as a result of 
alignment. Protein sequences were downloaded from UniProt in January 2019. 
 
 
Figure 2–15 Protein multiple sequence alignment of the ADD domain of Drosophila 
ADD1 and human ATRX  
The conservation of the zinc finger and PHD domains of the ADD domain in ATRX/ADD1 is 
shown. MSA was generated by ClustalOmega, exported into Jalview for visualising 
conserved amino acids as purple boxes. Protein sequences A1Z8R2 and P46100 were 
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Drosophila ADD1 localises to pericentromeric heterochromatin and telomeres, co-
localising with HP1a299. The add1 gene encodes three ADD1 protein isoforms 
generated by alternative splicing296. Reduced expression of the longest isoform of 
ADD1 (ADD1-RA) results in loss of HP1a at telomeric sequences without affecting 
HP1a localisation to other binding sites295.  
 
ADD1 interacts with HP1a, repetitive RNAs and the protein BONUS299. BONUS is 
the only known Drosophila homolog in the Transcription Intermediary Factor 1 
(TIF1) family300. In humans TIF1s phosphorylate HP1301,302 to regulate HP1 binding 
to DNA296. In Drosophila, bonus has not been identified as an interactor of HP1303, 
but potentially ADD1, BON and HP1a could be part of the same complex in vivo.  
 
2.7 ADD1-XNP Interaction  
ADD1 and XNP genetically interact. In a genetic screen conducted by Lopez-Falcon 
et al., 2014296, the percentage viability of heteroallelic XNP mutants (atrx1/atrx3) 
(49%) is increased in Drosophila expressing a hypomorphic allele of ADD1 
(dadd1NP1240/+;atrx1/atrx3) (72%); however, 12% of these Drosophila develop 
melanotic masses296. This suggests an epistatic relationship between ADD1 and 
XNP. 
 
Lopez-Falcon et al., 2014296 mapped a direct interaction between amino acid 
residues 1-620 of ADD1-RA and XNP-RA residues 1-221 (found only in the long 
isoform of XNP)296. This interaction was not found by Alekseyenko et al., 2014293. 
They demonstrate that XNP and ADD1 interact strongly with HP1a but ADD1 pull-
down shows no interaction with XNP293. The difference in these studies are the 
methods used to isolate ADD1 associated complexes, suggesting that certain 
conditions are required to maintain and observe an interaction between ADD1 and 
XNP.   
 
In Drosophila XNP does not constitutively associate with heterochromatin289. In 
contrast, ADD1 localises and interacts with heterochromatin proteins throughout the 
cell cycle303. XNP may localise with ADD1 and HP1 in certain circumstances or at 
specific chromatin regions.   
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2.8 SUMOylation of ADD1 and XNP 
XNP can be covalently modified by SMT3171. In the Heun lab, lysine 181 of XNP 
was identified as a SUMOylation site (within an N-terminal XNP fragment) in an in 
vitro bacterial SUMOylation assay (presented in the master’s thesis of Yvonne 
Steuernagel304). The mammalian ATRX homolog has also been identified as a 
SUMO substrate in mass spectrometry experiments looking to identify SUMO 
interactors by immunoprecipitation of SUMO-complexes from human and mouse 
tissue culture cells305.  
 
ADD1 was identified in a one-step purification of SUMOylated proteins in Drosophila 
S2 cells in non-denaturing conditions (Heun lab unpublished) where non-covalent 
modifications are maintained. This raises the question of whether ADD1 is itself 
SUMOylated or whether ADD1 interacts with SUMOylated targets through SIMs. 
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2.9 Hypothesis  
We hypothesise that PIAS-mediated SUMOylation of chromatin factors is 
responsible for establishing and/or maintaining heterochromatin.  
 
XNP is SUMOylated in Drosophila171. It was hypothesised that PIAS may act as the 
SUMO E3 ligase aiding SUMOylation of XNP. PIAS and XNP co-immunoprecipitate 
when overexpressed in S2 cells and an intimate relationship between PIAS and 
XNP was predicted based on their co-localization in S2 cells and Drosophila 
tissues144. It was also observed by the previous PhD student in the Heun lab that 
SUMO, PIAS and XNP localise to DAPI dense regions in pre-blastoderm nuclei of 
Drosophila embryos (Figure 2–16)144. This localisation coincides with 
heterochromatinization and thus a PIAS-XNP-SUMO complex may be important for 
XNP SUMOylation and heterochromatin establishment.   
 
 
Figure 2–16 Localisation of SUMO, PIAS and XNP to the DAPI dense regions of pre-
blastoderm nuclei in Drosophila embryos in nuclear cycle 14  
The observation was first made by Lorenz Kallenbach and was presented in his thesis in 
2011144. Images were taken by Lorenz Kallenbach and were compiled by myself for 
presentation in this thesis.  
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2.10 Aims of this thesis  
 
PIAS proteins in Drosophila can be studied to understand common roles for PIAS in 
other species. Based upon our hypothesis that PIAS-mediated SUMOylation of 
chromatin factors is responsible for establishing and/or maintaining heterochromatin, 
I identified four key aims:   
 
1. to develop tools for identifying PIAS, ADD1 and XNP interactomes at 
endogenous protein levels 
2. to understand whether the previously identified PIAS interaction with XNP 
occurs under physiological conditions 
3. to characterise the interaction between ADD1 and XNP with PIAS  
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2.11 Strategies to study PIAS localisation and interaction partners 
Previous experiments in the Heun lab, to characterise the localisation and 
interaction partners of PIAS, were performed by inducing expression of tagged PIAS 
transgenes from plasmids. In this thesis, use of the Drosophila anti-PIAS sheep 
antibody and CRISPR/Cas9 tagging of PIAS proteins allowed further experiments to 
be performed, to assess endogenous PIAS’s localisation and interaction partners. 
These strategies are outlined in Figure 2-17. 
 
Figure 2-17 Strategies to study PIAS localisation and interaction partners 
Drosophila and Drosophila S2 cells express 14 isoforms of PIAS. The first strategy 
involves inducible expression of a V5-PIAS-PE transgene, from a pMT-Pias9_V5 
plasmid stably maintained in an L2-4 S2 cell line, by the addition of copper sulphate 
(A). The second strategy involves tagging all 14 isoforms. Red marks the position of 
the C-terminal PIAS CORE tag (B). The third strategy uses anti-PIAS antibodies (C). 
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Chapter 3 Methods 
 
3.1 DNA and RNA protocols 
3.1.1 gDNA isolation  
Qiagen Quick Extract buffer (Qiagen) was used for extraction of gDNA from S2 cells 
following the manufacturer’s instructions.  
 
3.1.2 DNA extraction 
For a clean DNA preparation, DNA was prepared from 1x106 S2 cells. S2 cells were 
resuspended in genomic lysis buffer and were incubated at RT for 10min. Each 
sample was treated with 5μg/mL RNase, DNase-free (Roche) (0.5μL 500μg/mL 
stock solution) and incubated at 37°C for 30min, followed by proteinase K 
(200μg/mL) at 50°C overnight. The following day, proteinase K was heat inactivated 
at 80°C for 20min. DNA was extracted twice with 50μL Phenol:Chloroform:Isoamyl 
Alcohol (at ratios 25:24:1, Sigma, 77617) added to the DNA, vortexed then 
centrifuged for 5min at 10000 x g. The DNA-containing aqueous phase was added 
to 50μL Chloroform:Isoamyl Alcohol in a fresh tube, vortexed then centrifuged for 
4min at 10000 x g. DNA contained in the aqueous phase was then precipitated by 
adding 50% isopropanol and 150mM NaOAc pH 5.2 and incubating overnight at -
20°C. To pellet the precipitated DNA, samples were centrifuged at 18000 x g for 
10min at RT. The DNA pellet was then washed in 70% EtOH and air dried at RT for 
5min. The DNA was then resuspended in 5μL of ddH2O.  
 
3.1.3 DNA and RNA quantification 
DNA and RNA sample concentration and purity were assessed using a ND-1000 
Spectrophotometer (NanoDrop). The spectrum of absorbance and the A260 /A280 
ratio was used as an estimation of DNA/RNA sample purity.  
 
3.1.4 RNA extraction and cDNA synthesis  
RNA was extracted from approximately 1x107 S2 cells using the TRIzol method 
(Sigma). Cells were rinsed once with ice-cold PBS then 2.5mL ice-cold TRIzol was 
added and incubated for 5min on ice. Cells were resuspended to homogenize the 
Methods 
50   
solution and were transferred to a 15mL falcon and vortexed. RNA was recovered 
through phase separation by adding 500μL chloroform and vortexing. Samples were 
incubated at RT for 2min then centrifuged for 15min at 12000 x g at 4°C. The 
colourless aqueous upper phase was transferred into a fresh 2mL tube. 
 
RNA was precipitated by mixing the aqueous phase with an equal volume of 
isopropanol, incubated at RT for 10min, then centrifuged for 10min at 12000 x g at 
4°C. The RNA pellet was washed with 70% EtOH and resuspended in DEPC-
treated water. 15μg RNA was DNase treated with 2μL DNaseI (NEB) in a 50μL 
reaction for 1hr at 37°C. 5mM EDTA was added and the DNAseI heat inactivated by 
incubating at 75°C for 5min to stop the reaction. RNA was quantified using the ND-
1000 Spectrophotometer (NanoDrop) and LiCl precipitated (-20°C overnight). 
Samples were aliquoted and stored at -80°C until needed. 
 
First strand cDNA was generated from 1µg of total RNA. Firstly, 1μg RNA, 1μL 
Random Hexamers (100ng/μL) (Thermo Fisher Scientific) and 1μL dNTPs (10mM), 
were mixed, and the total volume brought to 13μL with ddH2O. The samples were 
denatured at 65°C for 5min and immediately put on ice to prevent re-annealing. 
Secondly, a mix containing 4μL 5x First-strand buffer, 1μL DTT (from 1M DTT 
stock), 1μL Superscript III Reverse Transcriptase (RT) (Invitrogen) and 1μL ddH2O 
were added to the first tube. Samples were then run on a thermocycler using the 
following programme: 25°C for 5min, 50°C for 1hr, 70°C for 15min. Samples were 
diluted 1:20 before PCR. A control sample was made by substituting for the RT with 
1μL of ddH2O (no RT). The concentration and purity of the cDNA were determined 
using the ND-1000 Spectrophotometer (NanoDrop). 
 
3.1.5 Polymerase Chain Reaction (PCR) 
PCR reactions were performed using Phusion® High-Fidelity DNA polymerase 
(NEB). Elongation time was adjusted on the assumption that processivity is 30s/kb. 
Extension and annealing temperatures were set according to the predicted melting 
temperature of the primer pair used. For the template DNA to be amplified, 
approximately 10ng from plasmid DNA, 1μL gDNA extract or 100ng cDNA was 
used. Reactions were carried out in 0.2mL thin-walled PCR tubes (STARLAB).  
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A standard 50μL PCR reaction contained: template DNA; 1x Phusion HF buffer; 
0.5μM forward primer; 0.5μM reverse primer; 25μM dATP; 25μM dGTP; 25μM 
dTTP; 25μM dCTP and 0.5μL Phusion® High-Fidelity DNA polymerase (NEB) 
brought to 50μL with ddH2O.   
 
The standard PCR programme was: 
 
95°C for 5min 
    95°C for 30s 
    55°C* for 30s  
    72°C for 30s/kb of product  
   [Repeat x 29 cycles] 
72°C for 10min  
4°C for 5min  
 
*(annealing temperature 5°C below the melting temperature (Tm) of the primers) 
 
3.1.6 Genotyping PCR 
PCR reactions were performed using primers designed to amplify gDNA across a 
target region (for primer sequences see Appendix Table 20). Primers were designed 
using SnapGene (version 4.3.5) and checked with PrimerBLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
 
3.1.7 Agarose gel electrophoresis 
For analysis of PCR products or DNA digestions, DNA was separated according to 
molecular size by agarose gel electrophoresis. Agarose (0.7%-3% w/v) was 
dissolved in 1x TAE buffer by heating in a microwave. Once cooled, 0.01% SYBR 
Safe DNA gel stain (Invitrogen) was added. DNA samples were loaded in 1x DNA 
Loading Buffer alongside a DNA molecular weight marker for size comparisons. An 
electric current (90-130V) was applied to the gel for 30-60min. Following 
electrophoresis, the DNA was visualized on a UV transilluminator Gene Flash 
Documentation System (Synergene) or on a Safe Imager 2.0 Blue-Light 
Transilluminator (Invitrogen) for excision of bands from the gel. 
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3.1.8 Design of CRISPR targeting constructs in S2 cells 
500ng of 500bp gene block DNA fragments were designed to act as homology 
directed repair templates (HDRT) for insertion of a tag into the genomic loci 
encoding either PIAS, ADD1 and XNP proteins. These HDRTs were designed using 
the extended gene regions of PIAS, ADD1 and XNP (downloaded from FlyBase  on 
03-12-2016). Tags, linker regions, restriction sites and a base pair change in the 
protospacer adjacent motif (PAM) sgRNA recognition sequence were introduced 
and at least 200bp of homology arms either side of the tag were synthesized by IDT. 
PIAS and ADD1 HDRT designs used to generate cell lines used as part of this study 
are outlined in the results section 4.3.12  and appendix 4 respectively.  
 
3.1.9 Cloning of plasmid repair templates for CRISPR targeting  
Plasmid cloning was used to generate homology directed repair in Escherichia coli. 
To prepare fragments for cloning, 250ng gene block and 1μg of vector were 
incubated with restriction enzymes (NEB) (10U/μg DNA to be digested) for 2hr at 
37°C. Age1 and Kpn1 were used for cloning of the ADD1 HDRT into pMT_GFP_lacI 
and KpnI and SacI were used for cloning of PIAS HDRT into pBlue. Digests were 
separated on 0.7% agarose in 1xTAE buffer at 130V for 30min and the bands of 
interest were cut from the gel and purified using the GenElute™ Gel Purification Kit 
(Sigma) following the manufacturer’s instructions. 
 
Insert and vector were ligated at ratios 5:1, using 50ng vector DNA in a 20μL 
reaction, for 2hr at RT with 1μL T4 DNA Ligase in 1x T4 ligase buffer (Thermo 
Fisher Scientific) following the recommended protocol. A negative reaction, 
prepared with vector only, was used to assess background self-ligation rate. 1μL of 
the ligation product was mixed with a 50μL aliquot of electrocompetent 10beta E. 
coli cells and the contents of the tube transferred to a pre-chilled 0.1cm 
electroporation cuvette. This was electroporated using an Eppendorf Eporator 
system (Eppendorf) set on P1 1800V. 1 mL of SOC medium was added to the 
cuvette and the cuvette contents were transferred to sterile tubes which were then 
shaken for 30min at 200rpm at 37°C  in a Thermo Mixer (Eppendorf). 100μL of the 
E. coli culture was then plated on LB plates containing selection antibiotics (see 
materials section) and grown overnight at 37°C until bacterial colonies could be 
observed growing on the plate.  
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Single colonies were picked to inoculate 2mL of LB broth containing selection 
antibiotic (1000x solutions were prepared as stocks, for concentration of antibiotics 
see Appendix materials section Table 17) and left overnight in a 37°C shaking 
incubator (200rpm). 
 
Plasmids were purified from E. coli using the GenElute™ Plasmid Miniprep Kit 
(Sigma) following the manufacturer’s instructions and quantified using the ND-1000 
Spectrophotometer (NanoDrop). Analytical restriction digests were performed to 
verify the final product of each construct. These were performed in 10μL reactions 
using 100ng plasmid DNA and 1U of each restriction enzyme. 
 
3.1.10 Ligation-independent cloning (LIC) 
3C LIC vectors, pFL and pFastBac, were obtained from Atlanta Cook for generation 
of GST and HIS tagged Sf9 protein expression vectors. The plasmid maps are in 
Appendix 3. 1μg parent vector was digested with 10U ZraI resulting in a linearized 
plasmid. Once linearized, the plasmid was run on 0.7% agarose and excised for gel-
purification using the GenElute™ Gel Purification Kit (Sigma) following the 
manufacturer’s instructions. 
 
For the insert, primers were designed to amplify the gene of interest from cDNA to 
include overhangs to allow processing for insertion into the 3C LIC vector backbone. 
The primers span the start and end of the sequence of the gene of interest flanked 
by LIC sites (Table 1). For PCR, 1μL of first strand cDNA was mixed with 1x 
Phusion HF buffer, 0.5μM forward primer, 0.5μM reverse primer, 25μM dATP, 25μM 
dGTP, 25μM dTTP, 25μM dCTP and 0.5μL Phusion® High-Fidelity DNA 
polymerase (NEB) brought to 50μL with ddH2O. The PCR was performed in two 
stages. This included an initial denaturation at 95°C for 3min followed by 13 cycles 
of denaturation at 95°C for 30s, annealing at 65°C for 30s, and extension at 72°C for 
2min. This was followed by 25 cycles of denaturation at 95°C for 30s, annealing at 
55°C for 30s, and extension at 72°C for 2min, with a final extension at 72°C for 
10min. The PCR products were separated on 0.7% agarose and excised for gel-
purification following the manufacturer’s instructions. 
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450ng vector was mixed with 0.45U T4 DNA polymerase LIC-qualified (Novagen 
70099-3) in 1x T4 DNA polymerase buffer, 5mM DTT and 2.5mM dTTP in a 30μL 
reaction. For the insert, 600ng of gel-purified PCR product was mixed with 0.6U T4 
DNA polymerase LIC-qualified (Novagen 70099-3) in 1x T4 DNA polymerase buffer, 
5mM DTT and 2.5mM dATP in a 20μL reaction. The reactions were left for 30min at 
RT, then heat inactivated for 20min at 75°C. In the presence of a single nucleotide 
the T4 DNA polymerase 3'->5'-exonuclease and 5'->3'-polymerase activity is in 
equilibrium at the site of the first occurrence of this nucleotide, which results in 
unique single stranded overhangs. 
 
The vector and insert were annealed by mixing 1μL vector:1μL insert and incubating 
for 10min at RT. Note that this is due to the large size of the insert and deviates 
from the Cook lab protocol. Addition of 1μL 25mM EDTA was added. After another 
10min at RT 2μL of the mix was transformed into electrocompetent 10beta E. coli 
cells for propagation of the protein expression vectors .  
 










Selected colonies were amplified in 2mL cultures and vector DNA was extracted by 
performing a miniprep following the manufacturer’s instructions. Restriction enzyme 
digests were used to identify likely positive clones of assembled plasmids, which 
were analysed via agarose gel electrophoresis. Two constructs were taken forward: 
pFL-GST-LIC_ADD1_RA and pFastBac-His-3C-LIC_XNP_RA for expression in 
insect cells. For pFastBac-XNP_RA, the plasmid is 8822bp (containing the 4332bp 
HIS-3C-XNP CDS), and digestion with ScaI results in 2 bands at 1519bp and 
7303bp (Appendix Figure 8–9). For pFL-GST-LIC_ADD1_RA, the plasmid is 9790bp 
(containing the 3594bp GST-LIC_ADD1_RA CDS), and digestion with Kpn1 results 
in 3 bands at 342bp ,2360bp and 7088bp (Appendix Figure 8–10). Once insertion 
was determined, the vectors were sequenced using primers sequencing into the 
inserted CDS from the backbone vector (Appendix Table 20). 
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3.1.11 DNA sequencing  
All plasmids generated using PCR amplified fragments were sequenced using 
Sanger sequencing with the ABI PRISM BigDye™ Terminator Cycle Sequencing kit 
v1.1 (Applied Biosystems) to confirm the sequence of the insert and insertion in the 
correct open reading frame (ORF). The sequencing reaction (12μL): 150ng 
Template, 2.4μL of Big Dye Terminator sequencing buffer (Applied Biosystems), 
2μL of 1μM primer, 0.5μL of Big Dye Terminator enzyme mix (Applied Biosystems) 
and nuclease-free water (Ambion) was performed using the thermocycler program 
SEQFAST: 1min 96°C followed by [10s 96°C, 50s 55°C, 4min 60°C] for 40 cycles 
and was sent to Edinburgh Genomics for sequence analysis.  
 
3.1.12 Glycerol Stock Preparation  
Glycerol stocks were prepared by adding 500μL 50% glycerol to 500μL of an 
overnight culture expressing the plasmid of interest grown in 2mL of LB broth, 
supplemented with antibiotic (37°C shaking at 200rpm) and snap frozen in liquid 
nitrogen for storage at -80°C.  
 
3.1.13 Bacmid generation and ethanol precipitation of DNA 
100ng of pFL or pFastBac plasmid was transformed into 50μL EMBacY competent 
cells (see section 3.6.2), which use blue-white selection. DNA and cells were mixed 
and incubated on ice for 30min, heat shocked for 45s at 42°C and left on ice for 
2min before addition of 1mL SOC. Cells were shaken at 200rpm for 4hr at 37°C 
then spun at 4°C for 1min at 6800 x g to concentrate the cells by removing 700μL of 
supernatant. Cells were then plated on EMBacY selection plates and incubated for 
48 hours at 37°C. After 48hr colonies were assessed. White colonies should contain 
the transposed baculovirus genome, which has disrupted the lacZ gene so it cannot 
metabolise X-gal. Ten white colonies and two blue colonies were re-streaked on 
EMBacY selection plates and incubated for 48hr at 37°C, then three white colonies 
from the streaked plate were grown overnight in 5mL LB broth containing the same 
selection antibiotics as the EMBacY selection plates shaking at 37°C. The next day, 
cell pellets were obtained by centrifugation at 6800 x g at 4°C for 10min and the 
baculovirus genome recovered by miniprep following the manufacturer’s instructions 
until the addition of N3. After neutralization, the solution was centrifuged at 18000 x 
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g for 10min. The supernatant was transferred to a new tube and added to 2.5 
volumes of ice-cold isopropanol. DNA pellets were obtained by spinning at 10000 x 
g for 15min at 4°C, the supernatant removed, the pellet was then washed twice in 2 
volumes of ice-cold 70% ethanol then air-dried and resuspended in 100μL of 
ddH2O.  
 
3.1.14 Synthesis of gRNAs 
Guide RNA sequences were selected using the flyCRISPR Target Finder 
(http://tools.flycrispr.molbio.wisc.edu/targetfinder/), by insertion of the sequence of 
interest to be targeted. This ensured no off-targets and a prediction of cutting 
efficiency. sgRNAs were synthesised as gene blocks containing a dU6.2 promoter, 
tracrRNA and pol3 terminator. sgRNA-containing gene blocks were resuspended to 
a final concentration of 50μM and were amplified using dU6_2_sgRNA_F and 
dU6_2_3_sgRNA_R primers. Sequences of gRNAs used to target S2 cell lines are 
listed in Table 2. 
 
Table 2 sgRNA gene block template names and sequences  
sgRNA template name  sgRNA sequence 
dU62 promoter-dPIAS_sgRNA3_IDT AATGGTGCAGATGCTTCGAG 
dU62 promoter-dPIAS_sgRNA4_IDT CAAAAAGGGATCCAACGTAC 
dU6.2_ADD1_sgRNA1_IDT TCATGAGTAACAGTGCTCC 
 
3.2 S2 cell culture  
3.2.1 Media and growth conditions  
Drosophila S2 Schneider Line 2 derived L2–4 cell line (S2) cells were cultured at 
25°C at a density between 1x106cells/mL- 1x107cells/mL in either: 
A) Schneider’s Drosophila Medium (SERVA) (AMS Biotechnology) supplemented 
with 10% fetal bovine serum (FBS), 0.3mg/mL penicillin, 0.3mg/mL streptomycin 
and 0.75µg/mL amphotericin (B. Schneider, I. (1964) J. Exp. Zool. 156, 91-104 and 
166) B) Lonza Schneider's Drosophila Medium Modified  
C) Schneider's Drosophila Medium (Gibco cat. No. 21720024).  
 
To keep cells in a growth phase, cells were passaged every 3-4 days. For S2 cell 
passaging, medium was brought to RT before use. For adherent cultures, the 
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medium was removed and the flask bashed to detach S2 cells from the plastic 
surface. 2mL fresh medium was added and the cells were resuspended. For routine 
splitting, cells were split 1:6, seeding at approximately 1x106cells/mL. For 
experiments, cells were counted using an automated cell counter TC20 (Biorad) in 
Trypan Blue Dye 0.4% solution (Biorad) and plated total live cell numbers in ratios 
corresponding to 3x106cells/ 3mL/ 25cm2 surface area. S2 cells were transferred to 
a 15mL falcon tube and pellets were obtained by centrifugation (300 x g, 5min, RT 
in a benchtop centrifuge). The cell pellet was resuspended in 3mL fresh culture 
medium and seeded in a fresh flask. For experiments, after harvesting, cells were 
washed twice with RT PBS. 
 
3.2.2 Cryogenic storage of S2 cell lines 
Exponentially growing cells were frozen at a density of 1x107cells/mL in 45% 
conditioned medium, 45% fresh medium and 10% dimethyl sulfoxide 
(DMSO)(Sigma) in aliquots of 1mL suspension per cryovial. Vials were placed in a 
Cryo Freezing Container (Nalgene) filled with 100% isopropanol (Fisher Scientific) 
and incubated overnight at -80°C, then transferred to liquid nitrogen for long-term 
storage.  
 
3.2.3 Thawing S2 cell lines 
Cryotubes were removed from storage and placed on dry ice for transfer to the 
tissue culture facility. Medium was prewarmed to 20°C and the cryovial was partially 
thawed in a 37°C water bath. When a small amount of ice remained, the vial was 
removed from the water bath, sprayed with ethanol and thawed to completion with 
the heat of the hand. The full contents of the tube were immediately pipetted into a 
15mL falcon containing 4mL of fresh medium. The cryovial was rinsed once with 
1mL medium and this added to the 15mL falcon. Cells were pelleted for 3min at 300 
x g at RT and resuspended in 3mL fresh medium. For stable cell lines, antibiotics 
were added after the first passage.  
 
3.2.4 Transfections in S2 cells 
5x105cells/24-well plate were plated in 500μL medium the evening before 
transfection. For transfection reactions, 100μL serum-free medium and 200ng DNA 
were mixed by vortexing. 1.5μL X-tremeGENE™ HP DNA Transfection reagent 
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(Roche) was pipetted into the DNA-medium mix and incubated for 30min at RT then 
added to S2 cells in a dropwise manner. Transfections reactions were scaled in the 
above ratios for transfecting different surface areas of plates. 100μL of resuspended 
S2 cells were harvested at 3-days-post-transfection for immunofluorescence to 
confirm successful transfection through expression of a tag on the plasmid. 
 
3.2.5 Generation of stable S2 cell lines  
For generation of stable S2 cell lines expressing XNP-FLAG, S2 cells transfected 
with pMT_ATRX_FLAG_hygro were maintained in medium containing 100μg/mL 
Hygromycin B to retain the plasmid under selection. For induction from the 
metallothionein promoter (pMT), 200µM CuSO4 was added to the medium three 
days before harvesting. 
 
3.2.6 CRISPR/Cas9 transfection and antibiotic selection for tagged gene of 
interest 
S2 cells were co-transfected with 190ng pIB_Cas9_CD4_Blast, 200ng homology 
directed repair template (HDRT) and 110ng PCR product delivering the single guide 
RNA (sgRNA). Details of the sgRNA and HDRT combinations to generate each cell 
line are listed in Table 3. 24hr post-transfection, medium was exchanged for 
medium containing blasticidin at 25mg/mL for selection of cells with the pIB_Cas9 
plasmid, where they remained under selection for 3 days. After 3 days, medium was 
exchanged for fresh medium without antibiotics and cells were recovered for a 
further 3 days before splitting and transferring to a new tissue culture flask, taking a 
sample for PCR to confirm stable integration of the tag at the targeted locus after 
the plasmid should have been lost. Primer sequences are listed in Appendix Table 
20.   
 
Table 3 Combinations of single guide RNA (sgRNA) and homology directed repair 
template (HDRT) transfected and the resulting cell lines generated 
 sgRNA template  HDRT Cell line  
1 dU62 promoter-dPIAS_sgRNA3_IDT pMT_PIASNter_V5_HDRT PIAS-N-V5  
2 dU62 promoter-dPIAS_sgRNA4_IDT pBlue_PIASC_V5_HDRT PIAS-C-V5 
3 dU6.2_ADD1_sgRNA1_IDT pMT_ADD1_HA_HDRT ADD1HA 
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3.2.7 CRISPR/Cas9 transfection for gene destruction  
S2 cells were co-transfected with 190ng pIB_Cas9_CD4_Blast and 110ng PCR 
product delivering the guide RNA. Knockdown was assessed by estimating the 
percentage of S2 cells transfected by immunofluorescsnce (IF) and, after 
expansion, western blotting for the protein of interest in knockdown and wild-type S2 
cell lysate loaded on SDS-PAGE in equal quantities as assayed by Bradford. 
 
3.2.8 Generation of S2 cell conditioned medium  
On day one, S2 cells were plated at a density of 3x106cells/mL. On day two 
,medium was exchanged and on day three, S2 growing at exponential rates were 
harvested and the supernatant collected by centrifugation at 300 x g for 10min. This 
medium contains growth factors secreted by healthy S2 cells. Supernatant was 
passed through a 0.22µM filter to ensure removal of any cellular material.  
 
3.2.9 S2 cell cloning  
Cells were plated in conditioned medium at a low density in 96-well plates, covering 
a range of dilutions, aiming for single cells. After one week, colonies of more than 20 
cells were picked and placed in a fresh well of conditioned medium in a 96-well 
plate. At this stage, clones were PCR screened for insertion of the CRISPR tag and 
those containing the inserted tag were expanded. Endogenously tagged cell lines 
were validated by PCR, IF and western blot then used for IP. 
 
3.3 Drosophila melanogaster husbandry and timed embryo collection  
Wild-type ORER flies were raised at 25°C on standard cornmeal medium for the 
duration of the study. For harvesting of embryos, newly emerging flies were 
collected 1-2 days post-hatching and set in cages with the number of females 5:1 
times more than males. Cages were generated from grape agar plates 
supplemented with a dollop of yeast paste. After overnight acclimatization, grape 
plates with fresh yeast were changed at regular intervals in the following schedules 
to collect as many embryos as possible.  
 
A) twice a day ((changed at 07:00 to collect at 11AM and 14.00) (1-3hour mixed 
embryos)) 
B) every hr from 14:00 to 19.00 (the best time for synchronised collection) 
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C) the plate changed at 06:00, 07:00 and 08.00 with the 07:00 plate left until 
19.00 to obtain 12hr embryos.  
 
The first plate of the day was discarded. For the duration of the synchronised 
embryo collection period, 6 cages were set up and cages were discarded after 4 
days and fresh cages set up with newly emerged flies. All cages contained 3-7-day-
old females. Plates were stored at 4°C and processed in batch. Embryos laid on 
grape agar plates were collected by washing grape-agar plates with embryo wash 
buffer and scrapping with a paintbrush into baskets sitting in embryo wash buffer. 
10g of embryos were dechorionated in 50% sodium hypochlorite for 3-5min, 
(observing by stereomicroscope when the antlers disappeared), and thoroughly 
washed under flowing tap water for at least 1min to remove the sodium hypochlorite. 
Processing was continued for protein extraction (section 3.4.1) or fixation and 
immunofluorescence (section 3.4.12). 
 
3.4 Protein protocols 
3.4.1 Drosophila embryo extract  
Dechorionated embryos were placed in 500µL embryo extraction buffer at 4°C and 
homogenized. The homogenate was centrifuged 3x at 20000rpm for 3min at 4°C, 
each time removing the upper lipid layer. The supernatant was retained and 
separated from yolk and cellular debris (adapted from Fromental-Ramain C, 
2017132).  
 
3.4.2 Protein extract from S2 cells using RIPA buffer 
Cell pellets were washed twice in PBS, resuspended in 50μL RIPA buffer, incubated 
on ice for 30min and spun at 180000 x g for 10min. The supernatant contains the 
solubilized protein, 6x LB was added to give final 1x LB and boiled for 5min at 95°C.  
 
3.4.3 Nuclear extract from S2 cells 
S2 cells harvested from one T175mL flask were washed twice in cold PBS, counted 
and 1x107cells resuspended in 400μL cell lysis buffer. The cells were then 
incubated on ice for 10min, passed through a 26.5G needle 12 times and incubated 
on ice for a further 10min. At this stage 20μL (5% total protein) for whole-cell extract 
(WCE) could be taken. The extract was then centrifuged at 500 x g for 5min to pellet 
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nuclei. The supernatant containing the cytoplasmic fraction was removed. Nuclei 
were resuspended in 100μL cell lysis buffer and washed once. After removal of 
supernatant, nuclei were resuspended in benzoase buffer and incubated on ice for 
1hr, flicking the tubes occasionally. 5μL (5% total protein) was taken as a sample for 
nuclear extract. NaCl was added to final concentration 500mM and incubated for 
30min on ice. Samples were centrifuged at 18000 x g at 4°C for 10min. Supernatant 
was transferred to a new tube and was quantified using a Bradford assay containing 
chromatin associated proteins. 
 
3.4.4 Chromatin release assay using sequential NaCl extraction 
S2 cells harvested from T175mL flasks were washed twice in cold PBS, counted 
and 1x107cells resuspended in 400μL cell lysis buffer, washed once and 
resuspended in cell lysis buffer containing 0.1M NaCl and 0.1% (v/v) Triton-X100, 
gently flicked then incubated on ice for 5min. Cells were centrifuged at 8000 x g for 
2min, and the supernatant containing the soluble sample was transferred to a new 
1.5mL Eppendorf tube and the insoluble sample was resuspended in 400μL cold 
lysis buffer. Incubations were then repeated with buffers containing 0.1% Triton-
X100 and sequentially increasing NaCl concentrations of 0.2M, 0.4M, 0.5M, 1M and 
2M. After the final incubation, the cell pellet was re-suspended in 100μL cell lysis 
buffer with no added NaCl. 2x SDS Loading Buffer was added to all samples and 
the cell pellet followed by incubation at 95°C for 5min. Samples were analysed by 
SDS-PAGE and western blotting. 
 
3.4.5 Protein quantification by Bradford Assay 
For Bradford assays (Biorad, 5000006), dye was mixed with MQ water at a ratio of 
1:4 and filtered through Whatman paper. The dilution was kept at RT. Bovine Serum 
Albumin (BSA) (Fisher Scientific) standards were prepared by dissolving 2mg BSA 
in 1mL in PBS. This stock of 2mg/mL was serially diluted, first transferring 100μL 
into 1mL of diluted Bradford then pipetting up and down 10 times between each 
transfer. Protein samples were incubated with Bradford for 5min at RT before 
determining the A595 reading on a spectrophotometer. A595 readings for standards 
were used to plot a standard curve of concentration vs A595. The protein 
concentration in samples was determined by comparison of A595 to the standard 
curve.  
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3.4.6 Immunoprecipitation (IP) 
After protein quantification, for each IP, 200μg of nuclear extract was diluted in high-
salt buffer to a volume of 100μL and brought to 500μL with IP buffer. 25μL (5% or 
7.5μg) of diluted nuclear extract was kept on ice or at 4°C for the duration of the IP 
to act as input. 
 
To couple antibody to beads, 3μg antibody was added to 30μL of either Protein A 
Dynabeads™ (Life Technologies) for rabbit antibodies or Protein G Dynabeads™ 
(Life Technologies) for sheep antibodies in 0.01%Tween-PBS and rotated for 10min 
at RT. Beads were then washed twice with 0.01%Tween-PBS and once with IP 
buffer. Alternatively, for HA and V5 IPs, coupled resins were purchased, Anti-V5 
agarose affinity gel (Sigma-Aldrich) and Pierce™ Anti-HA Magnetic Beads (Thermo 
Fisher Scientific). These were first washed in 0.01%Tween-PBS then washed and 
equilibrated in IP buffer before the nuclear lysate was added.  
 
Antibody coupled beads were added to diluted nuclear lysate and incubated at 4°C 
on a rotator for 2hr. Beads were washed 3 times in 1mL IP wash buffer, rotated for 
10min at 4°C on an overhead rotator and then washed another 3 times in IP wash 
buffer. After a final wash and complete removal of IP wash buffer, beads were 
resuspended in 30μL 1x LB and boiled at 95°C for 5min. 5μL 6x SDS-buffer was 
added to the input and boiled at the same time as boiling the beads for elution of 
immunoprecipitated material. 
 
3.4.7 SDS-PAGE protein analysis  
Protein samples were denatured in 1x SDS sample buffer for 5min at 95°C. Proteins 
were resolved through Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). For mass spectrometry, protein samples were denatured in 1x LDS. 
 
6 and 8 % SDS-PAGE gels, depending on desired resolution of protein sizes, were 
prepared using the Bio-Rad system. Gels were run at 140V through the stacking, 
after which the voltage was increased to 200V and run until the dye front left the gel. 
Novex™ 4-20% Tris-Glycine Mini Gels were used to resolve all proteins on a full-
length gel, assembled in XCell SureLock™ Mini-Cell (Thermo Fisher Scientific) and 
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run at 200V for 60min in 1x Novex™ Tris-Glycine SDS Running Buffer. For mass 
spectrometry, protein samples were run on NuPAGE™ 4-12% Bis-Tris Protein 
precast SDS-PAGE gels (Life Technologies) in 1x NuPAGE® MES Running Buffer 
(Life Technologies) through the stacking. 
 
Either a 180 kDa PageRuler™ Prestained Protein Ladder (Thermo Fisher Scientific) 
or a 250 kDa Color-coded Prestained Protein Marker, Broad Range (CST) were 
used to estimate molecular weights.  
 
3.4.8 Coomassie stain and Instant BlueTM 
After SDS-PAGE, gels were placed in dishes, washed briefly in MQ water and 
Coomassie stain was added to cover the gel. Gels were microwaved for 30s and 
rotated overnight to enhance the stain. Gels were then washed 3x10min in MQ 
water. For gels to be used for mass spectrometry, the gel was washed 3x10min in 
MQ and InstantBlue™(Expedeon) was added for 1hr, followed by 3x10min washes, 
before taking an image of the gel and/or extracting bands.  
 
3.4.9 Silver stain 
Silver stain was performed using the SilverQuest™ Silver Staining Kit (Invitrogen) 
following the manufacturer’s instructions. 
 
3.4.10 Western blot  
After SDS-PAGE, proteins were transferred to Hybond® ECL™ nitrocellulose 
membranes (GE healthcare) by wet blotting using the Bio-Rad system by transfer in 
a Mini Trans-Blot Cell® at 200mA for 2hr. Following transfer, membranes were 
blocked in blocking buffer for 1hr at RT. The membrane was washed 3x5min in 
PBS-Tween20 0.1%  and then incubated with primary antibody diluted in blocking 
buffer (see Appendix Table 18 for concentrations) overnight at 4°C. The membrane 
was then washed 3x5min in PBS-Tween20 0.1% and incubated with secondary 
antibody diluted in blocking buffer (see Appendix Table 19 for concentrations) for 
45min at RT. The membrane was then washed in PBS-Tween20 0.1% and 
developed using 990μL luminol solution and 10μL enhancer solution for standard 
western blots. For increased sensitivity of detection, SuperSignal™ West Femto 
Maximum Sensitivity Substrate (Thermo Fisher Scientific) was used. Western blots 
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using HRP coupled secondary antibodies were imaged on a ChemiDoc™ Touch 
Imaging System (Biorad). Quantification was performed using the Quantity Tools 
Relative protocol in ImageLab (Biorad). The membrane was then washed in PBS-
Tween20 0.1% and stored. 
  
For LICOR antibodies, washes in PBS-Tween20 0.1% were increased to 10min 
after secondary incubation and the final wash performed in PBS without detergent. 
Membranes were visualized on the Licor Odyssey CLx instrument.  
 
3.4.11 Ponceau 
After proteins were transferred from SDS-PAGE gels to a membrane, prior to 
blocking, the membrane was incubated in Ponceau at RT for 5min and was washed 
3x3min in 0.01%Tween-PBS to visualize protein bands. 
 
3.4.12 Immunofluorescence and microscopy 
For S2 cells, cells growing in exponential phase were resuspended and 100μL was 
pipetted onto poly-Lysine coated glass-slides. Poly-Lysine coated glass-slides were 
prepared in advance of the immunofluorescence by incubating slides (Corning) in 
10% Poly-L-Lysine for 30min in a Coplin jar, then were air-dried overnight. S2 cells 
were left to settle for 10min in a wet chamber and were then fixed in IF fixative for 
10min at RT. Slides were then washed in PBS-Triton 0.1% for 5min at RT and then 
blocked with Image-iT® FX signal enhancer (Thermo Fisher Scientific) for 30min at 
RT. Primary antibodies were diluted in goat antiserum (Life technologies) and 
incubated with the cells for 2hr at RT in a wet chamber or overnight at 4°C. Slides 
were washed 3x5min in PBS-Triton 0.1% vertically in a Coplin jar. Fluorescently 
labelled secondary antibodies were diluted in goat serum and incubated with the 
cells for 45min at RT in a wet chamber. Slides were then washed 3x5min in PBS-
Triton 0.1%. The DNA was stained by adding DAPI solution and incubated for 5min 
at RT. Following a 2min wash in PBS-Triton 0.1%, coverslips were mounted using 
SlowFade® Gold Antifade Solution (Invitrogen) and sealed with nail polish. Images 
were acquired on a DeltaVision RT Elite Microscope and imported into ImageJ to 
generate overlays and then deconvoluted using softWoRx Imaging workstation 
(Applied Precision). 
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All pictures shown are quick projections of all stacks. Per image, 30-60 stacks with 
0.2µm increments were taken with a 100x oil-immersion objective and a CoolSnap 
HQ Monochrome camera (Photometrics). 
 
For dechorionated Drosophila embryos, embryos were scraped into 1.5mL 
Eppendorfs containing heptane:methanol in equal ratios pre-chilled at -20ºC. 
Eppendorfs were shaken vigorously for 60s until embryos sank to the bottom of the 
Eppendorf and the vitelline membrane was removed. Embryos were washed once 
with ice cold methanol and stored at -20°C for at least 12hr. Embryos were 
rehydrated in 3x10min washes in PBS-Triton 0.05% at RT. Embryos were then 
blocked in PBTA for 1hr at RT and then transferred to PCR tubes. Primary 
antibodies in PBTA were added (for concentrations, see Table 18) and rotated 
overnight at 4°C. The following day, the embryos were washed 3 times in PBS-
Triton 0.05% and secondary antibodies (see Table 19 concentrations) in PBTA were 
added. Then the PCR tubes were rotated for 1hr at RT, covered in foil to maintain a 
light barrier. Embryos were washed 3 times in PBS-Triton 0.05% and DAPI solution 
was added for 5min. After a final wash in PBS-Triton 0.05%, embryos were 
resuspended in 30μL SlowFade® Gold Antifade Solution (Invitrogen) and were 
transferred to slides. A coverslip was placed over the embryos and the slide sealed 
with nail polish. Slides were left to air dry and then embryos were visualized using a 
Zeiss LSM 880 laser scanning confocal equipped with an Airyscan detector (Zeiss 
UK, Cambridge). Either a Plan Apochromat 20x/0.8 objective or an oil immersion 
Plan Apochromat 40x/1.30 objective was used for enhanced resolution. 
 
Firstly, the top and bottom of each embryo was marked, and a capture was taken in 
the DAPI channel of the middle section to determine the stage of the embryo. For 
timed embryo collection, 100-120 embryos were staged in three independent 
experiments. Plotted are the stage distributions from three experiments. Error bars 
show the mean and standard error of mean (SEM), generated using GraphPad 
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3.5 Mass Spectrometry Sample Preparation and Analysis   
3.5.1 Mass spectrometry preparation: in-gel digest and StageTip purification  
InstantBlue™ stained protein bands in SDS-PAGE gels were excised and cut into 
1mm3 sized pieces using a scalpel. Gel pieces were placed in a microcentrifuge 
tube, washed with 50mM ammonium bicarbonate (ABC) and 50mM acetonitrile 
(ACN), and shaken for 30min at 37°C. Washes with 50mM ABC/50mM ACN were 
carried out twice more. Proteins were reduced in 10mM DTT/50mM ABC whilst 
shaking for 30min at 37°C, followed by a wash with 50mM ABC and a second wash 
with 50mM ACN. Proteins were then alkylated in 55mM iodoacetamide in 50mM 
ABC for 20min at RT in the dark. After this incubation, the gel-pieces were washed 
in 50mM ABC/50mM ACN then incubated on ice in trypsin buffer for 15min, followed 
by digestion at 37°C overnight. Digestion was stopped with 1% trifluoroacetic acid 
(TFA) and spun through StageTips (Rappsilber et al., 2003306). 0.1% TFA in 80% 
ACN was added to the gel pieces for 5min at RT and the supernatant concentrated 
(concentrator 5301 [Eppendorf AG, Hamburg, Germany]). 100μL of 0.1% TFA was 
added to the dried peptides and passed through the stage tip. 
 
3.5.2 MALDI-TOF 
The saturated matrix solution was generated from: 10mg a-cyano-4-
hydroxycinnamic acid (CHCA), 400μL ddH2O, 100μL TFA and 500μL acetonitrile, 
mixed and sonicated for 5min in a water bath sonicator. The matrix solution was 
centrifuged at 5000rpm for 1min to pellet undissolved material. Peptides were eluted 
from StageTips in 2μL matrix solution. 0.5μL peptide solution was mixed with 0.5μL 
CHCA MALDI matrix and spotted onto a stainless steel MALDI sample plate and air 
dried to co-crystalize.  
 
MALDI-ToF peptide mass fingerprinting (PMF) was performed on an MALDI TOF-
TOF Bruker UltrafleXtreme in the Scottish Instrumentation and Resource Centre for 
Advanced Mass Spectrometry (SIRCAMS) facility. Fragment mass was calibrated 
from a peptide calibration standard (Bruker) and mass peaks were analysed in 
DataAnalysis software 4.4 (Bruker). The Mascot server 
(http://www.matrixscience.com/server.html) was used to identify protein fragments 
and to assign a protein identity.  
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3.5.3 Mass Spectrometry (MS) LC-MS2 analysis  
The digested peptides were run on a Q Exactive Hybrid Quadrupole-Orbitrap Mass 
Spectrometer or an Orbitrap Fusion Tribrid Mass Spectrometer by Dr. Christos 
Spanos (Mass Spectrometry facility). Xcalibur was used for quality control of elution 
spectra.  
 
3.5.4 Peptide identification and quantification using MaxQuant 
MaxQuant version 1.6.3.4 with the Andromeda algorithm was used for analysis of 
raw data for identification of proteins and post-translational modification sites. 
Peptides were searched against the Drosophila melanogaster reference proteome 
(3AUP000000803release 02.2015), downloaded from UniProt 15.11.2018.  
 
For mapping of peptides against a reference proteome containing one entry per 
gene, the UP000000803 7227 DROME(https://www.ebi.ac.uk/reference_proteomes) 
was used. Label-free quantification (LFQ) applied. Oxidation on methionine, 
carbamidomethyl on cysteine and acetyl on the N-terminus of proteins were 
included as fixed modifications. 20ppm of mass tolerance was applied. Protein 
identifiers were defined by UniProt (https://www.uniprot.org) and converted into 
gene names.  
 
3.5.5 Analysis of mass spectrometry data using Perseus 
Perseus, (version 1.3.0.4) downloaded 13.06.2018 (https://maxquant.net/perseus/), 
was used to determine the protein abundance in a quantitative proteome analysis 
using LFQ analysis. LFQ intensity expression values were pre-processed to filter out 
hits with protein identifications classified as only identified by site, reverse and 
contaminant. The LFQ expression values were log2 transformed, categorized into 
groups and filtered for valid values. Protein hits identified in a minimum of two out of 
three biological replicates and by two or more peptides were classed as interactors.  
 
Three types of quality control were performed on each dataset. Principal component 
analysis (PCA) was performed on LFQ intensity expression values from a randomly 
selected set of protein hits before transformation. This identified variations between 
the data in different conditions. The participation of the principal components in 
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explaining the data variance in terms of percentage is shown on the x- and y-axis of 
PCA plots. Multi scatter plots of log2 transformed LFQ intensity values were 
generated to visualise the degree of correlation between samples, controls and 
replicates. The Pearson’s correlation coefficient was calculated for each dataset in a 
pairwise comparison. A value between 0.8 and 1 shows high correlation, 0.6-0.8 
weak correlation and 0.3-0.5 no correlation. Histograms were generated from LFQ 
intensity expression values to ensure data were normally distributed.  
 
Missing values were imputed from normal distribution. The imputation function 
calculates the width and center of the distribution and shrinks the distributions to 
have a set standard deviation and equal variance within the groups of replicates. A 
two-tailed two-sample Student’s T-test was used to determine whether the 
difference between the means of the LFQ intensity expression values between two 
groups (e.g. PIAS IP and IgG IP or PIAS IP -NEM and PIAS IP +NEM) was 
significant. The negative log p-value and the log2 difference between the group 
means was plotted as a volcano plot. The threshold for significance of changes in 
protein abundance between the different groups (assigned p-value) was calculated 
using a permutation-based false discovery rate (FDR) value of 0.05 and minimal fold 
change value 0.1 or 2.0 (values stated in figure legends).  
 
For comparison of protein interactors in conditions with and without NEM, the mean 
LFQ value of bait protein was calculated for three +NEM and three -NEM samples. 
LFQ values for all other interactors were then normalised to the LFQ of the bait. 
Scatter plots of log2 transformed LFQ values were generated in Perseus after 
removing proteins identified by more than one peptide in IgG controls and filtering 
for proteins identified by two or more peptides in two out of three replicates.  
 
3.5.6 GO terms analysis  
A protein analysis through evolutionary relationships (PANTHER) 
overrepresentation test (http://pantherdb.org) against the complete GO Biological 
Process annotation dataset, GO-Slim Biological Process annotation dataset, GO-
Slim Molecular Function annotation dataset, GO-Slim Cellular Component 
annotation datasets and the Reactome pathways annotation dataset for Drosophila 
melanogaster was performed using Benjamini-Hochberg FDR. Functional 
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classification by Protein Class was also performed. For GO term confirmation, 
FlyMine (flymine.org)307 was used. FlyMine is an integrated database of genomic, 
expression and protein data for Drosophila, Anopheles and C. elegans. FlyMine also 
has a set of tools for conversion of protein IDs to gene IDs.   
 
3.5.7 IntAct and Cytoscape for network analysis  
Lists of Proteins identified by two or more peptides in an IP-MS were input as a 
query into the IntAct protein database (https://www.ebi.ac.uk/intact/). The network 
was exported for visualisation in Cytoscape (v.3.7.1) downloaded 03.01.2019 
(http://cytoscape.org). 
 
3.6 Protein expression and purification 
3.6.1 Preparation of electro-competent cells stocks  
When generating stocks of bacterial cells, streak plates on LB agar no-selection 
(without antibiotic), from existing glycerol stocks were made and incubated at 37°C 
overnight. A colony was picked and grown in 10mL LB broth shaking at 200rpm 
overnight at 37°C. The following day, the starter culture was added to 500mL of LB 
broth in a 2L flask and grown until the OD600 was 0.5. The culture flask was then 
cooled in the cold room on ice for 30min. After cooling, the culture was transferred 
into centrifuge tubes and the cells were pelleted at 4000 x g for 15min at 4°C in a 
JLA 16.25 rotor. The supernatant was discarded and the pellet of cells was 
resuspended in 500mL of 10% glycerol, was centrifuged, and was then re-washed 
in 250mL 10% glycerol, was centrifuged, and was resuspended in 20mL of 10% 
glycerol. After decanting the supernatant, the pellet was resuspended in 6mL of 
10% glycerol. 50μL aliquots were prepared in pre-chilled Eppendorfs, snap frozen in 
liquid nitrogen and stored at -80°C until needed.  
 
3.6.2 Preparation of EMBacY selection plates and competent cells stocks  
EMBacY selection plates were generated by adding 1x Kanamycin, Tetracycline, 
Carbenacillin and Gentamycin (concentrations in the materials section, Appendix 
Table 17 Antibiotic stocks) to melted LB-agar (<55°C) and poured into petri dishes. 
Once solidified, and on the day of use, plates were supplemented with 0.5mM IPTG 
(10μL of 1M stock) and 40μg/mL X-gal (100μL of 20mg/mL stock) by pipetting and 
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spreading onto the surface of the plate. Plates were allowed to dry for 30min at 
37°C.  
 
When generating a new stock of EMBacY cells, EMBacY cells from existing glycerol 
stocks were streaked onto an EMBacY selection plate and incubated for 16-20hr at 
37°C. A colony was picked and grown in 5mL LB broth supplemented with 1x 
Kanamycin, Tetracycline, Carbenacillin and Gentamycin, shaking at 200rpm 
overnight at 37°C. The following day, the starter culture was diluted 1:200 into 
250mL of pre-warmed LB (37°C) with 20mM MgSO4. Cultures were grown until the 
OD600 was 0.6, then the culture was cooled in the cold room on ice for 10min. After 
cooling, the culture was transferred into centrifuge tubes and spun at 4000 x g for 
5min at 4°C in a JLA 16.25 rotor. Supernatant was discarded and the cell pellet 
resuspended by gentle pipetting to homogenize the solution in 100mL of cold TFB1. 
After 5min on ice, cells were pelleted by centrifugation at 1400 x g at 4°C for 10min. 
The supernatant was discarded and the pellet resuspended in 10mL TFB2. After 
15min on ice, the cells were aliquoted into pre-chilled Eppendorfs, snap frozen in 
liquid nitrogen and stored at -80°C until needed.  
 
3.6.3 Sf9 cell culture  
Sf9 cells were obtained from Thermo Fisher Scientific (11496015). Upon thawing, 
the cells were expanded and maintained at a density between 0.5x106cells/mL and 
4x106cells/mL in Sf-900™II SFM (Gibco) in suspension culture, shaking at 200rpm at 
27°C. Growth was monitored by taking a cell count at each split and plotting growth 
curves over time. 
 
3.6.4 Sf9 cell freezing and thawing 
Exponentially growing cells with viability above 95% were frozen at a density of 
1x107cells/mL in Bambanker Cell Freezing Medium (Anachem) in aliquots of 1mL 
suspension per cryovial and stored at -80°C before being transferred to liquid 
nitrogen for long-term storage. To recover stocks from liquid nitrogen, one vial of 
cells was rapidly thawed in a 37°C water bath and immediately added to 20mL  
Sf-900™II SFM (Gibco) pre-warmed to 27°C and transferred to a shaking incubator 
at 200rpm for 3 days. On the third day, a 10μL aliquot was taken to assess viability 
by trypan blue stain. At 4 days, a second 10μL aliquot was taken and the growth 
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rate of the Sf9 cells determined. Sf9 cells were then either split to 0.5x106cells/mL 
for maintenance or the Sf9 cells were pelleted and the medium exchanged.  
 
3.6.5 Generation of viral stocks 
For generation of viral stocks, cells were plated at 1.8x106cells in 15mL Sf9II 
medium in a T75 flask and allowed to settle for 30min. Cells were transfected with 
40µg of bacmid DNA in 400µL of Sf-900 II medium. 16μL X-tremeGENE™ HP DNA 
Transfection reagent (Roche) was pipetted into the DNA-medium mix and incubated 
for 30min at RT then added to S2 cells in a dropwise manner. Flasks were 
incubated at 27°C for 36-48hr. Yellow-fluorescent protein (YFP) expression was 
visualized by placing flasks under a green-fluorescent protein (GFP) filter on a 
fluorescence microscope to confirm successful transfection through expression of a 
tag on one of the bacmid plasmids. Once more than 90% of the population of cells 
expressed YFP (usually between 4-7 days), the supernatant (containing virus) was 
collected. This virus stock is designated as the V0. V0 was filtered through a 0.22µm 
filter and stored wrapped in foil at 4°C. 
 
3.6.6 Small-Scale test expression in Sf9 cells 
After harvesting V0, the Sf9 cells 4-7 days post-transfection were resuspended in 3 
mL of Sf-900 II medium and harvested. The cell pellet was resuspended in 2mL 
GST purification buffer or HIS purification buffer (low imidazole), depending on the 
tag, and was sonicated using a Branson Digital Sonifier® (30s on/30s off at 35% 
amplitude for 10 cycles). The cell solution was centrifuged, and the supernatant 
retained as the soluble fraction. 10μL soluble (S) fraction was taken and added to 
10μL of 2x SDS sample buffer. 100μL of 2x SDS sample buffer was added to the 
pellet for the insoluble fraction (IS). The soluble fraction was added to 30μL Pierce™ 
Glutathione Agarose (Thermo Fisher Scientific, cat. No. 16100), rotated at 4°C for 
1hr then centrifuged to pellet the resin. The flow through was retained and a 10μL 
flow-through (FT) was taken and added to 10μL of 2x SDS sample buffer. The resin 
was washed three times in GST purification buffer or HIS purification buffer (low 
imidazole), depending on the tag, and 30μL 1x SDS sample buffer was added to the 
resin after the final wash. All samples were boiled for 5min at 95°C. SDS-PAGE 
followed by transfer to western blot was carried out, loading the wild-type, SOL, 
INSOL, PD and FT fractions to determine: firstly, if the protein was expressed; 
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secondly, whether it was soluble; and thirdly, if it was successfully pulled-down. 
Western blots were probed with antibodies against the tags (GST or HIS) and, if 
available, antibodies to the protein being expressed.  
 
3.6.7 Amplification of baculovirus  
Two 50mL cultures of Sf9 cells at a density of 2x106cells/mL were each infected with 
5mL V0 and grown at 27˚C in a shaking incubator for 3 days. After 3 days the 
supernatant was harvested as V1 and filtered through a 0.22µm filter and stored 
wrapped in foil at 4˚C. A third viral stock, V2, with increased titre was generated by 
adding 5mL of V1 into 100mL of Sf9 cells at 2x106cells/mL, grown for 3 days and 
the supernatant harvested and filtered through a 0.22µm filter and stored wrapped in 
foil at 4˚C. After 3 rounds of viral amplification, viral supernatant had high enough 
infectivity for large scale infection of Sf9 cells for protein expression to produce 
enough protein for purification as judged by expression levels on Coomassie-
stained SDS-PAGE. 
 
3.6.8 Large-scale protein expression in Sf9 cells 
Two 2L flasks each containing 800mL of Sf9 cells at a density of  
2x106cells/mL were infected by adding 16mL of V2 (1:50 virus:medium ratio).  
Sf9 cells were incubated for 2-3 days, monitoring the fluorescence and viability. 
Once YFP expression, expressed from the bacmid, was judged to be more than 
85%, with the viability of the cells more than 90%, cells were harvested by 
centrifugation at 300 x g for 10min at 4°C. The cell pellet was snap frozen in liquid 
nitrogen and stored at -80˚C. 
 
3.6.9 Protein purification of GST-ADD1-RA 
Sf9 cell pellets containing expressed GST-ADD1-RA were thawed in cold GST 
purification buffer (supplemented with 20μg/mL DNAse, PEFA bloc and 1x Roche 
cOmplete® EDTA-free Protease Inhibitors). Mg2+ was included in the buffer for 
stabilisation by providing divalent cations, DTT included to reduce oxidation damage 
and NaCl to maintain the ionic strength of the buffer. The cell suspension was then 
sonicated using a Branson Digital Sonifier® (30s on/10s off at 70% amplitude for 4 
cycles). The suspension was transferred to centrifuge tubes and spun at 10000 x g 
for 10min at 4°C. The clarified lysate was incubated with 5mL pre-washed and 
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equilibrated Pierce™ Glutathione Agarose (Thermo Fisher Scientific, cat. No. 
16100) for 2hr rotating at 4°C. The agarose was washed 5 times with 40mL GST 
purification buffer. Proteins were eluted from the agarose in 5 washes with GST 
purification buffer with glutathione. 250μL of 3C Protease (2mg/mL, communal stock 
purified from pGEX 3C made in the Cook laboratory) was added and incubated 
overnight, rotating at 4°C. The following day, the protein mix was concentrated using 
a Sartorius Vivaspin® 20 with 10,000 kDa molecular weight cut-off (MWCO) and run 
on size-exclusion chromatography to separate ADD1 from 3C-GST and free GST. 
 
3.6.10 Protein purification of HIS-XNP-RA 
Sf9 cell pellets containing expressed HIS-XNP-RA were thawed in cold HIS 
purification buffer (low imidazole) (supplemented with 20μg/mL DNAse,  
Pefabloc® SC (Roche) and 1x Roche cOmplete® EDTA-free Protease Inhibitors). 
The cell suspension was then sonicated using a Branson Digital Sonifier® (30s 
on/10s off at 70% amplitude for 4 cycles). The suspension was transferred to 
centrifuge tubes and spun at 10000 x g for 10min at 4°C. The clarified lysate was 
incubated with 5mL pre-washed and equilibrated HIS-Select® HF Nickel Affinity Gel 
slurry (Sigma, cat. No. P6611-25ML) for 2hr rotating at 4°C. An aliquot was kept as 
input. An aliquot of the flow- through was kept and the slurry was washed 5 times 
with 40mL of HIS Wash Buffer. Proteins were eluted from the HIS slurry in 5 washes 
with HIS purification buffer (high imidazole) and aliquots were taken and analysed 
by Western Blotting. The protein mix was concentrated using a Sartorius Vivaspin® 
20 with 10,000 kDa molecular weight cut-off (MWCO) and run on size-exclusion 




74   
 
Figure 3–1 Overview of recombinant protein constructs and associated information 
(A) Schematic of ADD1 and XNP tagged proteins. The 3C site for protease recognition and the position of the tags are marked. (B) The table shows key 
parameters generated by ExPASY (http://expasy.org) after input of the amino acid sequence, which are key for designing purification strategies and for 
quantification of protein generated.  In bold are the predicted molecular weights for tagged and untagged ADD1 and XNP. 
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3.6.11 Size-exclusion chromatography  
All buffers, water, and 20% ethanol, were filtered through 0.22µm membrane 
(Millipore) and degassed prior to use on ÄKTA systems. Concentrated protein 
samples and nuclear extracts were centrifuged at 10000 x g for 10min at 4°C to 
clear particulates before injecting the protein onto a Superdex 200™10/300 GL or a 
Superose 6 10/300 GL column (GE Healthcare). Columns were pre-equilibrated in 
either HIS purification buffer (low imidazole), GST purification buffer or nuclear 
extraction buffer, depending on the protein being purified or experiment being 
performed. All equipment was provided by the Edinburgh Protein Production Facility 
(EPPF) and all experiments were performed in the facility. The flow rate was set at 
1mL/min with 0.5mL fractions collected. Data points were exported from the 
UNICORN software and the A280 and A260 were plotted using GraphPad Prism 6 
(GraphPad Software Inc.). 
 
3.6.12 Final protein check and generation of purified stocks  
1μL 6x SB was added to 5μL taken from each fraction and boiled for SDS-PAGE 
analysis. The concentration of protein eluting in peaks was calculated in the 
UNICORN software and corroborated by measuring the A280 by NanoDrop 1000 
Spectrophotometer (NanoDrop) by using the expected molecular weight and 
calculated extinction coefficient, assuming all cysteine resides were reduced. 
Samples were blanked against the same aged buffer as present in the eluted 
protein sample fraction. Based on SDS-PAGE results, fractions containing the 
protein of interest were combined and concentrated to 1mg/mL using pre-
equilibrated Sartorius Vivaspin® 20 with 10,000 kDa molecular weight cut-off 
(MWCO). Aliquots of protein were snap frozen in liquid nitrogen and stored at -80°C.  
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3.6.13 Dynamic light scattering 
Dynamic light scattering was performed on a Zetasizer Auto Plate Sampler (Malvern 
Panalytical) using 384 polypropylene plates (Corning) to measure particle size in 
suspension. 1mg/mL aliquots of protein (pre- and post-thawing) were centrifuged for 
10min at 14000 rpm and diluted to 0.5mg/mL in HIS purification buffer (low 
imidazole) or GST purification buffer depending on the protein being purified 
(varying salt concentration from 0.1-0.5M NaCl). Buffer without protein was used as 
a blank. 50μL (25μg) was loaded per well. Each sample was measured three times 
following standard operating procedures as part of the Zetasizer software. All 
analysis was performed using Zetasizer software. The software uses a distribution 
analysis algorithm to give a distribution of sizes based on the decay rates contained 
in the correlation function.  
 
3.6.14 Generation and testing of antiserum  
The ADD1 protein was concentrated and sent to Orygen antibodies (Edinburgh) in 
June 2018. One rabbit was immunized, injected four times, on days 0, 25, 53 and 
81, with four bleeds taken: one pre-immune serum, bleed one at day 32, bleed two 
at day 60, and a final bleed at day 88. Bleed two and three serum were tested by 
western blot and immunofluorescence. In September 2018 XNP protein was sent for 
immunization. Unfortunately, the company ceased operations in November 2018 
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Chapter 4 Identification of PIAS interactors in 
S2 cells  
 
4.1 Objective  
In this chapter, I present PIAS immunoprecipitation followed by mass spectrometry 
(IP-MS) from Drosophila S2 cells to identify components of the PIAS interactome. 
Newly available tools aided in the identification of PIAS interactors, notably, an 
affinity purified Drosophila anti-PIAS sheep antibody (a kind gift from Professor Ron 
Hay’s lab, University of Dundee). This antibody was raised against the PIAS-RE 
isoform that contains only the exons included in the PIAS-CORE, which are shared 
by all isoforms. In addition, advances in genome editing allowed PIAS to be tagged 
at its endogenous locus using CRISPR/Cas9. 
 
In addition to identifying general PIAS interactors, it was hypothesized that XNP 
would be a robust interactor of PIAS. With this in mind, the position of XNP and 
proteins associated with it are highlighted and used as a starting point to make 
sense of PIAS interactors in different experimental settings. 
 
4.2 Aims 
• To develop methods to isolate endogenous PIAS complexes from S2 cells to 
confirm or disprove that XNP is a main binding partner of PIAS 
• To identify and validate other endogenous PIAS interaction partners  
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4.3 Results 
4.3.1 Characterisation of the Drosophila anti-PIAS sheep antibody  
The Drosophila anti-PIAS sheep antibody recognises epitopes in the core region of 
PIAS, which is shared by all PIAS isoforms. This antibody had previously been 
demonstrated in Ron Hay’s lab to recognise two clusters of PIAS proteins on 
western blots and work in immunofluorescence on fixed cells. I obtained this 
antibody and tested it to probe western blots of lysates from cells fractionated into 
cytoplasmic, nuclear, chromatin associated and insoluble fractions (Figure 4–1). 
This confirms that PIAS is mostly in the nucleus with a portion of it chromatin 
associated, as previously described with a PIAS guinea pig antibody in S2 cells141. 
 
Figure 4–1 PIAS protein is concentrated in the nucleus 
1x107 wild-type S2 cells were fractionated into cytoplasmic, nuclear, chromatin associated 
fractions and 20% of each fraction loaded. Whole cell extract (WCE), the fractions and the 
insoluble pellet were analysed on 4-20% SDS-PAGE (Invitrogen) followed by western blot 
probed with Drosophila anti-PIAS sheep antibody or anti-H3 rabbit antibody.  
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The Drosophila anti-PIAS sheep antibody recognises PIAS isoforms that have 
predicted molecular weights between 57.9 and 70.3 kDa (see Figure 2–3). PIAS-
complexes can be isolated from lysate by size exclusion chromatography (Figure 4–
2). These separate over a range of volumes corresponding to complexes of more 
than 700 kDa to less than 67 kDa (Figure 4–2), demonstrating that PIAS proteins 
form part of different complexes in the cell.    
 
 
Figure 4–2 Resolution of PIAS-complexes by size exclusion chromatography 
Protein extract from S2 cells separated by Superdex 200 size exclusion chromatography 
were analysed on 4-20% SDS-PAGE (Invitrogen) followed by western blot probed with 
Drosophila anti-PIAS sheep antibody. Elution fractions from B5-C10 are marked. The 
expected size of proteins in different fractions is marked. 
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I tested the Drosophila anti-PIAS sheep antibody in immunoprecipitation 
experiments on S2 cell nuclear extract, demonstrating that it could enrich for PIAS 
complexes when coupled to Protein G Dynabeads™ and immunodeplete the extract 
(Figure 4–3). To control for non-specific interactions, the same concentration of 
affinity purified IgG sheep antibody coupled to Protein G Dynabeads™ was 
incubated with S2 cell nuclear extract, resulting in no PIAS in the 




Figure 4–3 Immunoprecipitation with anti-PIAS sheep antibody immunodepletes S2 
cell nuclear extract. 
Protein extracts were made from wild-type S2 cells. The cytoplasmic (Cy), nuclear extract 
(NE), IP with affinity purified anti-IgG sheep antibody coupled to Protein G Dynabeads™ 
(IgG), IP with anti-PIAS sheep antibody coupled to Protein G Dynabeads™ (P) and flow 
through (FT) from the IgG and P IPs were analysed on 4-20% SDS-PAGE (Invitrogen) 
followed by western blot probed with Drosophila anti-PIAS sheep antibody. PIAS is enriched 
in the PIAS IP and is not detected in the PFT lane. PIAS is not detected in IgG IP but is 
detected in the IgGFT lane. Loading 5% input (NE), 50% IP and 5% FT.  
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4.3.2 PIAS interacts with HP1a  
Su(var)2-10 (PIAS) has several published interactors including Su(var)205 (HP1a) 
(Table 4). PIAS IP followed by western blot with antibody against HP1a showed that 
PIAS co-immunoprecipitates this known target (Figure 4–4). 
 
Table 4 Published physical interactors of Su(var)2-10 (PIAS) 
Interactors downloaded from BIOGRID (https://thebiogrid.org). In bold is the interaction 
between Su(var)205 (HP1a) and Su(var)2-10 (PIAS) 
 
Interactor A Interactor B Experimental System Reference 
CG7054 Su(var)2-10 Two-hybrid Giot L (2003) 
gcm Su(var)2-10 Affinity Capture-Western Jacques C (2009) 
gcm Su(var)2-10 Two-hybrid Jacques C (2009) 
p53 Su(var)2-10 Affinity Capture-Western Pardi N (2011) 
p53 Su(var)2-10 Two-hybrid Pardi N (2011) 
spn-A Su(var)2-10 Two-hybrid Formstecher E (2005) 
ssx Su(var)2-10 Two-hybrid Giot L (2003) 
stumps Su(var)2-10 Two-hybrid Battersby A (2003) 
Su(var)2-10 CG8155 Two-hybrid Giot L (2003) 





Figure 4–4 PIAS and HP1a co-immunoprecipitate. 
Nuclear extracts were made from wild-type S2 cells. The input (IN), IP with affinity purified 
anti-IgG sheep antibody coupled to Protein G Dynabeads™ (IgG) and IP with Drosophila 
anti-PIAS sheep antibody coupled to Protein G Dynabeads™ (IP) were analysed on 8% 
SDS-PAGE followed by western blot probed with Drosophila anti-PIAS sheep antibody or 
anti-HP1a mouse antibody.  
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4.3.3 PIAS co-elutes with HP1a and ADD1 in size exclusion chromatography  
To identify PIAS interactors within PIAS-complexes, Drosophila embryo protein 
lysate was separated over a size exclusion chromatography column (Figure 4–5A).  
Proteins in the excluded (void) volume eluted before fraction B2, while everything 
else is in the separation phase (after B2). Proteins that elute between 12-15mL 
correspond to proteins with sizes 600-700kDa (Figure 4–5A). Known 
heterochromatin proteins were probed for, demonstrating that HP1a, ADD1 and 
PIAS co-elute (Figure 4–5C) and co-immunoprecipitate from the co-eluted fractions 
(Figure 4–5D) with a bias for longer isoforms of PIAS co-immunoprecipitating with 
ADD1 (Figure 4–5C). Interaction of PIAS with other binding partners, such as XNP, 
was not observed by western blotting (data not shown). In fraction B2 XNP did not 
co-immunoprecipitate with PIAS-ADD1 complexes. This is either because the 
interactions are weak and have been lost during processing, or PIAS-XNP forms 
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Figure 4–5 Size exclusion chromatography of Drosophila embryo lysate 
(A) Elution profile from Superose 6 gel filtration column, in yellow is the area of protein 
elution collected as fractions, after the void volume of the column. The three denser yellow 
stripes represent the three fractions, B2, B4 and B6. The expected size of complexes that 
elute at a given volume are marked. (B) 10% of sample from fractions B2, B4 and B6 were 
analysed on SDS-PAGE followed by western blot probed with anti-ADD1 rabbit antibody (top 
panel), anti-XNP rat antibody (second panel), anti-PIAS sheep antibody (third panel) and 
anti-HP1a mouse antibody (bottom panel) (C) IP with affinity purified anti-IgG sheep 
antibody coupled to Protein G Dynabeads™ (IgG) and IP with Drosophila anti-PIAS sheep 
antibody coupled to Protein G Dynabeads™ from fractions B2, B4 and B6 were analysed on 
4-20% SDS-PAGE followed by western blot probed with anti-ADD1 rabbit antibody (top 
panel) Drosophila anti-PIAS sheep antibody (middle panel) or anti-HP1a mouse antibody 
(bottom panel).  
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4.3.4 Characterisation of V5-PIAS-PE  
Experiments performed to characterise PIAS localisation and interaction partners in 
S2 cells involved induced expression of V5-PIAS-PE from cells transfected with a 
pMT-Pias9_V5 plasmid (the shortest isoform and closest to PIAS-CORE, Figure 2-
17). This results in higher than physiological PIAS levels in the cell (Figure 4–6). To 
quantify levels of PIAS proteins in wild-type cells and cells expressing V5-PIAS-PE, 
proteins were resolved on 8% SDS-PAGE, and were analysed by western blot 
probing with Drosophila anti-PIAS sheep antibody. Quantification of PIAS levels, 
normalising to the largest PIAS isoform in both the top and bottom cluster of PIAS 
proteins, demonstrated that there was approximately 40% more PIAS protein in the 
extract compared to endogenous levels. For the blot in Figure 4–6, the total intensity 
in lane 1 is 9.23 and for lane 3 is 12.83. The difference between these is 3.65. The 
percentage increase is 3.65/9.23*100= 39.5%. 
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Figure 4–6 Quantitative western blot of overexpressed V5-PIAS-PE  
(A) Nuclear extracts were made from wild-type Schneider S2 cells and S2 cells transfected 
with pMT-Pias9_V5 in the absence of NEM. Expression of V5-PIAS-PE was induced from 
the pMT-Pias9_V5 plasmid by addition of 200μM CuSO4 for 3 days prior to harvesting. Cell 
lysate was subject to V5 immunoprecipitation using anti-V5 agarose (Invitrogen). The input 
(IN) and immunoprecipitation (IP) from wild-type S2 cells (WT) and from Pias9_V5 
expressing S2 cells (P9-V5) were analysed on 8% SDS-PAGE followed by western blot, and 
probed with Drosophila anti-PIAS sheep antibody followed by detected with anti-IgG sheep 
HRP secondary antibody. (B) Western blot A with lanes and shared anti-PIAS bands marked 
in Image Lab™ (Biorad). (C) Relative front (Rf) (x-axis) and Intensity (Int) (y-axis) of lanes 1-
4 of the western blot in A and B. The western blot was performed by Dr. Manuella Marescotti 
in the Heun lab, quantified for the purpose of this thesis by myself. The experiment and the 
sample preparation was overseen by myself.  
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V5-PIAS-PE can associate and form PIAS bodies308. V5-PIAS-PE self-associates in 
puncta visible by immunofluorescence (Figure 4–7) and can be observed on 
western blot as a ladder of high molecular weight V5-PIAS-PE proteins (Figure 4–8). 
High molecular weight proteins are not present in the absence of NEM, suggesting 
V5-PIAS-PE forms higher MW structures promoted by SUMOylation. Previously in 
the Heun lab, co-transfection of pMT-Pias9_V5 and 
pMT_FlagHis_SUMO_GG_Hygro followed by analysis of cell lysates on SDS-PAGE 




Figure 4–7 PIAS bodies form in S2 cells when PIAS is overexpressed 
Immunofluorescence staining of PIAS, in a Drosophila S2 cell, detected by a mouse anti-V5 
antibody. V5-PIAS-PE was expressed from a pMT-Pias9_V5 plasmid or a PIAS-C-V5 
CRISPR cell line was stained (see section 4.3.12).  
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Figure 4–8 Overexpressed V5-PIAS-PE forms higher MW structures  
(A) Nuclear extracts were made from wild-type Schneider S2 cells and S2 cells transfected 
with pMT-Pias9_V5 in the presence (+NEM) and absence (-NEM) of NEM. Expression of 
V5-PIAS-PE was induced from the pMT-Pias9_V5 plasmid by addition of 200μM CuSO4 for 
3 days prior to harvesting. Cell lysate was subject to V5 immunoprecipitation using anti-V5 
agarose (Invitrogen). The input (IN), IP from wild-type S2 cells (WT) and IP from Pias9_V5 
expressing S2 cells (P9-V5) were anlaysed on 4-20% SDS-PAGE (Novagen) followed by 
western blot probed with anti-V5 mouse antibody. The bracket marks higher molecular 
weight species recognised by the anti-V5 antibody in +NEM conditions (B) Blot A re-probed 
with anti-SMT3 rabbit antibody. The bracket marks SUMOylated species recognised by the 
anti-SMT3 antibody in +NEM conditions. 
 
4.3.5 Characterisation of endogenous PIAS  
To investigate the effect of NEM on the solubility of endogenous PIAS, chromatin 
release assays were performed309. Nuclei were isolated from cells lysed in lysis 
buffer with and without 20mM NEM. Nuclei were treated with stepwise increases in 
NaCl concentration from 0.1-2.0M NaCl to sequentially extract proteins from 
chromatin. Proteins that form weak associations with DNA dissociate at lower NaCl 
concentrations than tightly bound proteins. Extracts were run on SDS-PAGE and 
levels of PIAS, SMT3, ADD1 and XNP assessed by western blotting (Figure 4–9).  
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Figure 4–9 DeSUMOylation inhibitor NEM causes delayed release of PIAS in chromatin 
release assay. 
Cells were lysed in lysis buffer with or without NEM before nuclear extraction. Nuclear 
extracts were washed in increasing NaCl concentrations for fractionation release from 
chromatin. Fractionations and solubilised pellet were anlaysed on SDS-PAGE followed by 
western blot probed for (A) ADD1, (B) XNP, (C) PIAS, (D) H3, (E) SMT3 and (F) ubiquitin. 
Release of H3 at 1.0M NaCl shows loss of chromatin structure. P= solublised pellet. Blots 
were cut for probing with multiple antibodies.  
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The presence of PIAS across the salt fractions shows sequential release of PIAS 
from chromatin. This suggests that different pools of PIAS are present in the cell 
with different solubilities. In the presence of NEM, PIAS resists extraction from 
chromatin even at high (2.0M) NaCl concentration, indicating that SUMOylation is 
responsible for chromatin association. NEM prevents the removal of ubiquitin-like 
substrates. SMT3 levels were higher in +NEM conditions. SMT3 was released 
between 0.2-0.5M NaCl (Figure 4–9), with a fraction remaining insoluble in +NEM.  
Although not present in the -NEM conditions, SUMOylated species are released 
between 0.2 and 0.5M NaCl in +NEM conditions. The extraction profile for 
ubiquitinated proteins was similar with and without NEM, with the majority of 
ubiquitinated proteins remaining insoluble in both conditions. Higher levels of 
ubiquitin were detected in the fraction released at 0.5M in +NEM. ADD1 and XNP 
have similar extraction profiles to each other and to PIAS, with more released at 
0.5M NaCl in +NEM conditions (Figure 4–9). Probing for Histone H3 was used as a 
loading control, in addition to showing the concentration of NaCl at which chromatin 
is disrupted and histones are released into the soluble fraction. In this case 
chromatin integrity was intact up to 0.5M NaCl.  
  
PIAS interactors in S2 cells 
90   
 
4.3.6 Affinity purification of PIAS-complexes from S2 cells  
For immunoprecipitation experiments to compare PIAS interactors in the presence 
and absence of NEM, nuclear lysates were prepared by digestion of nucleic acids 
with 150U benzoase for 1hr on ice in low salt conditions (20mM). This was followed 
by salt extraction in 500mM NaCl, which solubilises PIAS in both the presence and 
absence of NEM (Figure 4–10).  
 
Like V5-PIAS-PE (Figure 4–8), endogenous PIAS can associate and form higher 
molecular weight species which are maintained only in the presence of NEM (Figure 
4–10). In wild-type S2 cells, endogenous PIAS forms stable complexes that resist 
denaturation by boiling in SDS and are visible on western blot probing with the 
Drosophila anti-PIAS sheep antibody. This implies that these are very tight non-
covalent interactions whereas it is more likely that the higher Mw species are 
covalently attached to SMT3. These bands are visible in the presence of NEM but 
not visible in its absence (Figure 4–10). In the presence of NEM, there is a 
difference in the PIAS western blot profile with fewer clusters of lower molecular 
weight proteins (Figure 4–10).  
 
Figure 4–10 NEM treatment results in oligomerisation of PIAS and these oligomers 
can be immunoprecipitated using the Drosophila anti-PIAS sheep antibody. 
Nuclear extracts were made from wild-type S2 cells in the presence (+NEM) and absence (-
NEM) of NEM. The input (IN) and material immunoprecipitated with Drosophila anti-PIAS 
sheep antibody coupled to Protein G Dynabeads™ (IP) were analysed on 4-20% SDS-
PAGE (Invitrogen) followed by western blot probed with Drosophila anti-PIAS sheep 
antibody or anti-SMT3 rabbit antibody.  
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4.3.7 Mass spectrometry of affinity purified PIAS-complexes from S2 cells  
After optimising the conditions, immunoprecipitation followed by mass spectrometry 
(IP-MS) of PIAS, was performed to identify proteins that co-immunoprecipitate with 
PIAS in the absence and presence of NEM. The elution from the control IgG and 
PIAS IPs were visualised on silver stained SDS-PAGE gels (Appendix Figure 8–3) 
showing proteins specific to the PIAS IP are absent in the IgG control.  
 
Over 1400 proteins were identified in a trial of PIAS IP-MS (Figure 4–11), with more 
peptides and proteins identified in NEM conditions. A large proportion of these hits 
were cytoskeletal, involved in translation initiation and involved in transport of 
material from the nucleus to the cytoplasm. Datasets were compared to see which 
proteins immunoprecipitated with PIAS in the presence and absence of NEM. This 
allowed identification of PIAS interactions that are dependent upon SUMOylation. 
1400 proteins were detected in -NEM and 1800 in +NEM. The reference FASTA 
contained 41,655 protein entries meaning that PIAS interacts with approximately 4-
5% of the Drosophila proteome. As many proteins were identified, further 
optimisation of IP conditions was performed.  
 
 
Figure 4–11 Number of peptide and protein hits from immunoprecipitation of PIAS-
associated complexes 
Nuclear extracts were made from wild-type S2 cells in the presence (+NEM) and absence (-
NEM) of NEM. The material that co-immunoprecipitated with Drosophila anti-PIAS sheep 
antibody or anti-IgG sheep antibody coupled to Protein G Dynabeads™ (IP) was analysed 
by mass spectrometry (IP-MS). Numbers of peptide (A) and protein (B) hits are plotted. This 
is the result of one experiment. 
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Two methods were used to increase the stringency of the IP: firstly, increasing the 
number of washes from five to eight and secondly, increasing the NaCl 
concentration from 0.1M to 0.5M in the IP wash buffer.  
 
After five washes, the majority of unbound protein was removed. Increasing to eight 
washes, as visualised by silver stain, did not result in further protein loss (data not 
shown). Initially IP washes used low salt concentrations (100mM) to preserve 
interactions, but washes in IP wash buffer containing 300mM and 500mM NaCl 
were also tested. In the presence of NEM the number of peptides and proteins 
identified remained similar with higher salt washes (Figure 4–12). This indicates 
robust interactions between PIAS and interactors when NEM is present, which could 
be due to maintenance of post-translational modifications or the nature of SUMO-
SIM interactions remaining unaffected by increasing salt concentrations. However, 
in the absence of NEM, fewer peptides and proteins were identified when the PIAS-
IPs were washed in IP wash buffer containing higher NaCl concentrations (Figure 
4–12). IP washes in IP wash buffer containing 500mM NaCl emphasised the 
difference in interaction strength between PIAS and its interaction partners in the 
presence and absence of NEM (Figure 4–12). Also, using 500mM NaCl in washes, 
the bait bound to antibody-bead complexes was not compromised and increased 
the amount of PIAS detected, increasing the stringency of the IP-MS. 
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Figure 4–12 Number of peptide and proteins hits from immunoprecipitation of PIAS-
associated complexes after varying the concentration of salt in IP washes 
Nuclear extracts were made from wild-type S2 cells in the presence (+NEM) (left) and 
absence (-NEM) (right) of NEM. The material that co-immunoprecipitated with Drosophila 
anti-PIAS sheep antibody or anti-IgG sheep antibody coupled to Protein G Dynabeads™ 
was washed with IP wash buffer containing either 100, 300 or 500mM NaCl. The IP samples 
were then analysed by mass spectrometry. Numbers of peptide (top) and protein (bottom) 
hits are plotted. This is the result of one experiment.  
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Following PIAS IP and western blot, XNP was probed for as an example of a protein 
known to be SUMOylated and to interact with PIAS171. Western blotting for XNP in 
PIAS immunoprecipitations showed XNP is retained in PIAS IPs when washed with 
IP wash buffer containing 0.5M NaCl in the presence of NEM, but is not retained in 




Figure 4–13 PIAS co-immunoprecipitates XNP in an NEM-dependent manner  
Nuclear extracts were made from wild-type S2 cells in buffers with or without NEM. IP with 
affinity purified anti-IgG sheep antibody coupled to Protein G Dynabeads™ (IgG) and IP with 
anti-PIAS sheep antibody coupled to Protein G Dynabeads™ (IP) were washed with IP wash 
buffer containing 0.1, 0.3 or 0.5M NaCl. Input (IN) and immunoprecipitation (IP) were 
analysed on 4-20% SDS-PAGE followed by western blot. The blot was cut and blotted for 
XNP, PIAS and SMT3. The Ponceau for the bottom half of the blot is shown, showing 




  PIAS interactors in S2 cells 
  95 
 
PIAS and IgG IPs were performed on protein extracted from 1x107 S2 cells from 
three biological replicates, processed in parallel, with eight washes of 0.5M NaCl 
prior to elution from beads. Samples were prepared for mass spectrometry and 
were run with identical instrument settings. Label free quantitation (LFQ) was used 
as a measure of the abundance of proteins. PIAS (the bait) had the highest LFQ 
values validating that the IP was efficient and specific (Figure 4–15). 
 
4.3.8 PIAS isoform identification by mass spectrometry 
Peptides mapping to unique amino acid sequences in PIAS isoforms: L/J, I/G/B, H/E 
and A/C/D were identified in different PIAS IP-MS runs, confirming 
immunoprecipitation of multiple PIAS isoforms with the Drosophila anti-PIAS sheep 
antibody. Most peptides map to the shared core region of PIAS, which makes up the 
majority of the PIAS sequence (Figure 4–14). In S2 cells most peptides mapped to 
PIAS isoform L (Figure 4–15). Some peptides mapped to PIAS isoform H, as these 
included a sequence at the end of the core region not present in isoform L (Figure 
4–14, Figure 4–15). It would not be possible to comment on enrichment of particular 
isoforms, only their presence, due to few peptides mapping to unique isoform 
specific sequences. Only PIAS isoforms L and H were included in data analysis 
from PIAS- IP-MS in S2 cells as only these isoforms were identified by two or more 
peptides in two out of three replicates.  
 
Figure 4–14 PIAS isoforms highlighting C-terminal exons shared between isoforms. 
14 PIAS isoforms (A-N), exons in the core region are shown as black boxes, coloured boxes  
represent sequences not present in all isoforms. To the right are the number of amino acids 
(No.aa) and molecular weights (Mw) of each PIAS isoform. 
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4.3.9 Mass spectrometry analysis of PIAS interactors in S2 cells  
Scatter plots of LFQ values of each protein identified in IP-MS samples were plotted 
against all other samples and controls. Pearson correlation values over 0.9 between 
replicates of IP with anti-PIAS sheep antibody coupled to Protein G Dynabeads™ in 
+NEM and -NEM conditions showed reproducibly between samples (Appendix 
Figure 8–4). Correlation between IP with affinity purified anti-IgG sheep antibody 
coupled to Protein G Dynabeads™ negative controls indicates that common 
contaminants are present, but there is no correlation between samples and controls. 
A principle component analysis (Appendix Figure 8–5) showed ~90% of variation in 
the dataset could be summarised by the difference between IP with anti-PIAS sheep 
antibody coupled to Protein G Dynabeads™ and IP with affinity purified anti-IgG 
sheep antibody coupled to Protein G Dynabeads™, indicating that the largest 
difference is between groups and not within the data itself. 
 
Volcano plots were generated using Perseus to visualise the result of a Student’s T-
test comparing interactors identified in PIAS-IP and IgG-IP conditions after filtering 
for proteins identified in at least two out of three replicates and identified by two or 
more peptides per protein (Figure 4–15). Proteins identified by two or more peptides 
in the IgG control were excluded from analysis. Also plotted are proteins identified 
by 20 or more peptides (Figure 4–16) as this increases confidence that these are 
genuine PIAS binding partners. 
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Figure 4–15 Volcano plot of PIAS protein interactors in S2 cells in the absence and presence of NEM, two or more peptides 
Immunoprecipitation (IP) using Drosophila affinity purified anti-PIAS antibody (PIAS) or control sheep anti-IgG antibody (Control) coupled to Protein G 
Dynabeads™ was performed from S2 cell lines. IP samples were prepared as described in methods and analysed by mass spectrometry. PIAS 
interactors in conditions without NEM (A) and with NEM (B) are plotted. Each dot represents one protein. For determining the PIAS interactome, a 
MaxQuant label-free quantitation pipeline was used. Student’s T-test was performed on log2 transformed LFQ values from three control and three PIAS 
IPs after filtering for proteins identified by two or more peptides and found in at least two of three replicates. T-test difference ratios (x-axis) were plotted 
against the negative logarithmic p-value of the T-test (y-axis). Proteins in red are proteins of interest to this PhD study including PIAS, BEAF-32, Ibf1, 
Ibf2, ADD1, XNP and H3.3. Proteins in purple are linked to RNAi silencing pathways. Proteins in black are consistent PIAS interactors. Proteins in blue 
are transcription activation proteins (Tafs). SMT3 is in green and HP1a, dre4 and Ssrp-RA are in navy blue. The confidence line was generated using a 
permutation-based FDR value of 0.05 and a minimal fold change value of 0.1. 
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Figure 4–16 Volcano plot of PIAS protein interactors in S2 cells in the absence and presence of NEM, twenty or more peptides 
Immunoprecipitation (IP) using Drosophila affinity purified anti-PIAS antibody (PIAS) or control sheep anti-IgG antibody (control) coupled to Protein G 
Dynabeads™ was performed from S2 cell lines. IP samples were prepared as described in methods and analysed by mass spectrometry. PIAS 
interactors in conditions without NEM (A) and with NEM (B) are plotted. Each dot represents one protein. For determining the PIAS interactome, a 
MaxQuant label-free quantitation pipeline was used. Student’s T-test was performed on log2 transformed LFQ values from three control and three PIAS 
IPs after filtering for proteins identified by 20 or more peptides and found in at least two of three replicates. T-test difference ratios (x-axis) were plotted 
against the negative logarithmic p-value of the T-test (y-axis). PIAS is in red. Proteins in purple are linked to RNAi silencing pathways. Proteins in black 
are consistent PIAS interactors. Proteins in blue are transcription activation proteins (Tafs). Dre4 is in navy blue. The confidence line was generated 
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In this one step purification, a large number of interactors were discovered, with 
many involved in RNA polymerase II transcription, RNA processing and chromatin 
binding. PIAS also interacts with components of the RNAi machinery (AGO2, Ars2, 
Fmr1, r2d2, Rm62, Tudor-SN, bel, Dcr-2, aub) and Tafs. This is compatible with 
PIAS being involved in the transcription of repetitive elements for silencing of 




Focussing on proteins identified by two or more peptides, one of the most enriched 
proteins, by more than eight-fold in the PIAS IP compared to control, is histone 3.3 
(H3.3) (Figure 4–15). H3.3 is incorporated into nucleosomes at telomeres, 
pericentromeres and transposable elements by its chaperone DAXX, aided by the 
ATRX chromatin remodeller. In Drosophila DAXX-like protein (DLP) interacts with 
XNP and has two verified SIMs
132
. DLP was not identified as a PIAS interactor in 
this IP-MS, but interaction between PIAS and H3.3 could mediate SUMO dependent 
incorporation into chromatin. Notably, XNP was identified in +NEM conditions, 
enriched four-fold over background (Figure 4–15). 
 
Of the significant proteins identified by 20 or more peptides, 230 were identified in -
NEM and 313 in +NEM IP conditions (Figure 4–16). PIAS interacts with Tafs, 
consistent with a role for PIAS in regulation of transcription and in agreement with 
interactions found for human PIAS proteins in two-hybrid assays
310
. The 
transcription factors, without children (woc) and relative of woc (row) were identified. 
Both interact with the HP1c complex at developmentally regulated and stimulus-





Woc and row co-purify with Boundary Element Associated Factor 32 (BEAF-32) 
which acts as an insulator, binding near transcription start sites (often of 
housekeeping genes)
312
. Knockdown of BEAF-32 has minimal effects on 
topologically associated domain (TAD) organisation
313
 characteristic of redundancy 
among insulator proteins. Insulator proteins (Ibf1 and Ibf2) were also identified as 
PIAS interactors. PIAS and BEAF-32 bind at similar sites in the genome
57
 consistent 
with a role for PIAS mediated SUMOylation in co-ordinating transcription units. 
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Other proteins that co-immunoprecipitated with PIAS, but are not highlighted on 
volcano plots, include proteins involved in mRNA splicing and the spliceosome. Of 
the 313 proteins significantly enriched and identified by more than 20 peptides, 218 
had annotated GO terms in FlyMine. 132 of these proteins were involved in nucleic 
acid metabolism: 51 in RNA metabolism and 40 in splicing. The transcription 
elongation factor spt5 was more than 10-fold enriched in PIAS IP over control IgG 
IP. Spt5 is involved in co-transcriptional spliceosome assembly with the pre-
mRNA processing protein Prp8 at intron containing genes
314
. Prp8 was also over 
eight-fold enriched in PIAS IP over control IgG IP. For the role of SUMOylation in 
splicing see section 2.3.10.  
 
Of the published Drosophila PIAS interactors (Table 4), only HP1a was present in 
this IP-MS. The position of the protein Bonus (bon) is marked as this is responsible 
for HP1a phosphorylation. Many proteins identified in the PIAS IP-MS are known to 
be SUMOylated. For example, CENP-C which was identified by 38 peptides in 
+NEM conditions. 
 
Normalisation of the LFQ values of proteins that co-immunoprecipitate with PIAS 
allowed a comparison of PIAS interactors in the absence and presence of NEM 
(Figure 4–17). A correlation plot of PIAS interactors comparing the mean log2 
transformed LFQ values from three biological replicates in PIAS IP-MS in + and -
NEM conditions was generated to identify PIAS interactors unique to NEM 
conditions. 732 proteins interacted with PIAS only in the presence of NEM, 710 
proteins interacted with PIAS in both the presence and absence of NEM and 135 
proteins were identified only in conditions when NEM was not present (Figure 4–17). 
Of the 710 proteins enriched in both PIAS IP-MS conditions, in the presence and 
absence of NEM, 92 proteins differed less than two-fold. A Gene Ontology (GO) 
terms analysis of these interactors found chromosome organisation to be the most 
significant biological process that these factors were involved (Table 5). 34 factors 
including ADD1, Cenp-C and BEAF-32 were found in this category. In Table 6 are 
the proteins which do not significantly change between PIAS IP in conditions with 
and without NEM categorised into groups based on their biological processes. 
Interestingly, analysis of the 92 proteins by FlyMine identified an enrichment for 
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proteins with a zinc-finger, PHD-type domain. These include: enok, Cfp1, CG1815, 
Br140, bip2, rno, UPset and ADD1. FlyMine also identified pathway enrichment for 
RNA polymerase II transcription, transport of mature mRNA derived from an 
intronless transcript and regulation of TP53 Activity. 
 
Of the proteins identified to interact with PIAS in both + and -NEM conditions, 614 
proteins were identified by LFQ values greater than two-fold enriched in +NEM 
conditions compared to three proteins identified by LFQ values greater than two-fold 
enriched in -NEM conditions (Figure 4–17), possibly suggesting SUMO presence is 
involved in stabilising protein complexes. 732 vs 135 proteins interact with PIAS in 
the presence of NEM compared to when NEM is not present (Figure 4–17). In PIAS 
+NEM conditions, SMT3 is enriched more than two-fold and components of the 
RNAi machinery (Rm62, bel, Tudor-SN, Dcr2, Fmr1) are also enriched more than 
two-fold (Figure 4-17).  
 
GO terms analysed against the GO-Slim Biological Process annotation dataset, GO-
Slim Molecular Function annotation dataset, GO-Slim Cellular Component 
annotation datasets and the Reactome pathways annotation dataset was performed 
for the 732 proteins that interacted with PIAS only in the presence of NEM (Table 7) 
and the 135 proteins that were only identified in the absence of NEM (Table 8). The 
GO-Slim terms highlight that the common properties of proteins identified to interact 
with PIAS in the absence of NEM are involved in transcription and gene expression 
(Table 8). In contrast in the presence of NEM, where SUMOylation is maintained, a 
greater number of processes were identified, with a common theme of involvement 
of PIAS associated complexes in general nucleic acid metabolism (Table 7).  
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Figure 4–17 Scatter plot comparing PIAS protein interactors in S2 cells in the absence 
and presence of NEM 
Mean log2 transformed LFQ values calculated from three biological replicates, normalised to 
PIAS isoform L, from PIAS IP in +NEM and -NEM conditions. Each dot represents one 
protein. The top plot shows all proteins and the bottom plot shows proteins found only in 
both conditions. Proteins in red are of interest to this PhD study including PIAS, BEAF-32, 
Ibf1, Ibf2, ADD1, XNP and H3.3. HP1a is in navy blue. Proteins in purple are linked to RNAi 
silencing pathways. Proteins in black are consistent PIAS interactors. Proteins in blue are 
Tafs. SUMO (SMT3) is in green. Diagonal lines mark two log2 fold change from zero.  
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Table 5 Gene ontology (GO) terms associated with proteins identified in PIAS IP-MS 
from S2 cells in conditions with and without NEM 
Gene Ontology analysis using the FlyMine complete GO biological process annotation 
dataset of proteins identified in PIAS IP-MS from S2 cells with less than two log2 fold change 
with and without NEM. Bonferroni test correction was applied. Matches are unique proteins 
within a given GO term. List is ordered by significance p-value. 
 
GO term: Biological Process p-value matches 
chromosome organization [GO:0051276] 8.82E-17 34 
peptidyl-lysine modification [GO:0018205] 7.09E-10 15 
chromatin organization [GO:0006325] 1.52E-09 23 
histone modification [GO:0016570] 2.54E-09 16 
covalent chromatin modification [GO:0016569] 3.22E-09 16 
organelle organization [GO:0006996] 6.17E-09 41 
RNA metabolic process [GO:0016070] 5.59E-08 39 
cellular component organization [GO:0016043] 1.22E-07 48 
regulation of gene expression [GO:0010468] 1.34E-07 35 
cellular component organization or biogenesis [GO:0071840] 1.44E-07 49 
nucleic acid metabolic process [GO:0090304] 3.8E-07 40 
histone acetylation [GO:0016573] 1.42E-06 10 
internal protein amino acid acetylation [GO:0006475] 1.82E-06 10 
internal peptidyl-lysine acetylation [GO:0018393] 1.82E-06 10 
peptidyl-lysine acetylation [GO:0018394] 1.82E-06 10 
regulation of RNA metabolic process [GO:0051252] 1.84E-06 30 
peptidyl-amino acid modification [GO:0018193] 2.04E-06 17 
regulation of cellular process [GO:0050794] 2.18E-06 51 
regulation of nucleobase-containing compound metabolic process 
[GO:0019219] 3.19E-06 30 
regulation of biological process [GO:0050789] 3.53E-06 53 
regulation of transcription, DNA-templated [GO:0006355] 4.64E-06 28 
regulation of nucleic acid-templated transcription [GO:1903506] 4.64E-06 28 
regulation of RNA biosynthetic process [GO:2001141] 4.64E-06 28 
protein acetylation [GO:0006473] 5.2E-06 10 
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Table 6 SUMOylation-independent PIAS interactors in S2 cells 
Proteins with less than two log2 fold change in PIAS IP-MS with and without NEM 
categorised into groups based on their biological processes. Proteins with multiple functions 
are listed in one category only. Underlined proteins are involved in chromosome 






BEAF-32 ,bip2, Cfp1, CG1815, dbr, enok, Hcf, hyx, koko, mip130, mip40, rept, 
Sec13, spen, Ssp, stwl, Taf5, Taf6, Taf8  
Mitotic cell 
cycle 
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Table 7 Top gene ontology (GO) terms associated with proteins identified in PIAS IP-
MS from S2 cells, in NEM conditions only  
The analysis is a PANTHER overrepresentation test against the complete A) GO-Slim 
Biological Process B) GO-Slim Molecular Function C) Cellular Component annotation 
datasets and D) Reactome pathways with Bonferroni correction applied.  N=731 
(A) PANTHER GO-Slim Biological Process Fold Enrichment P value 
mitotic sister chromatid segregation 9.82 0.023 
mRNA export from nucleus 9.42 0.029 
mRNA-containing ribonucleoprotein complex export 
from nucleus 9.42 0.029 
ribonucleoprotein complex localization 8.73 0.044 
ribonucleoprotein complex export from nucleus 8.73 0.044 
DNA-dependent DNA replication 8.01 0.002 
rRNA processing 7.57 0.009 
RNA catabolic process 6.12 0.016 
DNA replication 5.85 0.003 
cellular macromolecule biosynthetic process 5.61 0.005 
   
(B) PANTHER GO-Slim Molecular Function Fold Enrichment P value 
DNA-directed 5'-3' RNA polymerase activity 7.36 0.0451 
5'-3' RNA polymerase activity 7.36 0.0451 
RNA polymerase activity 7.36 0.0451 
catalytic activity, acting on RNA 3.88 0.00793 
ligase activity 3.51 0.00141 
RNA binding 3.43 5.26E-08 
nucleic acid binding 2.76 2.3E-11 
heterocyclic compound binding 2.72 3.05E-11 
transferase activity, transferring phosphorus-containing 
groups 2.42 0.0202 
transferase activity 1.96 0.00105 
   
(C) PANTHER GO-Slim Cellular Component Fold Enrichment P value 
preribosome, large subunit precursor 13.77 0.0000481 
90S preribosome 10.86 0.0000595 
preribosome 10.43 4.62E-12 
proteasome accessory complex 10.24 0.00598 
proteasome regulatory particle 10.24 0.00598 
t-UTP complex 9.31 0.00000395 
nucleolus 9.26 2.07E-17 
small-subunit processome 8.91 0.000989 
nucleolar part 8.1 0.0000161 
nuclear chromosome 5.85 0.0481 
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(D) Reactome pathways Fold Enrichment P value 
Processive synthesis on the lagging strand 16.83 0.01 
Lagging Strand Synthesis 11.88 0.0483 
Activation of the pre-replicative complex 10.1 0.00163 
DNA Replication Pre-Initiation 9.77 0.00205 
M/G1 Transition 9.77 0.00205 
Degradation of CLK 7.48 0.0417 
RNA polymerase II transcribes snRNA genes 5.52 0.0448 
Synthesis of DNA 5.24 0.0000298 
DNA Replication 5.04 0.0000529 





Table 8 Top gene ontology (GO) terms associated with proteins identified in PIAS IP-
MS from S2 cells, in the absence of NEM  
The analysis is a PANTHER overrepresentation test against the complete A) GO-Slim 
Biological Process B) GO-Slim Molecular Function C) Cellular Component annotation 
datasets and D) Reactome pathways with Bonferroni correction applied. N=134  
 
(A) PANTHER GO-Slim Biological Process Fold Enrichment P value 
gene expression 3.34 0.0305 
 
organic substance metabolic process 
 
2.42 0.0275 
   
(B) PANTHER GO-Slim Molecular Function Fold Enrichment P value 
DNA binding 5.04 0.0121 
   
(C) PANTHER GO-Slim Cellular Component Fold Enrichment P value 





   
(D) Reactome pathways Fold Enrichment P value 
RNA Polymerase II Pre-transcription Events 15.93 0.0038 
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4.3.10 Validation of PIAS interactors by co-immunoprecipitation followed by 
western blot 
For validation of endogenous PIAS interactions identified by PIAS IP-MS, IP 
followed by western blot was performed for targets of interest where antibodies were 
available. As already shown, HP1a (Figure 4–4) and XNP (Figure 4–13) co-
immunoprecipitate with PIAS. PIAS interacts with ADD1 in the absence or presence 
of NEM. BEAF-32 and Cenp-C followed the same pattern (Table 6).  
 
PIAS interaction with ADD1, BEAF-32, Cenp-C and HP1a was validated by 
immunoprecipitation of PIAS followed by blotting with antibodies specific to the 
predicted interaction partners (Figure 4–18). The PIAS-ADD1 interaction is 
maintained in +/-NEM conditions (Figure 4–18A), suggesting that it is not strongly 
influenced by SUMOylation. BEAF-32 co-immunoprecipitated with PIAS (Figure 4–
18Bi). However, in the reverse experiment PIAS did not co-immunoprecipitate with 
BEAF-32 (Figure 4–18Bii). This may be because the BEAF-32 antibody prevents 
interaction between the two proteins (e.g. by recognising an epitope that is within 
their binding site), therefore preventing the co-immunoprecipitation of PIAS-BEAF-
32 complexes. BEAF-32 did not co-immunoprecipitate with SUMOylated proteins 
and SUMOylation of BEAF32 is not obvious on western blot (data not shown). This 
supports that PIAS interacts with BEAF-32 in a manner independent of 
SUMOylation. PIAS and Cenp-C co-immunoprecipitated (Figure 4–18C), but 
whether this is a soluble pool of Cenp-C or one capable of integrating into chromatin 
would require further characterisation.  
 
HP1a was only slightly enriched in PIAS IP-MS in NEM conditions (Figure 4–17), 
therefore HP1a was probed for in PIAS IP. HP1a co-immunoprecipitates with PIAS 
in both the absence and present of NEM, with an additional band (migrating at a 
slower rate) in NEM conditions (Figure 4–18D). The identify of this band was not 
confirmed.  
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Figure 4–18 PIAS co-immunoprecipitates with ADD1, BEAF-32, Cenp-C and HP1a 
regardless of the presence of NEM 
Nuclear extracts were made from wild-type Schneider S2 cells. The input (IN), IP with affinity 
purified anti-IgG sheep antibody coupled to Protein G Dynabeads™ (IgG) and IP with anti-
PIAS sheep antibody coupled to Protein G Dynabeads™ (IP) (PIAS IP) were analysed on 4-
20% SDS-PAGE followed by western blot probed with Drosophila anti-PIAS sheep antibody 
and anti-ADD1 rabbit antibody (A) or anti-BEAF-32 mouse antibody (B) or anti-Cenp-C rat 
antibody (C) or anti-HP1a mouse antibody (D).  
(Bii) IP with affinity purified anti-IgG mouse antibody coupled to Protein A Dynabeads™ 
(IgG) and IP with anti-BEAF-32 mouse antibody coupled to Protein A Dynabeads™ (IP)  
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4.3.11 PIAS post-translational modification identification 
Post-translational modifications (PTMs) of PIAS have been previously identified. 
These may influence its interactions with other proteins. Mass spectrometry 
identified peptides mapping to PIAS that were modified by phosphoryl groups, acetyl 
groups and SMT3, which indicates SUMOylation. These sites are marked on the 
schematic diagram of PIAS isoforms (Figure 4–19). A SUMOylation site was found 
in exon 4 of PIAS in the RLD of the PIAS-CORE region. Phosphorylation was found 
in exon 9, an exon found only in isoforms J and L, which could be important for cell 
cycle regulation. These peptides were identified from PIAS IP-MS from S2 cells by 
one peptide in one out of six experiments, suggesting that these are dynamic 
modifications, present on few proteins in the cell.  
 
 
Figure 4–19 Post-translational modifications on PIAS 
Phosphorylated peptides were found mapping to the C-terminus exons in isoforms J and L, 
Acetylation was found mapping to exon 2 in PIAS-CORE region and SUMOylation was 
found in the Ring-like domain (RLD). The amino acid sequence of PIAS RLD is shown, 
residues in blue mark the amino acid residues important for the RING structure. K where 
SUMO is conjugated is marked in green.   
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4.3.12 Generation of PIAS
V5
 CRISPR Cas9 tagged cell lines 
Single guide RNAs (sgRNA) and homology directed repair templates (HDRT) were 
designed to target the core region of the su(var) 2-10 locus on chromosome 2R 
using CRISPR/Cas9 in S2 cells (Figure 4–20A). Single guide RNAs targeting the N-
terminus of the PIAS core region at the Su(var) 2-10 gene locus resulted in reduced 
expression of the higher molecular weight cluster of PIAS isoforms (Figure 4–20B). 
Only the higher isoforms incorporated the V5 tag (Figure 4–20C). No PIAS-N-V5 S2 
cell line clones with all copies of PIAS tagged were recovered.  
 
 
Figure 4–20 Generation of the PIAS-N-V5 allele 
(A) Schematic diagram of the targeting strategy using CRISPR/Cas9 for the insertion of a V5 
tag at the N-terminus of PIAS- CORE by targeting the Su(var)2-10 locus on chromosome 2R 
in Drosophila S2 cells to create the cell line PIAS-N-V5. (B) sgRNAs targeting Su(var)2-10 to 
test sgRNA efficiency through knock-down of PIAS levels. WT=wild-type cell line without 
transfection, - control sgRNAs, sgRNA2 and sgRNA 3 target the Su(var)2-10 gene locus. 
Equal concentrations of protein were analysed by SDS-PAGE followed by western blot 
probed with Drosophila anti-PIAS sheep antibody (C) Western blot analysis of protein 
extracts from wild-type (WT) and PIAS-N-V5 cell lines, left-hand-blot probed with anti-PIAS 
sheep antibody recognising endogenous protein and right-hand-blot probed with anti-V5 
mouse antibody recognising tagged isoforms.  
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The L2-4 clone of S2 cells used in the Heun lab are pseudo-tetraploid with 13 






, 1x 2L fragment). Therefore, for all PIAS 
proteins to be tagged, all four Su(var)2-10 alleles on chromosome 2R must be 
targeted. 
 
With C-terminal tagging of PIAS- CORE, it was possible to derive knock-in S2 cell 
lines expressing a V5-tag at the C-terminus of PIAS (PIAS-C-V5) from all four 
copies of the endogenous Su(var)2-10 locus (describe in Figure 4–21), resulting in 
all endogenous PIAS proteins being tagged. Integration of the tag into the genomic 
DNA was confirmed by PCR and cell lines were plated at low density to form clonal 
populations which were screened for cells in which all four alleles of Su(var)2-10 
were successfully tagged, resulting in the cell line PIAS-C-V5 (Figure 4–21C). PIAS-
C-V5 was validated by western blot (Figure 4–21D). In the process of incorporating 
the tag, some isoforms of PIAS were lost, potentially by tagging affecting alternative 
splicing. Cells doubled at a normal rate and maintained the tag, suggesting that the 
V5 tag did not impair PIAS function. Immunofluorescence of the V5 tag in PIAS-C-
V5 showed a similar general nuclear localisation pattern as observed for 
endogenous PIAS in interphase S2 cells (Figure 4–21E). While PIAS-CORE 
overexpression from pMT-Pias9_V5 showed localisation in nuclear bodies (Figure 
4–7), PIAS bodies were not observed using endogenously tagged cell lines or by 
staining with the endogenous antibody (Figure 4–21E) at any stage in the cell cycle. 
PIAS-C-V5 was also amenable to immunoprecipitation using the Drosophila anti-
PIAS sheep antibody (Figure 4–21F). In wild-type cells the anti-PIAS sheep 
antibody recognises all isoforms of PIAS whereas the number of isoforms of PIAS in 
PIAS-C-V5 is reduced (Figure 4–21F). 
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Figure 4–21 Generation of the PIAS-C-V5 allele 
(A) Schematic diagram of the targeting strategy using CRISPR/Cas9 for the insertion of a V5 
tag at the C-terminus of the PIAS core region on chromosome 2R in Drosophila S2 cells to 
create PIAS-C-V5. (B) Schematic diagram of the repair construct showing the recognition 
site of the sgRNA used for targeting and the primers used to confirm insertion of the tag at 
the endogenous locus. The homology arms are not to scale. (C) 3% agarose gel analysis of 
PCR products, showing a band shift from 186 to 359bp when the primers amplify across the 
locus containing the inserted repair construct (D) Western blot of protein extracts from wild-
type and PIAS-C-V5 cell lines, left-hand blot probed with anti-PIAS sheep antibody 
recognising endogenous protein and right hand blot anti-V5 antibody recognising tagged 
isoforms. (E) Immunofluorescence staining of untagged and V5-tagged PIAS proteins in S2 
cells. PIAS-C-V5 visualised by an anti- V5 antibody and untagged PIAS visualised by the 
anti-PIAS sheep antibody display nuclear localisation. Scale bar=2µm (F) Western blot of 
input (IN) and immunoprecipitation (IP) samples using the anti-PIAS sheep antibody from 
wild-type (WT) and Pias-C-V5 S2 cell lines probed with anti-PIAS sheep antibody.  
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4.3.13 Immunoprecipitation of PIAS-C-V5 
To validate endogenous PIAS IPs using the Drosophila anti-PIAS sheep antibody, I 
performed IPs using the V5 tag in PIAS-C-V5 S2 cell lines (Figure 4–22A and B). 
PIAS-C-V5, allows analysis of PIAS’s interaction partners in the absence of any 
PIAS antibody-generated background. IP using the V5 tag in PIAS-C-V5 cells did 
not show the expected enrichment of SUMOylated proteins in +NEM conditions by 
western blot (Figure 4–22C) compared to IP using the endogenous antibody (Figure 
4–10). It is possible that specific PIAS isoforms, lost with the V5 tag, are needed to 
form some PIAS-SUMO containing complexes, or that IP via the V5 tag 
immunoprecipitated SUMOylated proteins at below the limit of detection of western 
blot. However, IP-MS using the V5 tag to immunoprecipitate PIAS-C-V5 did 
replicate findings from the endogenous PIAS IP-MS, finding many of the same 
proteins including the FACT complex subunit (dre4), Topoisomerase 2 (Top2) and 
XNP (Figure 4–22D). IP-MS from PIAS-C-V5 was carried out once and so statistics 
were not performed on interaction partners identified and data is presented as a 
table. In addition, a greater number of peptides and proteins were identified in 
+NEM conditions (Figure 4–22E).  
 
To validate V5-IP of PIAS-C-V5, ADD1 was probed for on western blot. This showed 
that ADD1 co-immunoprecipitated with PIAS-C-V5 (Figure 4–22F) regardless of the 
presence of NEM, exhibiting the same behaviour as observed with endogenous 
PIAS IP. Endogenous interactors of PIAS identified from IP with Drosophila anti-
PIAS sheep antibody and V5-IP from PIAS-C-V5 in +NEM conditions were 
compared, identifying 519 PIAS interactors in common, including: HP1a, XNP, 
SMT3 and H3.3 (Figure 4–23).  
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Figure 4–22 PIAS-C-V5 interactors 
(A) Western blot showing input (IN) and immunoprecipitation (IP) of V5 tagged species from 
wild-type (WT) or PIAS-C-V5 Schneider S2 cell nuclear extract, probed with mouse anti-V5 
antibody. (B) Immunoprecipitation of PIAS using the Drosophila anti-PIAS sheep antibody or 
immunoprecipitation using sheep anti-IgG sheep antibody as a control from PIAS-C-V5 
Schneider S2 cell nuclear extract, western blot with anti-V5 mouse antibody. (C) 
Immunoprecipitation of PIAS using the Drosophila anti-PIAS sheep antibody from PIAS-C-
V5 Schneider S2 cell nuclear extract in the presence and absence of NEM. Samples were 
run on 4-20% SDS-PAGE for western blot probed with Drosophila anti-PIAS sheep antibody 
and the gel was re-probed with anti-SMT3 rabbit antibody. (D) Table: List of Proteins 
identified in a V5-IP from PIAS-C-V5 Schneider S2 cell nuclear extract using anti-V5 agarose 
with WT cells as a negative control. (E) Table listing the number of peptides and proteins in 
PIAS-C-V5 mass spectrometry. (F) Immunoprecipitation of PIAS using the Drosophila anti-
PIAS sheep antibody (P) or immunoprecipitation using anti-IgG sheep antibody (G) from 
PIAS-C-V5 Schneider S2 cell nuclear extract in the presence and absence of NEM. Input 
(IN) and IP samples were run on 4-20% SDS-PAGE for western blot probed with anti-PIAS 
sheep antibody or anti-ADD1 rabbit antibody. 
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Figure 4–23 PIAS interactors in +NEM conditions 
Venn diagram of proteins identified in PIAS IP-MS from wild-type and PIAS-C-V5 S2 cells. 
Chromatin associated proteins of interest found in both conditions listed in alphabetical 
order. Those discussed in this thesis are in bold.   
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4.4 Summary 
This chapter described the method development for identification of endogenous 
PIAS interaction partners by immunoprecipitation followed by mass spectrometry 
(IP-MS) with the aim to define interaction partners of PIAS. PIAS was 
immunoprecipitated from S2 cell lysate in the presence and absence of NEM, to 
identify interactions that are maintained in the presence and absence of 
SUMOylation. PIAS IPs were performed using the Drosophila anti-PIAS sheep 
antibody and a tagged version of PIAS proteins to cross-validate the PIAS 
interactors identified. PIAS IP-MS identified many PIAS interactors, including those 
involved in chromosome organization, transcription, mRNA processing (Table 5) and 
RNA interference pathways (Figure 4–15 and Figure 4–16). 
 
Characterisation of PIAS in NEM conditions, where SMT3 conjugation to substrate 
proteins is maintained (compared to when NEM is not present), clarified which PIAS 
interactors depend on the presence of SUMOylation. Overexpression of PIAS in S2 
cells causes sequestration into nuclear bodies probably dependent on large SIM-
SUMO networks (Figure 4–7).  
 
XNP co-immunoprecipitated with PIAS only in the presence of NEM (Figure 4–13), 
supportive of the hypothesis that PIAS SUMOylates XNP. However, by PIAS IP-MS, 
XNP was not identified as a top PIAS interactor in wild-type S2 cells (Figure 4–15 
and Figure 4–16), this could be a limitation of using mass spectrometry (which 
requires the presence of unique peptides to identify the protein and requires that 
these peptides fly in the experiment) and should be confirmed by alternative 
methods. However, size exclusion chromatography separating PIAS-complexes 
suggests the presence of many complexes which don’t contain XNP (Figure 4–2).  
 
I have confirmed an interaction between PIAS and heterochromatin protein HP1a ( 
Figure 4–4), validating an interactor from the HP1a interactome of Alekseyenko et 
al., 2014299 (Table 4). I also show by size exclusion chromatography that PIAS and 
HP1 proteins co-elute and co-immunoprecipitate (Figure 4–5), suggesting the 
identity of different HP1a-PIAS complexes.  
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4.4.1 Evaluation of the approach  
4.4.1.1 Immunoprecipitation using endogenous antibodies  
As SUMOylated proteins can form large complexes through SUMO-SIM 
interactions, expression levels are important for understanding physiological 
interactions of SUMOylated proteins. Previous work has demonstrated that PIAS 
levels have to be maintained within a certain level; as both over expression and 
knockdown have lethal effects in vivo144. PIAS proteins have multiple functions in 
Drosophila, one of which is to enhance SMT3 conjugation to substrate proteins 
through their E3 ligase activity. NEM was used as an inhibitor of de-SUMOylation in 
lysis buffers to prevent the action of SUMO proteases. This meant that there was no 
disruption to cellular metabolism by addition of enzymes or knockdown of proteins 
prior to cell lysis and endogenous protein levels could be assessed.  
 
Many studies have focused on the identification of SMT3  and SUMO substrates by 
proteomic approaches using mass spectrometry
199
. These studies vary in their 
organism, tissue or cell type of choice, combined with using different stresses, 
buffers and growth conditions which give maximum conjugation of SMT3 or SUMO 
to target proteins. Two main types of experiments have been performed: looking at 
substrates covalently modified by SUMO using denaturing conditions, or less 
stringent IPs, under non-denaturing conditions, where large SUMO-SIM networks 
have been maintained. Despite SMT3-substrates being identified and the 
SUMOylation of those substrates being characterised, the enzymes responsible for 
targeting SMT3 conjugation have not been so well characterised. 
 
Since NEM is a general inhibitor of cysteine proteases, it prevents the action of any 
enzyme that contains thiol residues in its active site, including all UBLs. Therefore, 
further work is required to understand whether a SUMOylation-dependent function 
of PIAS is part of its mechanism of action as a chromatin factor. Although there are 
caveats associated with the use of NEM, it has the advantage of not interfering with 
cellular processes, only taking effect post-lysis to preserve interactions. An 
alternative experiment to identify PIAS interactors that depend on PIAS’s SUMO E3 
ligase activity, would be to compare endogenous PIAS IP from wild-type and the 
homozygous Su(var)2-101 Drosophila line, which contains a point mutation in the 
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catalytic RING domain, inactivating PIAS’s E3 ligase activity. However, there are no 
available data describing this mutant in homozygosity. In addition, it is likely to be 
lethal. When trans-heterozygous with Su(var)2-102, aberrant chromosome defects 
make amplification of Drosophila difficult, creating a challenge for biochemical 
experiments that require a large amount of starting material. A knock-in strategy 
using CRISPR/Cas9 to introduce a inducible point mutation in the Su(var)2-10 
locus, as has recently been performed to explore the catalytic activity of Polycomb 
repressive complex 2
315
, would be the optimal strategy. However, this would require 
editing of all four alleles in S2 cells, would be technically challenging and may be 
lethal once induced, when E3 ligase activity is lost. 
 
4.4.1.2 IP-MS data analysis to compare interactors in the presence and 
absence of NEM  
Scatter plots showing log2 transformed LFQ data allowed separation of three 
populations of PIAS interactors (Figure 4–17): those that only interact with PIAS in 
the absence of NEM; those that only interact with PIAS in the presence of NEM; and 
those that interact with PIAS in both conditions. 
 
Volcano plots comparing IP-MS in conditions with and without NEM fail to identify 
proteins that interact with PIAS independently of SUMOylation to those that 
significantly differ in binding with and without NEM (found both with and without 
NEM). Therefore scatter plots of protein abundance (with IgG control subtracted) 
with and without the presence of NEM illustrates that there was a huge increase in 
protein binding in the presence of NEM (Figure 4–17), indicating that a number of 
interactors are only observed when SUMOylation is maintained (XNP and Dcr-2).  
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4.4.1.3 Generation of tagged cell lines  
Affinity purification using endogenous antibodies has the disadvantage of needing a 
highly specific and efficient antibody against the target protein and requires a 
suitable control for background levels of non-specific immunoprecipitation. 
Immunoprecipitation of PIAS by a V5 epitope-tag independently validates interactors 
identified with the Drosophila anti-PIAS sheep antibody (Figure 4–23).  
 
Tagging of the core region of PIAS resulted in disruption of isoforms (Figure 4–21); 
the extent to which this affects PIAS function in S2 cells is unknown as no obvious 
defects were observed. It is thought that the PIAS isoforms may play important roles 
during development due to partial rescue of lethality in trans-heterozygous Su(var)2-
101/Su(var)2-102 mutants by expression of PIAS-PE144. An alternative approach 
would be to delete the endogenous locus by insertion of LoxP sites and expression 
of a Cre recombinase alongside insertion of the cDNA sequence (without introns) to 
replace the Su(var)2-10 locus to overcome the problem of alternative splicing 
interference and multiple isoforms of PIAS. Also, by amplifying different cDNAs, it 
would be possible to address which PIAS isoforms are necessary for certain 
interactions. However, the health of the cells may be compromised, as it has not 
been demonstrated in a precise PIAS knockout that the CORE region is sufficient to 
rescue PIAS knockdown. Isoform-specific interaction studies or studies in a system 
with fewer PIAS isoforms could help decipher the action and subcellular distribution 
of PIAS proteins and determine their importance at heterochromatin and within 
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Chapter 5 Identification of PIAS interactors in 
Drosophila embryos  
 
5.1 Objectives  
As the Heun lab was interested in the role of PIAS in the establishment of 
heterochromatin domains through SUMOylation of chromatin proteins, and in light of 
recent data linking PIAS to the Piwi/piRNA pathway
126,316
, I decided to perform PIAS 
IP-MS from Drosophila embryos at different timepoints in Drosophila development 
with the aim of identifying proteins responsible for heterochromatin formation that 
could possibly require PIAS mediated SUMOylation for their function.  
 
The aim of this chapter was to identify PIAS interactors in Drosophila embryos. I 
used the previously tested affinity purified Drosophila anti-PIAS sheep antibody that 
recognises all PIAS isoforms (Chapter 4) for immunoprecipitation of PIAS from wild-
type embryos. Firstly, I compared mixed populations of embryos either in nuclear 
cycles 1-14 (1-3hours) during the blastula stages of embryogenesis or after the 
nuclear cycles were complete (12-15 hours) post-gastrulation once tissues had 
been specified. I went onto identify PIAS interactors at more specific timepoints 
during the mid-blastula transition and heterochromatinization. Finally, I used the 
data from S2 cells (presented in Chapter 4) to complete a bioinformatic comparison 
of PIAS interactors identified in S2 cells versus embryos at different timepoints in 
development to identify interactors specific to early Drosophila embryos. In the 
Schneider 2 (S2) cell line (clone L2-4 originally derived from 20-24hr Drosophila 
melanogaster embryos), PIAS does not localise to heterochromatin and is instead 
found at euchromatic regions
57
. Therefore, comparison of PIAS IP-MS from timed 
Drosophila embryos and S2 cells could allow categorisation of constitutive PIAS 
interactors (found to co-immunoprecipitate with PIAS in all conditions) or identify 
proteins that interacted with PIAS specifically in the early embryo, when PIAS is 
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5.2 Aims 
• To identify PIAS interactors in Drosophila embryos 
• To identify whether PIAS interactors change during Drosophila embryo 
development 
• To identify whether ADD1 co-localises with PIAS in Drosophila embryos 
• To identify common PIAS interactors in S2 cells and embryos 
• To identify common properties, biological roles and molecular functions of 
PIAS interactors  
  
  PIAS interactors in embryos 
  127 
 
5.3 Results 
5.3.1 Identifying PIAS interactors in vivo, in Drosophila embryos  
By identifying PIAS interactors in vivo, I hoped to shed light on the biological 
function of PIAS in early embryos where its role remains largely elusive. I started by 
using IP-MS to identify PIAS interactors in Drosophila embryos at early and late 
timepoints in development. Protein identified to interact with PIAS in Drosophila 
embryos between 1-3 hr (Figure 5–1) and 12-15 hr (Figure 5–2) were compared to 
IgG IP-MS from equivalent extracts using volcano plots to visualise proteins that co-
immunoprecipitated with PIAS and were enriched in PIAS IP-MS compared to IgG 
control IP-MS. Proteins identified by two or more peptides and 30 or more peptides 
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Figure 5–1 Volcano plot of PIAS protein interactors in Drosophila embryos between 1-3 hours in development 
Immunoprecipitation (IP) using Drosophila affinity purified anti-PIAS antibody (PIAS) or control sheep anti-IgG (Control) coupled to Protein G 
Dynabeads™ was performed from embryo lysate. IP samples were prepared as described in methods and analysed by mass spectrometry. PIAS 
interactors in conditions with NEM are plotted. To determine the PIAS interactome, a MaxQuant label-free quantitation pipeline was used. Student’s T-
test was performed on log2 transformed LFQ values from three control and three PIAS IPs after filtering for proteins identified by two or more peptides 
(A) or 30 or more peptides (B) and found in at least two of three replicates. T-test difference ratios (x-axis) were plotted against the negative 
logarithmic p-value of the T-test (y-axis). Each dot represents one protein. PIAS is in red. Proteins in purple are linked to RNAi silencing pathways. 
Proteins in black are consistent PIAS interactors. Proteins in navy blue are chromatin proteins. SMT3 is in green. Polyadenylate-binding protein and 
proteins involved in post-transcriptional regulation are in pink. The confidence line was generated using a permutation-based FDR value of 0.05 and a 
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Figure 5–2 Volcano plots of PIAS protein interactors in Drosophila embryos between 12-15 hours in development 
Immunoprecipitation (IP) using Drosophila affinity purified anti-PIAS antibody (PIAS) or control sheep anti-IgG antibody (Control) coupled to Protein G 
Dynabeads™ was performed from embryo lysate. IP samples were prepared as described in methods and analysed by mass spectrometry. PIAS 
interactors in conditions with NEM are plotted. To determine the PIAS interactome, a MaxQuant label-free quantitation pipeline was used. Student’s T-
test was performed on log2 transformed LFQ values from three control and three PIAS IPs after filtering for proteins identified by two or more peptides 
(A) or 30 or more peptides (B) and found in at least two of three replicates. T-test difference ratios (x-axis) were plotted against the negative 
logarithmic p-value of the T-test (y-axis). Each dot represents one protein. PIAS in red. Proteins in purple are linked to RNAi silencing pathways. 
Proteins in black are consistent PIAS interactors. Proteins in navy blue are chromatin proteins. SMT3 is in green. Polyadenylate-binding protein and 
proteins involved in post-transcriptional regulation are in pink. The confidence line was generated using a permutation-based FDR value of 0.05 and a 





PIAS interactors in embryos 
132   
 
 
In 1-3hr embryos, Piwi and aub (components of the Piwi-piRNA pathway) were 
identified, as were other components associated with RNAi silencing complexes 
including: Fmr1, Tudor-SN, AGO2, vig2, bel and Dcr-2 (Figure 5–1). RISC complex 
components found to interact with PIAS in early embryos were also present in PIAS 
IP-MS from 12-15hr embryos (Figure 5–1 and Figure 5–2). Piwi was identified by 
more than 30 peptides in 1-3hr embryos (Figure 5–1); this is in agreement with the 
recent findings of Ninova et al., 2019163, who identified an interaction between PIAS 
and Piwi.  
 
Other proteins active in gene silencing pathways were identified in PIAS IP-MS. 
PIAS interaction with pABP and proteins involved in post-transcriptional gene 
silencing were identified in both 1-3hr and 12-15hr embryos (Figure 5–1, Figure 5–
2). These include Atx2, me31B, pcm, Upf1 and Rm62. Seven proteins found in the 
nuage/p-granule/germ plasm were identified: tral, TER94, Fs(2)ket, me31B, Fmr1, 
CG9425 and bel. Tral and cup were also identified. These interact with me31b to 
regulate the translation state of eIF4E1 bound mRNAs (which when mature are 
bound by pABP)317. Cup promotes deadenylation and protects deadenylated 
mRNAs from degradation, acting to maintain mRNAs in a repressed state318.  
 
In addition to proteins normally found in the cytoplasm or in specialised organelles 
such as p-granules, in a tissue specific manner, proteins involved in chromosome 
structure and function were also identified. These include SMC2, Top2, Gnf1, glu, 
Rm62, Nipped-A, Nup153, msps, Dp1, brm, cmet, Dhc64C, row, Mi-2 and Mtor. 
Also Rif1, woc, piwi, Rad50 and PIAS were identified and are associated with 
telomeric chromatin. Top2 was identified by 30 or more peptides in both 1-3hr 
embryos and 12- 15hr embryos. Woc and row were also identified in both conditions 
by 30 or more peptides (Figure 5–1, Figure 5–2).  
 
In 12-15hr embryos, the boundary element associated factor BEAF-32 was 
identified as a significant interactor of PIAS by PIAS IP-MS (Figure 5–2) and was 
not identified in 1-3hr embryos (Figure 5–1).  
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5.3.2 Identifying PIAS interactors during early Drosophila embryonic 
development  
To assess whether PIAS interactors change during early Drosophila development, 
embryos were harvested at more specifically defined timepoints. I aimed to identify 
how PIAS interactors change over developmental time and possibly identify proteins 
involved in heterochromatin formation through PIAS-mediated SUMOylation.  
 
Early embryos undergo rapid cycles of cell division, which dilutes the chromatin 
marks inherited from the parental lineage. In Drosophila, chromatin marks are re-
introduced as the rapid cycles of cell division slow, nearing the mid-blastula 
transition and zygotic genome activation123. The earliest observed heterochromatin 
mark is H3K9me2 at nuclear cycle 1285 with methylation of H3K9 and recruitment of 
HP1a to chromatin increasing between NC12-14, visible in domains by NC14123. 
PIAS is also observed during these timepoints and is first detected at chromatin in 
NC10 (Heun lab unpublished).  
 
Embryos were collected at three timepoints early in Drosophila development, with 
the bulk of the embryos at either before (mean at nuclear cycle 9), during (mean at 
nuclear cycle 12) or after (mean just after nuclear cycles have been completed, in 
gastrulation) heterochromatin establishment (Figure 5–3A). Representative images 
of DAPI stained embryos are shown in Figure 5–3B. Drosophila embryo protein 
extracts contain PIAS proteins amenable to immunoprecipitation (Figure 5–3C). 
Therefore PIAS interaction partners at these different stages in early development 
could be identified by IP-MS and compared to interactors identified from 12 hour 
embryos (referred to as timepoint 12), when heterochromatin localisation of PIAS 
has been lost and chromatin domains have been established. 
 
The log2 transformed LFQ values of proteins identified to interact with PIAS were 
plotted as scatter plots (Figure 5–4, Figure 5–5, Figure 5–6) comparing the 
abundance of proteins identified in PIAS IP-MS from different timepoints. This 
allowed visualisation of changes in abundance of PIAS interactors that are in 
common in each timepoint  as well as visualization of the number of proteins that 
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are only identified by PIAS IP-MS to co-immunoprecipitate with PIAS at one 




Figure 5–3 Collection of embryos at defined timepoints in development 
(A) Embryo nuclear cycles quantified for timepoints 1, 2 or 3, to validate embryo ages of 
timepoints collected. Embryos were staged by DAPI stain based on nuclear cycles 1-14.  
n=100/timepoint. Grey shading marks nuclear cycles 10-14 during which heterochromatin is 
established. Mean +/- standard error (B) Representative confocal microscope images of 
timepoint one, timepoint  two and timepoint three DAPI stained embryos. (C) Western blot 
probed with anti-PIAS sheep antibody analysing immunoprecipitations (IP) using affinity 
purified Drosophila anti-PIAS sheep antibody or control anti-IgG sheep antibody coupled to 
Protein G Dynabeads™ from embryo protein extracts made from ORER Drosophila 
collected timepoints 1-3.   
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Figure 5–4 Scatter plot comparing PIAS protein interactors in embryos at timepoint 1 
and timepoint 2 
Mean log2 transformed LFQ values calculated from three biological replicates, from PIAS IP 
from timepoint 1 and timepoint 2 embryos in +NEM. Each dot represents one protein. The 
top plot shows all proteins and the bottom plot shows proteins found only in both conditions. 
PIAS is in red. In purple are proteins linked to RNAi silencing pathways. In blue are selected 
proteins which change in interaction specificity during development. In orange are 
developmental specific RNAi components. SMT3 is in green. Diagonal lines mark two log2 
fold change from zero. 
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Figure 5–5 Scatter plot comparing PIAS protein interactors in embryos at timepoint 1 
and timepoint 3 
Mean log2 transformed LFQ values calculated from three biological replicates, from PIAS IP 
from timepoint 1 and timepoint 3 embryos in +NEM. Each dot represents one protein. The 
top plot shows all proteins and the bottom plot shows proteins found only in both conditions. 
PIAS is in red. In purple are proteins linked to RNAi silencing pathways. In blue are selected 
proteins which change in interaction specificity during development. In orange are 
developmental specific RNAi components. SMT3 is in green. Diagonal lines mark two log2 
fold change from zero. 
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Figure 5–6 Scatter plot comparing PIAS protein interactors in embryos at timepoint 1 
and timepoint 12 
Mean log2 transformed LFQ values calculated from three biological replicates, from PIAS IP 
from timepoint 1 and timepoint 12 embryos in +NEM. Each dot represents one protein. The 
top plot shows all proteins and the bottom plot shows proteins found only in both conditions. 
PIAS is in red. In purple are proteins linked to RNAi silencing pathways. In blue are selected 
proteins that change in interaction specificity during development. In orange are 
developmental-specific RNAi components. SMT3 is in green. Diagonal lines mark two log2 
fold change from zero.  
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No differences greater than log2 two-fold were observed between shared PIAS 
interaction partners between timepoints 1 and 2 (Figure 5–4) and timepoints 1 and 
3, with the exception of me31B which was detected in higher abundance in 1hr 
compared to 3hr embryos (Figure 5–5). 
 
There are a small number of differences between timepoints 1 and 2 (Figure 5–4), 
with 512 proteins found at both timepoints and 132 proteins unique to either 
timepoint. The 105 proteins found to interact with PIAS in timepoint 1 embryos 
include mitotic checkpoint control protein kinase BUB1 (BubR1), chromatin 
assembly factor 1, (Caf1) and inner centromere protein (INCENP). Along with 26 
other proteins, AGO1 is present in timepoint 2 onwards, and has been shown to 
have activity at later timepoints in development. AGO1 functions in an RNA induced 
silencing pathway to silence microRNAs and is important for patterning in the 
embryo319. 
 
Between timepoints 1 and 3, the chromatin component Nurf-38 was only found to 
interact with PIAS in timepoint 3 embryos. Interestingly, cup, bicC and PIAS isoform 
D are not identified in timepoint 3 (Figure 5–5). 
 
Differences greater than log2 two-fold were observed between LFQ values of 
interactors co-immunoprecipitating with PIAS from embryos harvested at timepoints 
1 and 12 (Figure 5–6). 516 proteins were present at both timepoints and 704 
proteins unique to either timepoint. BEAF- 32 was only identified as a PIAS 
interactor in timepoint 12 embryos. In Figure 5–6 piwi and aub were present in 
timepoint 1 not timepoint 12 likely due to their specific developmental role.  
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5.3.3 Comparison of PIAS interactors identified by IP-MS from Drosophila 
embryos and S2 cells 
Proteins identified by two or more peptides in PIAS IP-MS from S2 cells and 
embryos at timepoints 1,2,3 and 12, in the presence of NEM conditions were 
compared. The number of overlapping UniProt protein IDs identified are shown in a 
five-way Venn diagram (Figure 5–7). Negative control samples were included in this 
analysis, where protein lysate was incubated with IgG-coupled beads. Any protein 
identified by more than one peptide in the negative control samples was excluded 
from the overlap as a non-specific interactor of antibody-bead complexes.  
 
A comparison between interactors identified from S2 cells, embryos at 12-15hr and 
embryos at 1-3hr in NEM conditions found 357 proteins in common between the IP-
MS from embryos and S2 cells and 552 interactors in common between S2 cells 
and 12-15hr embryos (Figure 5–7B) once tissues have been specified320. 
  
PIAS interactors in embryos 








Figure 5–7 Venn diagrams showing the number of proteins identified in PIAS IP-MS  
PIAS IP-MS experiments (A) from S2 cells and embryos at timepoints 1,2, 3 and 12 (B) S2 
cells, embryos at 12-15hr and embryos at 1-3hr. All experiments were conducted in the 
presence of NEM. 
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5.3.4 Gene ontology (GO) terms analysis of PIAS interactors found in 
embryos and S2 cells in the presence of NEM 
Protein IDs were imported into FlyMine (http://www.flymine.org/) to categorise PIAS 
interactors based on Gene Ontology (GO) terms, homology searches and pathway 
enrichment. Of the 357 proteins identified as PIAS interactors in S2 cells, embryos 
at 1-3hr and embryos at 12-15hr (Figure 5–7B), 331 had GO terms associated with 
them in FlyMine. The top GO terms associated with PIAS binding partners in S2 
cells also found in 1-3hr and 12-15hr embryos are listed in Table 9.  
 
Table 9 Gene ontology (GO) terms associated with proteins identified in all PIAS IP-
MS  
Gene Ontology analysis, using the FlyMine complete GO biological process annotation 
dataset, of proteins identified in PIAS IP-MS from S2 cells, embryos at 1-3 and 12-15hr. 
Bonferroni test correction was applied. Matches are unique proteins within each GO term. In 
bold are terms of interest. 
 
GO term: Biological Process p-value matches 
cytoplasmic translation [GO:0002181] 1.07E-73 76 
gene expression [GO:0010467] 3.89E-48 234 
cellular nitrogen compound metabolic process [GO:0034641] 3.12E-41 245 
chromatin assembly or disassembly [GO:0006333] 2.33E-38 54 
chromosome organization [GO:0051276] 3.45E-33 104 
translation [GO:0006412] 4.75E-31 107 
peptide biosynthetic process [GO:0043043] 9.60E-30 108 
amide biosynthetic process [GO:0043604] 2.29E-28 108 
organelle organization [GO:0006996] 2.33E-27 165 
cellular macromolecule biosynthetic process [GO:0034645] 3.57E-27 180 
cellular nitrogen compound biosynthetic process [GO:0044271] 1.29E-26 179 
macromolecule biosynthetic process [GO:0009059] 1.65E-26 180 
peptide metabolic process [GO:0006518] 7.73E-26 108 
cellular process [GO:0009987] 1.10E-24 354 
cellular component organization or biogenesis [GO:0071840] 1.60E-23 207 
chromatin organization [GO:0006325] 1.63E-23 75 
cellular amide metabolic process [GO:0043603] 3.22E-23 109 
protein-containing complex subunit organization [GO:0043933] 3.46E-22 88 
protein-containing complex assembly [GO:0065003] 7.43E-22 79 
cellular protein-containing complex assembly [GO:0034622] 1.52E-21 75 
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cellular component organization [GO:0016043] 2.41E-20 195 
DNA-templated transcription, initiation [GO:0006352] 6.45E-20 35 
nucleic acid metabolic process [GO:0090304] 7.03E-20 158 
mRNA metabolic process [GO:0016071] 1.07E-19 63 
macromolecule metabolic process [GO:0043170] 2.41E-19 264 
RNA metabolic process [GO:0016070] 5.19E-19 146 
cellular biosynthetic process [GO:0044249] 1.08E-18 186 
cellular component biogenesis [GO:0044085] 1.52E-18 122 
RNA processing [GO:0006396] 2.32E-18 75 
organic substance biosynthetic process [GO:1901576] 4.14E-18 187 
biosynthetic process [GO:0009058] 1.13E-17 187 
DNA conformation change [GO:0071103] 2.53E-17 41 
mRNA processing [GO:0006397] 3.18E-17 54 
nucleobase-containing compound metabolic process [GO:0006139] 5.10E-17 164 




In order for a GO terms category to be assigned, the protein ID has to be 
recognised in the database and have that GO term associated with it. The same list 
of PIAS interactors (found in all three settings: in S2 cells and embryos at 1-3hr and 
12-15hr (Figure 5–7B)), was imported into PANTHER (http://www.pantherdb.org/) 
for gene ontology (GO) term analysis to categorise the interactors and validate 
results from FlyMine. Of the 357 proteins, 201 had GO terms associated with them. 
The top GO terms associated with PIAS interactors are listed in Table 10, ordered 
by fold enrichment. Fold enrichment is the observed value over the expected value. 
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Table 10 Top gene ontology (GO) terms associated with proteins identified in PIAS IP-
MS in NEM conditions 
Gene Ontology analysis of proteins identified in PIAS IP-MS from S2 cells, embryos at 1-3 
and 12-15hr. The analysis is a PANTHER overrepresentation test against the complete GO-
Slim biological process annotation dataset with Bonferroni correction applied.  
 
PANTHER GO-Slim Biological Process  Fold Enrichment p-value 
negative regulation of mitotic cell cycle 22.83 3.34E-02 
mitotic cell cycle checkpoint 22.83 3.34E-02 
ribonucleoprotein complex assembly 10.9 4.72E-03 
chromosome organization 9.97 5.55E-08 
chromatin organization 8.81 1.17E-03 
RNA processing 7.07 1.73E-06 
mRNA splicing, via spliceosome 6.85 8.71E-04 
RNA splicing, via transesterification reactions 6.79 9.50E-04 
translation 6.68 3.93E-08 
RNA splicing 6.61 1.23E-03 
formation of translation initiation ternary complex 6.58 1.53E-06 
translational termination 6.58 1.53E-06 
translational elongation 6.58 1.53E-06 
cellular component organization or biogenesis 6.19 3.21E-05 
cellular component biogenesis 6.19 3.21E-05 
ribonucleoprotein complex biogenesis 5.42 7.93E-03 
nucleic acid metabolic process 4.14 4.67E-03 
organelle organization 3.96 1.32E-05 
gene expression 3.48 1.13E-11 
macromolecule metabolic process 3.13 1.49E-13 
cellular component organization 2.52 6.94E-03 
organic substance metabolic process 2.14 1.10E-06 
metabolic process 1.88 7.28E-05 
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Cell cycle processes were identified in FlyMine with a p-value of 0.001659 and 47 
independent matches. Proteins involved in the mitotic cell cycle include Bub1-
related kinase (A1Z6I7), DNA topoisomerase 2 (P15348), Bub1 kinase isoform A 
(Q9VMS5), Bub3 isoform A (Q9VAJ2). Interactors of PIAS that are involved in 
chromatin remodelling include Caf1, H2A, H2B, FACT complex dre4, Iswi. More 
specifically involved in heterochromatin assembly are Su(var)2-HP2, Dp1, Fmr1 and 
HP1a. Nuclear pore protein Nup98-96 was identified. Nup98-96 plays a role in 
chromosome organisation by tethering genes transcribed by RNA Pol II at the 
nuclear periphery and promotes transcription activation by influencing promoter-
enhancer looping. Structural maintenance of chromosomes 2 (SMC2), glu (part of 
the Condensin complex), and Topoisomerase 2 (Top2) involved in chromosome 
condensation were also identified. The protein “will die slowly” (wds) that catalyses 
methylation of histone H3-K4 was also identified. 
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Classification of GO terms by protein type using PANTHER found that out of 148 
molecular function hits, nucleic acid binding was identified on 71 occasions. 
Hydrolases (proteases, deacetylases, phosphatases) and transferase 
(acetyltransferase, kinase, methyltransferase) were the next most commonly 




Figure 5–8 PIAS interactors categorised into PANTHER protein class level 1  
Proteins identified in PIAS +NEM conditions from S2 cells, embryos at 12-15hr and at 1-3hr 
were input into The PANTHER Classification System (www.pantherdb.org) for assigning 
protein class based on GO terms. 
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Of the nucleic acid binding proteins, 54 proteins were classified as binding to RNA 
and 14 were classified as DNA binding proteins (Figure 5–9).  
 
Figure 5–9 PIAS interactors categorised into PANTHER protein class level 2, for 
nucleic acid binding 
 
The DNA binding proteins included DNA polymerases and chromatin-binding 
proteins (Figure 5–10). 
 
Figure 5–10 PIAS interactors categorised into PANTHER protein class level 3, for DNA 
binding 
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Of the RNA binding proteins ribosomal proteins were represented by 20 different 
proteins (Figure 5–11). Ribosomes are assembled in the nucleus and ribosomal 
proteins are highly abundant in the nucleus. 14 mRNA processing proteins were 
identified (Figure 5–11), 10 of which are involved in mRNA splicing and two are 
involved in mRNA polyadenylation. 
 
Figure 5–11 PIAS interactors categorised into PANTHER protein class level 3, for RNA 
binding 
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5.3.5 PIAS interactors found only in early embryos  
Next, to identify proteins that interacted with PIAS specifically in early Drosophila 
embryos (when heterochromatin is being established), I annotated the PIAS 
interactors found uniquely in timepoint 1 (Table 11) and timepoint 2 (Table 15) 
embryos, and the interactors found at both of these timepoints (Table 13). My 
rationale was that if PIAS only localises at heterochromatin in Drosophila embryos, 
and in S2 cells binds euchromatin, something that interacts with PIAS in the early 
stages of development before heterochromatin establishment could be important for 
this process. I also queried these protein lists in a GO terms analysis (Table 12 and 
Table 14). 
 
GO terms enrichment of PIAS interactors from timepoint 1 embryos found terms 
associated with replication, cell cycle and chromosome segregation (Table 12). For 
proteins which interact with PIAS in timepoint 1 and 2 embryos, proteins involved in 
gamete generation and reproductive processes were enriched (Table 14). No 
enrichment for GO terms was found from timepoint 2 embryos. 
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Table 11 PIAS interacting proteins unique to timepoint 1 embryos identified by PIAS IP-MS 
 Mapped UniProt ID Gene Name Protein name Function 
1 A0A0B4K713 fl(2)d Female lethal d mRNA methylation, regulation of alternative splicing 
2 A0A0B4K730 ced-6  Ced-6 PTB domain-containing adapter protein 
3 A0A0B4KFV0 nopo  No poles  DNA polymerase binding, mitotic cell cycle regulation 
4 A0A0B4KHU1 Rlip  Ral interacting protein GTPase activator activity 
5 A0A0B4KHY8 CG10254   Ubiquitin-protein transferase activity 
6 A0A0B4LG06 gem  Gemini DNA binding transcription factor activity 
7 A0A0B4LGC0 TppII Tripeptidyl-peptidase II Serine-type endopeptidase activity 
8 A0A0H4Y1G0 Nelf-A  FI24705p1 Negative elongation factor 
9 A1Z6H4 vlc  RE52822p signaling 
10 B7Z0A9 sowah  Sosondowah  
11 B7Z138 CG34408  GTPase activator 
12 C0MIY3 CG2867    
13 E8NH59 WRNexo RE48478p 3’-5’ exonuclease activity 
14 H1UUH1 eco  FI18257p1 Sister chromatid cohesion and meiotic chromosome segregation 
15 L0CRU3 mael Maelstrom Regulation of gene silencing by miRNA 
16 M9NDA6 Lasp Lasp  
17 M9PCF1 Duox Dual oxidase Response to oxidative stress 
18 M9PFF9 tral  Trailer hitch Cytoskeleton organisation 
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19 M9W9W1 Chd3  FI21135p1 ATP binding chromatin remodeller 
20 O18475 mus308  DNA polymerase theta Promotes non-homologous end-joining DNA  
21 O76912 CG2701 EG:95B7.9 (high expression in eye disks) 
22 P20439-3 CycB-RB  G2/mitotic-specific cyclin-B Cell cycle regulation 
23 P25158-2 osk  Maternal effect protein oskar Organises the germ plasm  
24 P25171 Rcc1  Regulator of chromosome condensation 
Promotes the exchange of Ran-bound GDP by GTP. Involved in the regulation of onset 
of chromosome condensation in the S phase 
25 P54622 mtSSB  Single-stranded DNA-binding protein, mitochondria 
This protein binds preferentially and cooperatively to pyrimidine rich ss-DNA. Required 
for mitochondrial DNA replication. 
26 P54733-2 CycE G1/S-specific cyclin-E Cell cycle regulation 
27 Q05913 TfIIFalpha  General transcription factor IIF subunit 1 
TFIIF is a general transcription initiation factor that binds to RNA polymerase II and 
helps to recruit it to the initiation complex in collaboration with TFIIB. 
 
28 Q0KHS7 Lsd-2  Lipid storage droplet-2  
29 Q24154 RpL29  60S ribosomal protein L29 chromatin binding321, structural constituent of ribosome 
30 Q24558 tos  Exonuclease 1 5'->3' double-stranded DNA exonuclease which may also contain a cryptic 3'->5' double-stranded DNA exonuclease activity 
31 Q29QV6 N/A  IP14020p DNA repair 
32 Q32KD2 egg  Eggless Histone-lysine N-methyltransferase, trimethylates histone 3 lysine 9  
33 Q59DT6 Rb97D  Ribonuclear protein at 97D Germ cell development and mRNA binding 
34 Q5U118 AMPKalpha  Non-specific serine/threonine protein kinase  
35 Q5UEC2 Taf12L  TAF-like protein Transcription initiation from RNA polymerase II promoter 
36 Q7JUM5 MCPH1  LD43341p Mitotic cell cycle 
37 Q7JXA2 PRAS40 LOBE Negative regulation of protein kinase activity 
38 Q7KJQ4 IKKepsilon  Protein kinase DIK2 protein kinase 
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39 Q86NY8 Tomosyn  LD44990p GTPase activator activity, cell polarity establishment or maintenance  
40 Q8IPM0 srl  Spargel mRNA binding, transcription coregulator activity, energy homeostasis 
41 Q8IR24 sun  Protein stunted Activates the G-protein coupled receptor mth in vitro, leading to increased intracellular calcium ion levels. 
42 Q8IRG9 Iml1  GATOR complex protein Iml1 TORC1 pathway regulation, to mediate metabolic homeostasis, female gametogenesis  
43 Q8T389 EndoB Endophilin B Membrane organisation 
44 Q960Y4 drosha LD29995p siRNA production for RNA interference 
45 Q9I7N6 mus201  DNA repair endonuclease Double-strand break repair and nucleotide-excision repair 
46 Q9I7U4-3 sls Titin Muscle protein 
47 Q9U3V9 xmas-2 Xmas-2 GERMINAL-CENTER ASSOCIATED NUCLEAR PROTEIN  Required for spermatogenesis, oogenesis and embryogenesis, mRNA export from nucleus 
48 Q9U8Q0 px  Plexus Imaginal disc-derived wing vein morphogenesis 
49 Q9V9V7 pasha LD23072p Double-stranded RNA binding, gene silencing by miRNA 
50 Q9VBA3 BcDNA:GH07466  AT30002p  
51 Q9VD66 fit  Female-specific independent of transformer  
52 Q9VDR1 MED25  Mediator of RNA polymerase II transcription subunit 25 
Component of the Mediator complex, a coactivator involved in the regulated 
transcription of nearly all RNA polymerase II-dependent genes 
53 Q9VEH1 Mps1  LD04521p Protein kinase, chromosome segregation 
54 Q9VFP2-3 rdx; Protein roadkill Involved in segment polarity 
55 Q9VI72 Sas-4  Spindle assembly abnormal 4 centromere protein J,  centrosome separation 
56 Q9VIS5 CG10631  Uncharacterised protein Negative regulation of transcription by RNA polymerase II 
57 Q9VK08 CG44085  Uncharacterised protein MAP-kinase scaffold activity 
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58 Q9VKH9 cana  CENP-ana, isoform A CENTROMERE-ASSOCIATED PROTEIN E  metaphase/anaphase transition of mitotic cell cycle 
59 Q9VL20 ova  RE35195p core promoter sequence-specific DNA binding 
60 Q9VLR5 Ssb-c31a  RNA polymerase II transcriptional coactivator 
General coactivator that functions cooperatively with TAFs and mediates functional 
interactions between upstream activators and the general transcriptional machinery 
61 Q9VM45 Nuf2  Nuf2 Chromosome segregation 
62 Q9VMX6 Marcal1  
SWI/SNF-related matrix-
associated actin-dependent 
regulator of chromatin 
subfamily A-like protein 1 
ATP-dependent annealing helicase that catalyzes the rewinding of the stably unwound 
DNA 
63 Q9VNE4 asl  Asterless Asymmetric cell division 
64 Q9VNR6 l(3)04053  Lethal (3) 04053  
65 Q9VP12 SMC5  Structural maintenance of chromosomes 5 
double-strand break repair via homologous recombination 
protein sumoylation 
66 Q9VP94 CG10588 Uncharacterised protein  
67 Q9VPY0 IntS14  Integrator complex 14 Component of the Integrator complex, a complex involved in the transcription of small nuclear RNAs (snRNA) 
68 Q9VS48 mus312  Structure-specific endonuclease subunit SLX4 resolving diverse forms of deleterious DNA structures 
69 Q9VSP0 CG6511  IP13783p  
70 Q9VUI0 gnu CG5272 Protein kinase activator activity, mitotic cell cycle regulation 
71 Q9VX63 CG8915-RA  FI18001p1 ATP-DEPENDENT RNA HELICASE YTHDC2-RELATED  N6-methyladenosine-containing RNA binding 
72 Q9VXA0 Nprl2  GATOR complex protein NPRL2 TORC1 signaling pathway 
73 Q9VYR0 Lsm12  LSM12 Component of the Atx2-tyf activator complex 
74 Q9VZ04 GCS1  Glucosidase 1 Protein N-linked glycosylation 
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75 Q9W028 yellow-g2 IP19120p Cuticle pigmentation, melanin biosynthetic process 
76 Q9W4W7 EG:100G10.6  RE68603p POLYCOMB PROTEIN SCM  
77 Q9W5Y4 Marf1  MIP18541p Regulator of gene expression 
78 Q9XZ03 mbf1  Multiprotein Bridging Factor 1 DNA binding, central nervous system development 
79 T2FFI3 mei-9  FI21265p1 DNA repair 
80 X2J6U8 ssp3  Short spindle 3 cytoskeleton 
81 X2JKF2 CG9213  Uncharacterised protein  
82 X2JKM9 kat80  Katanin p80 WD40 repeat-containing subunit B1 Microtubule binding  
 
Table 12: GO terms analysis of the 82 PIAS interacting proteins unique to timepoint 1 embryos identified by PIAS IP-MS 
GO term: Biological process p value  matches 
nuclear chromosome segregation [GO:0098813] 0.001056 10 
DNA replication [GO:0006260] 0.001726 8 
chromosome segregation [GO:0007059] 0.002525 10 
cell cycle [GO:0007049] 0.013219 17 
regulation of DNA replication [GO:0006275] 0.018052 5 
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Name Protein Name Function 
1 A0A0B4KGX7 gwl  Greatwall, isoform B 
chromosome condensation, negative regulation of phosphoprotein phosphatase 
activity 
2 A0A0B4KGY9 msi Musashi, isoform H 
translation repressor activity, mRNA regulatory element binding, cell fate 
determination 
3 A0APA5 CG3509  CG3509 protein DNA binding, nucleosome assembly 
4 A1A708 CG4951 Uncharacterized protein   
5 A1Z6E6 d4  D4, isoform C histone acetyltransferase activity, transcription regulation 
6 A1ZAP7 CG6967  Uncharacterized protein posttranscriptional gene silencing by RNA 
7 G7H828 
CG9247-
RA RE72821p1 3'-5' exonuclease activity 
8 M9NDR2 BicD Bicaudal D, isoform B cytoskeletal adaptor activity 
9 M9PHL6 bif  Bifocal, isoform E axon guidance, female meiosis chromosome segregation 
10 O46112 toc  Toucan protein syncytial blastoderm mitotic cell cycle 
11 O96828 Psi  EG:EG0003.2 mRNA processing 
12 Q4V527 CG15415 IP13307p  
13 Q7KSP6 Sbf  SET domain binding factor, isoform B histone acetyltransferase and methyltransferase activity, transcription regulation 
14 Q86RA0 Mbs  Myosin phosphatase DMBS-L phosphatase regulator activity 
15 Q8I9J8 scaf6  SR-related CTD associated factor 6 RNA processing 
16 Q8IGK3 
Su(var)2-
10  RE73180p, isoform D  
17 Q8INW9 fon  Fondue, isoform A metamorphosis 
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18 Q8MR83 muskelin  AT11715p regulation of cell-matrix adhesion 
19 Q9NH11 RecQ4  RECQ4 
ATP-dependent 3'-5' DNA helicase activity, telomere maintenance, DNA repair and 
replication 
20 Q9VBI4 Exo84  Exocyst 84, isoform A establishment or maintenance of cell polarity 
21 Q9VDE3 slmb  LD08669p phosphoprotein binding 
22 Q9VQM4 gkt  
Probable tyrosyl-DNA 
phosphodiesterase DNA repair enzyme  
23 Q9VV79 spd-2  BcDNA.LD24702 phosphohydrolase activity 
24 Q9VW68 Gabat 
Gamma-aminobutyric acid 
transaminase, isoform A metabolic process 
25 Q9W3C4 Hexo2  Beta-hexosaminidase metabolic process 
26 X2JC02 CG45186  Supervillin  
27 X2JEK3 wisp Wispy, isoform B polynucleotide adenylyltransferase activity 
 
Table 14 GO terms analysis of the 27 PIAS interacting proteins shared in timepoint 1 and timepoint 2 embryos 
GO term: Biological process p-value matches 
multi-organism process [GO:0051704] 0.001913 15 
reproduction [GO:0000003] 0.008982 14 
reproductive process [GO:0022414] 0.015306 13 
cellular process involved in reproduction in multicellular organism [GO:0022412] 0.017972 11 
multicellular organism reproduction [GO:0032504] 0.022163 13 
multi-organism reproductive process [GO:0044703] 0.026886 12 
gamete generation [GO:0007276] 0.04792 11 
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Table 15 PIAS interacting proteins unique to timepoint 2 embryos identified by PIAS IP-MS 
 Mapped 
UniProtID Gene Name Protein Name Function 
1 A0A0B4LFQ7 CG9646-RA Uncharacterized protein  
2 A1Z6G3 Fis1 Mitochondrial fission 1  Involved in the fragmentation of the mitochondrial network and its perinuclear clustering 
3 B6IDY8 Nprl3 FI07656p negative regulation of TOR signaling 
4 B7Z026 PDZ-GEF Dizzy isoform CII 
Ras GTPase binding, germ-line stem cell population maintenance, imaginal disc-derived male genitalia 
development, imaginal disc-derived wing morphogenesis, regulation of compound eye photoreceptor 
development 
5 D1Z363 Cp36 RT04026p  
6 E1JHK3 dl Dorsal DNA-binding transcription factor activity 
7 M9PBB5 vas Vasa intracellular mRNA and protein localization 
8 M9PHK2 Tao Tao MAP kinase kinase kinase activity 
9 O17468-3 Hira HIRA homolog DNA replication-independent nucleosome assembly, transcription corepressor activity, sperm chromatin decondensation, regulation of chromatin silencing 
10 P42283 lola Longitudinals lacking protein 
Putative transcription factor required for axon growth and guidance in the central and peripheral 
nervous systems 
11 Q24169 Orc5 Origin recognition complex subunit 5 Component of the origin recognition complex (ORC) that binds origins of replication 
12 Q59E36-4 CoRest REST corepressor represses transcription of neuron-specific genes in non-neuronal cells 
13 Q6NR30 BEST:LD13441 RE38958p  
14 Q7JRH2 ReepA Receptor expression-enhancing protein 
 
15 Q7JRM5 CG11127 GH12965p  
16 Q7JW66 CG12129 LD21545p  
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17 Q7K1D9 CG15512 GH14951p  
18 Q7YU52 E23 RE53253p regulation of circadian rhythm 
19 Q8IGH0 CG5484-RB   
20 Q8MQR6 CG7029 P RH23428p  
21 Q8SYF6 Cyp4s3 RE63964p  
22 Q8SYX1 CG32576 RE29988p  
23 Q8SZD0 Grip71  gamma-tubulin binding, mitotic cell cycle 
24 Q8T921 CG11710 AT04454p transcription coactivator activity 
25 Q95V48 CCY Coiled-coil Y protein  
26 Q9V3E9 spag FI17138p1 negative regulation of motor neuron apoptotic process 
27 Q9V8K2 Sec6 Exocyst complex component 3 SNARE binding 
28 Q9VE79 CG14309 Uncharacterized protein  
29 Q9VG32 Men Malic enzyme determination of adult lifespan 
30 Q9VHN4 CG8043 GH14121p  
31 Q9VNC2 HDAC3 Histone deacetylase histone H3 and H4 deacetylation 
32 Q9VPX4 Tfb4 FI01003p RNA polymerase II CTD heptapeptide repeat kinase activity 
33 Q9VSV2 CG4476 Transporter neurotransmitter transport 
34 Q9VZ69 Imp IGF-II mRNA-binding protein neuron remodeling 
35 Q9W158 CG4612 LD36772p long-term memory, positive regulation of translation 
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5.3.6 XNP and ADD1 (ATRX) as interactors of PIAS in embryos  
As the Heun lab is interested in the role of PIAS mediated SUMOylated of chromatin 
associated factors, I focused on XNP and ADD1. XNP had previously been 
observed to co-localise with DAPI dense regions of pre-blastoderm nuclei in 
Drosophila embryos144, coinciding with the timings of heterochromatin formation and 
it was identified as a SUMO target in both a study in the Heun lab by a previous 
student304 and independently by Nie et al., 2009171. ADD1 was of interest because it 
interacts with XNP296 and could possibly aid chromatin recognition of XNP if acting 
in a similar manner to its mammalian ATRX homolog.  
 
I had shown that ADD1 interacts with PIAS in S2 cells and that the PIAS-XNP 
interaction only occurred in the presence of NEM, suggesting that that interaction 
depends on SUMOylation. Whether an interaction between XNP and ADD1 is  
observed in Drosophila, using the same tools as used in S2 cells, might clarify 
whether ADD1-XNP is maintained in vivo.  
 
XNP is moderately expressed in the embryo, whereas ADD1 has very low 
expression levels, (Appendix Figure 9–6)139. Endogenous XNP was not detectable 
above background levels in Drosophila embryos when stained with the anti-XNP 
rabbit antibody (generated in this study- see 6.3.6) (data not shown). However, the 
anti-ADD1 rabbit antibody (generated in this study- see 6.3.6) recognised ADD1 
epitopes in Drosophila embryos despite ADD1 having lower expression levels than 
XNP139. This suggests that the anti-ADD1 antibody is more sensitive than the anti-
XNP antibody, which is not surprising given that XNP immunization schedule was 
terminated early, likely before the time when the antibodies have reached their 
optimum recognition of targets after a certain number of boosts.  
 
ADD1 co-localises with DAPI dense regions of pre-blastoderm nuclei in the 
Drosophila embryo (Figure 5–12). Interestingly, ADD1 is found at discrete sites 
(Figure 5–12), that likely correspond to telomere ends as ADD1, XNP and PIAS bind 
telomeric DNA sequences of chromosome 2L322 and ADD1 and HP1a co-localise at 
the tips of the chromosome arms in wild-type polytene chromosomes295. 
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Figure 5–12 ADD1 localises at heterochromatin in nuclear cycles 12-14 in Drosophila 
embryos. 
Representative confocal image of a pre-blastoderm cell in a Drosophila embryo at nuclear 




Localisation of PIAS and ADD1 was analysed in Drosophila embryos. PIAS and 





Figure 5–13 PIAS and ADD1 colocalise at heterochromatin in nuclear cycle 13-14 
Drosophila embryos. 
Representative confocal image of pre-blastoderm cells in Drosophila embryos at nuclear 
cycle 14 (NC14). Embryos were stained with affinity purified anti-PIAS sheep antibody (red), 
anti-ADD1 antisera (green) and DAPI.  
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ADD1 and XNP were not identified as interactors of PIAS in Drosophila embryos by 
IP-MS. ADD1 was detected by one peptide in PIAS IP-MS from 12-15hr embryos, 
however two or more peptides of a protein need to be detected to identify a protein 
in mass spectrometry studies. XNP was not identified. However, PIAS IP followed 
by western blot probing with anti-ADD1 and anti-XNP antibodies showed that PIAS, 
ADD1 and XNP co-immunoprecipitate from 1-3hr embryos and 12-15hr embryos 




Figure 5–14 ADD1 and XNP co-immunoprecipitate with PIAS in Drosophila embryos. 
Protein extracts were made from Drosophila embryos. The input (IN), IP with affinity purified 
anti-IgG sheep antibody (IgG) and IP with anti-PIAS sheep antibody (IP) were analysed on 
8% SDS-PAGE followed by western blot probed with Drosophila anti-PIAS sheep antibody, 
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5.4 Summary 
To identify common functions of PIAS interactors, proteins identified in PIAS IP-MS 
from S2 cells (section 4.3.9) and from embryos collected at different timepoints 
(Figure 5–3) were compared. This revealed a common set of PIAS interactors 
identified in all conditions (Figure 5–7), as-well as a number of proteins that co-
immunoprecipitated with PIAS either specifically in either embryos or S2 cells. GO 
terms analysis by PANTHER overrepresentation test and identification of associated 
GO terms of PIAS interactors allowed inference of the biological processes that 
PIAS interactors are involved in.  
 
5.4.1 Common functions of PIAS interactors 
PIAS interactors are enriched with nucleic acid binding proteins (Figure 5–8). The 
nucleic acid binding proteins represented interaction with DNA binding proteins and 
RNA binding proteins, in particular, chromatin proteins, DNA polymerases, 
ribosomal proteins and mRNA processing proteins (Figure 5–9, Figure 5–10, Figure 
5–11). Overall, this suggests that PIAS mediated SUMOylation is involved in 
different stages of gene expression regulation. However, the exact role of PIAS 
mediated SUMOylation is as yet unknown. Experiments removing the E3 ligase 
activity of PIAS would need to be performed to assign the function of PIAS 
interaction in aiding SUMOylation of these proteins. 
 
5.4.2 PIAS interactors only present in embryos 
In PIAS IP-MS from timepoint 1 embryos, Eggless was identified (Table 11). 
Eggless is of interest in the context of heterochromatin establishment in Drosophila 
embryos (see section 2.1.1). The mechanism of Eggless recruitment to chromatin is 
currently unknown and is hypothesised to be recruited to chromatin through 
interaction with small RNAs. It is plausible that, like HP1ɑ in mouse tissue culture 
cells (discussed in section  2.3.13), SUMOylation could be involved in Eggless-RNA 
guided recruitment to establish heterochromatin.  
 
If SUMOylation is involved in establishment of processes, proteins which require 
SUMO may only display an interaction with PIAS transiently at a specific timepoint. 
For example, processes such as sister chromatid cohesion323,324, kinetochore 
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assembly325,326 and centromere identification327 require SUMO mediated processes. 
Immunofluorescence staining in early Drosophila embryos has identified co-
localization of PIAS and the centromere identifier protein (CID) uniquely in early 
embryos (Heun lab unpublished). Identification of INCENP as an interactor of PIAS 
supports a role of PIAS mediated SUMOylation in the establishment of centromere 
protein localisation at centromeric chromatin regions. 
 
5.4.3 ADD1 and XNP co-immunoprecipitate with PIAS in Drosophila embryos 
During nuclear cycles (NC) 12-14, ADD1 is apically localised in pre-blastoderm 
nuclei at DAPI dense regions (Figure 5–12), in a similar pattern to SMT3328, PIAS144, 
XNP144 and H3.3144, coinciding with the timepoint for de novo establishment of 
heterochromatin. Although ADD1 and XNP co-immunoprecipitate with PIAS in 
embryos (Figure 5–14), neither protein was identified by two or more peptides in 
PIAS IP-MS. There are several potential reasons for this. Firstly, ADD1 is expressed 
at low levels142 and might be outcompeted by other interactors for binding to PIAS. 
Secondly, many ADD1 bands were detected on western blot in 1-3hr embryos 
(Figure 5–14), which could mean alterative degradation products or post-
translational modifications, which results in ADD1 peptides not being identified in IP-
MS experiments.  
 
5.4.4 PIAS co-immunopreciptates with Piwi and aub in early embryos and 
PIAS co-immunopreciptates RNAi pathway components 
I was interested in confirming the interaction between PIAS and Piwi as the Aravin 
and Toth labs had identified PIAS as an interactor of Piwi316 and have proposed that 
PIAS interacts with Eggless126, providing a link between the Piwi/piRNA silencing 
pathway and proteins required for deposition of H3K9me3 at chromatin and 
recruitment of HP1a to form heterochromatin domains to silence regions of the 
genome which contain transposable elements126. Piwi and aub were found to 
interact with PIAS at timepoint 1 but not timepoint 12 (Figure 5–6), likely due to their 
specific developmental role. SUMOylation may be essential for localisation of 
proteins to carry out Piwi-piRNA mediated transcriptional repression and to establish 
heterochromatin. Similarly, SUMOylation by PIAS may play a similar role in related 
RNAi pathways as RNAi components were also identified to interact with PIAS 
(Figure 5–1 and Figure 5–2). 
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PIAS co-immunoprecipitates with bel, AGO2, Tudor-SN and FMR1 (Figure 5–1, 
Figure 5–2). This supports a role for PIAS (possibly through PIAS mediated 
SUMOylation) in influencing interactions with components of the RNA-induced 
silencing complex (RISC) to aid their function in an RNAi mediated pathway that is 
active throughout Drosophila development in tissues and in cell lines. SUMOylation 
of AGO2 has been investigated243. AGO2 can be SUMOylated by PIAS proteins, 
with SUMO protecting AGO2 from degradation and mediating AGO2 association 
with Dicer243. Therefore it is possible that PIAS mediated SUMOylation may regulate 
RNAi pathway activity through aiding RISC complex formation.  
 
5.4.5 PIAS has non-chromatin associated interactions 
PIAS is also likely to be involved in regulation of post-transcriptional gene silencing 
(PTGS) in the early embryo. The protein with the greatest difference in LFQ value 
between PIAS IP and control was polyadenylate-binding protein (pAbp) (Figure 5–1 
and Figure 5–2). This binds poly(A) tails of mature mRNAs, and signals that the 
transcript has properly matured, marking it for translation and protects mRNAs from 
degradation. pAbp interacts with the translation initiation factor eIF4G to stimulate 
translation329. 
 
Proteins found in the nuage/p-granule/germ plasm may be SUMOylated by PIAS, 
which may facilitate SUMO mediated storage or release. For example, to maintain 
repressive SUMO states or release components when required, as in, a mechanism 
for FMRP SUMOylation330. SUMO mediated mechanisms in the Drosophila embryo 
may be important for the correct timings of protein expression and protein 
localisation in developmentally regulatory pathways, balancing expression and 
degradation of mRNA transcripts. Enrichment of cup, eIF4E1 and e1F4G in PIAS 
IP-MS (Figure 5–1, Figure 5–2) is interesting as cup is a SUMO substrate171 
involved in maternal mRNA regulation331,332. By binding to mRNAs, the protein cup 
can prevent interaction between eIF4E1 and e1F4G332. The role of SUMOylated cup 
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PIAS is a maternally deposited protein and is highly abundant in Drosophila 
embryos, with both nuclei-associated and cytoplasmic localisation (Figure 2–4). 
pAbp, me31Β, eIF4E1, tral and cup were identified in PIAS IP-MS from 
embryos(Figure 5–1). Together these form a ribonucleoprotein complex in 
Drosophila embryos during nuclear cycles 1-11 that bind to maternal mRNAs to 
downregulate transcript expression during the maternal to zygotic transition. pAbp 
forms a complex with eIF4G333, tyf and Atx2 which interacts with Not1 to degrade 
mRNA transcripts in circadian pacemaker neurones334. Atx2 interaction with tyf and 
Lsm12 activates PTGS, whereas Atx2 interaction with me31B represses PTGS to 
regulate translation of genes involved in circadian rhythms335. eIF4G is SUMOylated 
in S. pombe336 and in S. cerevisiae337, suggesting a level of SUMO mediated 
regulation that could be mediated by PIAS in Drosophila embryos. 
 
5.4.6 PIAS interacts with insulator proteins after nuclear cycles are complete 
BEAF- 32 was only identified as a PIAS interactor in 12-15hr and timepoint 12 
embryos. This is of notable interest because BEAF-32 was shown to co-
immunoprecipitate with PIAS in S2 cells (Figure 4–18B), which are derived from late 
stage (20-24hr) embryos. This could suggest a role for PIAS mediated SUMOylation 
of chromatin insulator proteins. This interactions is only found at later stages in 
Drosophila development, once chromatin states have been defined and is not 
observed in early stage embryos undergoing nuclear cycle divisions. 
 
5.4.7 Evaluation of the approach 
5.4.7.1 Protein extract and IP-MS from timed embryos  
Embryos at specific developmental stages were collected. This enabled 
identification of PIAS interaction partners that otherwise would not have been 
represented in a mixed or a later pool of embryos (Figure 5–4, Figure 5–5, Figure 5–
6). All proteins that are part of PIAS-associated complexes were 
immunoprecipitated and detected by mass spectrometry. This resulted in a large 
number of proteins identified, especially in timepoint 12 embryos (compared to 
timepoints 1,2 and 3) where there are different tissues specified. It is likely that the 
requirements for PIAS expression and localisation differs between these timepoints. 
Live imaging of GFP-PIAS in the developing embryo identified PIAS in the 
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cytoplasm and only showed only partial co-localisation with DAPI stained 
chromosomes in interphase and early prophase (Figure 2-4). During prometaphase 
PIAS formed non-chromatin associated discrete structures in the cytoplasm (Figure 
2-4), which dissipated after metaphase, which could coincide with the shut-off of 
translation. However, PIAS is maternally deposited, which results in large amounts 
of PIAS in Drosophila embryos138,139 , therefore these PIAS-associated complexes 
could reflect a stored pool of the protein. For Drosophila PIAS protein levels 
assessed through development, determined by quantitative mass spectrometry, see 
data collated in Casas-Vila et al., 2017142 (Appendix Figure 9–6). Improved 
sensitivity in detecting low levels of proteins or use of alternative methods may 
enable identification of interactors from more specific timepoints, earlier in 
development or from less starting material. To identify developmental specific roles 
of PIAS, within different cellular compartments in early embryos would be useful and 
interesting. The approach I think most suitable for this would be the expression of 
tagged-PIAS in a specific tissue to allow isolation of PIAS-associated complexes 
from that tissue. For example, this is important to separate PIAS-associated protein 
complexes in the oocyte from PIAS-associated protein complexes in the male 
gamete. Identifying PIAS interactors within a cellular compartment may reduce the 
detection of proteins that interact with large pools of maternally deposited protein 
that is merely being storage for controlled release when needed at later points in 
development. 
 
Due to localisation of PIAS at heterochromatin in embryos144 and at euchromatin in 
Kc167 cells57, I hypothesised that PIAS would have differential functions and 
therefore change its interactome. However, the PIAS interactome might largely 
reflect a change in the proteome and not all interactions are necessarily functionally 
important. For example, if proteins are present but stored until a later timepoint in 
development, then they might appear to interact with other stored proteins. 
 
5.4.7.2 Identifying unique PIAS interactors in early embryos 
Comparison of proteins identified in PIAS IP-MS from Drosophila embryos taken at 
early timepoints in development allowed separation of PIAS interactors that only 
occur at specific developmental times. After subtracting common PIAS interacting 
proteins from the list of proteins identified in early embryos, proteins that specifically 
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interacted with PIAS in Drosophila embryos were involved in gamete generation, 
reproductive processes, replication, cell cycle and chromosome segregation. I would 
expect proteins involved in these processes to be subject to post-translational 
modification by SUMOylation to regulate their functions.  
 
5.4.7.3 Comparison of PIAS interactors in S2 cells and embryos 
One drawback of GO analysis is that process annotation is dependent on the 
database used for the search. Proteins or genes in pathways that are more studied 
have more GO terms assigned to them. This causes an effect similar to confirmation 
bias where pathways already established are more likely to be noted than those not 
established, and an increase in false detection as more comparisons (individual GO 
terms) are being run for some molecular pathways than others.  
 
5.4.7.4 Immunofluorescence in Drosophila embryos  
The Drosophila anti-PIAS sheep antibody can detect PIAS in early embryos, 
showing enrichment at heterochromatin in NC14 (Figure 5–13). ADD1 also localises 
to this region (Figure 5–13). Further analysis of the timings and order of appearance 
have been explored by Matilde Fabe in the Heun lab during the writing of this thesis. 
XNP bleed 2 antibodies in serum were at too low levels to be used for detection 
above background and would require concentration and purification before use in 
immunofluorescence.  
 
5.4.7.5 ADD1 and XNP as interactors of PIAS Drosophila embryos  
Use of proteomics to determine protein levels in Drosophila embryos, as in the study 
conducted by Casas-Vila et al., 2017142, identified low expression of ADD1, 
moderate expression of XNP and high expression of PIAS. It is possible that ADD1 
was not detected as an interactor of PIAS in embryos, not only due to its low 
expression, but due to limitations in the experimental technique. This could be 
because mass spectrometry studies rely on the detection of peptides that map 
uniquely to one protein, and are therefore assigned to that protein. The ADD1-XNP-
PIAS interaction in Drosophila embryos should be explored further, as a conclusion 
cannot be made about the hypothesis that ADD1 and XNP interaction with PIAS 
might be required for the establishment of heterochromatin. 
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Chapter 6 Production and purification of 
recombinant XNP and ADD1 and 




SUMOylation failure of XNP and ADD1 was of interest to the Heun lab as a potential 
mechanism of PIAS’ phenotype at chromatin. Therefore, I aimed to purify XNP, 
ADD1, SMT3 and PIAS proteins to confirm a direct interaction between these 
proteins and SUMOylation of XNP in vitro. In this chapter I describe the strategy that 
I used to produce and purify recombinant XNP and ADD1. Due to a lack of 
information on the key interaction residues and post-translational modification sites, 
we decided to purify full length XNP and ADD1. Neither Drosophila protein had been 
purified before. Unfortunately, these proteins did not form stable species in vitro 
under the conditions tested but the constructs and methods provide a useful starting 
point for future purification method development.  
 
In addition, there are no commercial antibodies available for ADD1 or XNP. A 
Drosophila rat ATRX antibody (from Andreas Thomae) can detect denatured forms 
of XNP on western blot but does not recognise native protein for 
immunofluorescence and immunoprecipitation. Antibodies against ADD1 were 
generated by Lopez Falcon et al., 2014296, which recognise a 150kDa band on WB 
but a 150kDa band is not detected with HA-tagged ADD1, with purified protein or 
with endogenous protein, leading to a question over the antibodies specificity. 




• To produce and purify recombinant full length ADD1 and XNP 
• To identify SUMOylation sites on ADD1 and XNP  
• To confirm and characterise an interaction between XNP and PIAS in vitro 
• To generate and validate antibodies against ADD1 and XNP  
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6.3 Results 
6.3.1 Expression and purification trials for full length XNP and ADD1 protein 
Expression constructs for ADD1 and XNP were generated by a ligation independent 
cloning method, by designing primers for PCR amplification of the target sequence 
for insertion into insect expression vectors (provided by the Cook laboratory). 
Sequences were confirmed by Sanger sequencing using primers spanning every 
couple of hundred base pairs of DNA (Appendix Figure 8–9, Figure 8–10). 
 
Test expression assays were carried out for GST-ADD1-RA and His-XNP-RA 
protein expression in Sf9 cells. Western blots probed with anti-GST antibodies or a 
Ni2+-HRP probe detected expression of the GST or the HIS tag respectively (Figure 
6–1). GST-ADD1 was detected at ~200kDa, which is higher than its predicted 
molecular weight. To confirm that the expressed bands were the correct proteins, 
the pull down samples were run on SDS-PAGE, the gel was Coomassie stained, the 
bands were excised and the proteins were digested with trypsin. MALDI-TOF 
analysis of tryptic peptides confirmed the proteins expressed were Drosophila ADD1 
and XNP by >30% peptide coverage. 
 
 
Figure 6–1 Test expression assays for GST-ADD1-RA and His-XNP-RA protein 
expression in Sf9 cells 
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(A) Western blot probed with a Ni2+-HRP probe showing the result of a test expression from 
Sf9 cells infected with the pFastBac-HIS-XNP-RA bacmid. Whole cell extract (WCE), soluble 
(SOL) and insoluble (INSOL) samples were generated from a 50mL culture of Sf9 cells after 
3 days-post-infection. The SOL fraction was subjected to pull down (PD) with Ni2+-NTA resin  
which recognises the HIS tag on HIS-XNP-RA, resulting in HIS-XNP-RA enrichment in the 
PD lane at the expected molecular weight of 151kDa. (B) Western blot probed with an anti-
GST rabbit antibody showing the result of a test expression from Sf9 cells infected with the 
pFL-GST-ADD1-RA bacmid. Whole cell extract (WCE), soluble (SOL) and insoluble (INSOL) 
samples were generated from a 50mL culture of Sf9 cells after 3 days-post-infection. The 
SOL fraction was subjected to pull down (PD) with GSH resin which recognises the GST tag 
on GST-ADD1- RA, resulting in GST-ADD1-RA enrichment in the PD lane. 
 
After test expressions, several rounds of protein purification were trialled to identify 
conditions for purification of properly folded ADD1 and XNP proteins. 
 
6.3.2 Purification of HIS-XNP-RA 
HIS-XNP-RA was purified from Sf9 cell lysate by batch incubation with Ni2+-NTA 
affinity resin. Washes removed non-specific proteins resulting in an isolated HIS-
XNP-RA protein (Figure 6–2A) and HIS-XNP-RA eluted in 300mM imidazole (Figure 
6–2A). The E1 fraction was diluted and analysed on SDS-PAGE (Figure 6–2A). 
Samples from batch purification were also run on SDS-PAGE and transferred to 
nitrocellulose membrane for western blot probed with the rat anti-ATRX antibody 
(Figure 6–2B), confirming the identity of the protein as XNP. Despite running as a 
single band on SDS-PAGE, XNP apparently did not form single species in vitro. 
HIS-XNP-RA was injected on a Superdex 200 size exclusion column to: separate 
XNP; to buffer exchange to reduce imidazole concentrations; and to confirm the size 
of XNP species. XNP eluted close to the void volume of the Superdex 200 column 
(Figure 6–2C). A size exclusion chromatography column with a different resin 
composition, Superpose 6 (which has a greater resolving range for higher molecular 
weight proteins) was trialled to separate XNP. XNP eluted over a broad range (from 
10-20mL) (Figure 6–2D), characteristic of high molecular weight complexes, partially 
folded proteins or aggregates. XNP fractions were concentrated and snap frozen as 
separate fractions; however, XNP still formed aggregates in solution. This suggests 
that for XNP to be usable in in vitro assays, fresh batches must be prepared.  
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Figure 6–2 Summary of HIS-XNP-RA purification from Sf9 cells 
(A) Coomassie stained SDS-PAGE gel showing the input (soluble fraction applied to the 
resin), FT (from batch binding to Ni-NTA resin), washes in low imidazole (20mM) and elution 
from Ni2+-NTA resin with high imidazole (300mM) washes. Coomassie stained SDS-PAGE 
gel loaded with different concentrations of the elution fraction E1 (from A) showing HIS-XNP-
RA running above the 180 kDa molecular weight marker on denaturing SDS-PAGE (B) The 
same samples as in A analysed by SDS-PAGE followed by western blot probed with anti-
ATRX (XNP) rat antibody to confirm expression of XNP-HIS-RA. The arrow marks the 
expected size of HIS-XNP-RA (C) A280 elution trace of HIS-XNP-RA from a Superdex 200 
size exclusion chromatography column, below is a Coomassie stained SDS-PAGE gel taking 
protein sample from the fractions highlighted in yellow. Elution fractions 1-5 were pooled and 
frozen. The red line marks the void volume of the column. (D) A280 elution trace of HIS-
XNP-RA from a Superose 6 size exclusion chromatography column from an analytical run, 
below is a Coomassie stained SDS-PAGE gel taking protein sample from fractions 1-10 
highlighted in yellow. The red line marks the void volume of the column. In all panels the 
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6.3.3 Purification of ADD1-RA 
GST-ADD1-RA protein was expressed (Figure 6–3A) and purified from Sf9 cell 
lysate by batch incubation with GSH affinity resin. GST-ADD1-RA bound to the resin 
and was eluted by competition with excess reduced glutathione (Figure 6–3B). The 
GST tag was removed by cleavage with GST-3C protease (Figure 6–3C). Once 
isolated from its tag, ADD1-RA was injected on a Superdex 200 size exclusion 
column to separate the ADD1-RA, GST-3C protease and free GST by size 
exclusion chromatography (Figure 6–3D). The elution profile contains three peaks 
representative of these three species and Coomassie stained SDS-PAGE of 
selected elution fractions shows the separation of ADD1-RA from GST (Figure 6–
3D). Elution fractions containing ADD1-RA were pooled and concentrated. ADD1-
RA eluted close to the void volume of the column, indicating that the protein did not 






Figure 6–3 Summary of ADD1-RA purification from Sf9 cells 
(A) Coomassie stained SDS-PAGE gel showing the soluble fraction applied to the GSH resin 
and elutions (E1-4) from batch binding to GSH resin. Free GST is at 26kDa and GST-ADD1-
RA is above the 180kDa marker. (B) Cleavage of the GST tag from GST-ADD1-RA by 
addition of GST-3C, Left-hand-side: Coomassie stained SDS-PAGE gel showing pre-
cleaved GST-ADD1-RA and free GST at 26kDa in lane 1, GST-3C in lane 2, and cleaved 
GST-ADD1-RA and free GST in lane 3. Right-hand-side: western blot probed with anti-GST 
antibodies. (C) A280 elution trace from a Superdex 200 size exclusion chromatography 
column separating ADD1-RA from 3C and GST which are shown as three peaks. 
Coomassie stained SDS-PAGE gel shows separation of ADD1-RA (lanes 1 and 2) from free 
GST (lanes 3 and 4) taking protein sample from the labelled fractions. The red line marks the 
void volume of the column. In all panels the marker is PageRuler™ Prestained Protein 
Ladder, 10 to 180 kDa (Thermo Fisher Scientific). 
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6.3.4 XNP and ADD1 purified protein characterisation 
Upon thawing, XNP was observed on Coomassie stained SDS-PAGE (Figure 6–4) 
as higher molecular mass species. This suggested that the protein might be forming 
aggregates that migrate through the gel at a slower rate than expected. The HIS-
XNP-RA purification protocol was adapted to use high salt and TCEP as a reducing 
agent throughout the purification procedure, resulting in the same outcome. 
 
Figure 6–4 SDS resistant XNP-RA bands 
Coomassie stained 6% SDS-PAGE gel showing recombinant full-length HIS-XNP-RA 
protein, eluted from pool 2 (the peak) of XNP fractions after size exclusion chromatography, 
after freeze thawing. The marker (L) is 250 kDa Color-coded Prestained Protein Marker, 
Broad Range (CST). 
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Intriguingly, ADD1-RA runs at a higher molecular weight than expected based on its 
predicted molecular weight on SDS-PAGE under reducing conditions (Figure 6–5). 
This may be due to a variety of factors such as the proteins isoelectric point (pI), the 
amount of SDS bound to the protein or the addition of post-translational 
modifications. ADD1-RA runs between 190kDA and 200kDa on semi-native, tris-
glycine and bis-tris gels. Denaturation in urea buffer and longer boiling in SDS buffer 
did not alter the protein mobility (data not shown).  
 
 
Figure 6–5 ADD1-RA runs at a higher than expected molecular weight 
Coomassie stained 6% SDS-PAGE gel showing recombinant full-length ADD1-RA protein 
(grey arrow) which has an expected size of 131 kDa (open arrow). The marker (L) is 250 
kDa Color-coded Prestained Protein Marker, Broad Range (CST). 
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Dynamic light scattering (DLS) gives a measure of particle size in suspension by 
detecting photons from scattered laser light projected a through a sample in 
suspension at short consecutive intervals. The speed of particles undergoing 
Brownian motion is used to calculate particle size using the Stokes-Einstein 
equation. DLS was used to check for protein aggregation in the HIS-XNP-RA and 
ADD1-RA purified protein samples in solution, as larger particles diffuse more slowly 
in solution and can give an estimate of sample uniformity and size. HIS-XNP-RA 
had a size distribution between 10-100 d.nm in NaCl concentrations between 0.1-
0.5M (Figure 6–6). HIS-XNP-RA was polydisperse in solution. This may also be 
responsible for a lower (0.5) correlation coefficient value at 0.1μs for HIS-XNP-RA, 
which is indicative of a low signal to noise ratio of scattered light detected in the 
HIS-XNP-RA sample over background. Ionic strength, surface structure and shape 
can all influence these readings.  
 
The large particles in the ADD1-RA sample could be broken up by the increase in 
salt concentration from 200mM to 500mM (Figure 6–6). In 500mM NaCl, ADD1-RA 
existed in solution as 10% monodisperse and 90% polydisperse; indicating that the 
sample was not homogeneous. From the monodisperse peak, the mean particle 
size (z-average hydrodynamic diameter) of 320kDa was derived from the intensity 
weighted mean diameter derived from the cumulant analysis. However, it is not 
possible to determine the oligomeric state through this assay as DLS bases its size 
estimations on a number of assumptions, the main assumption being that the 
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Figure 6–6 DLS Intensity plots for XNP and ADD1 purified protein 
Dynamic light scattering (DLS) of recombinant full-length HIS-XNP-RA and ADD1-RA. Left: 
size distribution by mass plot showing intensity peaks. Right: raw correlation data. For 
ADD1-RA three salt concentrations are shown to highlight changes in the size distribution 
profile in buffer containing 200mM, 300mM and 500mM NaCl . 
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6.3.5 Identification of post-translational modifications on XNP and ADD1  
Proteins modified by PTMs can run at different mobilities than expected based on 
their calculated molecular weight when unmodified, due to changes in protein size 
or structure influenced by folding or aggregation. I hoped, that by using mass 
spectrometry, I might be able to identify PTMs which could be responsible for the 
SDS denaturation resistant HIS-XNP-RA bands and modifications to explain the 
apparent size of ADD1-RA. The protein containing bands were excised from SDS-
PAGE gels, washed, reduced and alkylated followed by in-gel tryptic digest and 
peptides were precipitated for identification by mass spectrometry. The peptides 
identified were scanned for post-translational modifications (PTMs) which were 
sustained through the purification procedure. 714 peptides mapping to ADD1-RA 
were identified in the purified ADD1-RA sample and for HIS-XNP-RA 391 peptides 
were identified. This amounted to 69% and 79% coverage of the proteins 
respectively (Figure 6–7). Post-translational modifications were concentrated in the 
N-terminal region of HIS-XNP-RA (Figure 6–7A). Ubiquitination on HIS-XNP-RA at 
site K181 was identified. For ADD1-RA protein a QQTGG(K) SUMOylation site was 
identified, in exon 4 of ADD-RA, which is only present in this ADD1 isoform, the 
longest isoform.  
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Figure 6–7 XNP and ADD1 post-translational modifications 
(A and B) Amino acid sequences of ADD1-RA and XNP-RA, coloured sequences indicate 
peptide coverage from mass spectrometry of HIS-XNP-RA or ADD1-RA protein. The sites of 
PTMs identified by mass spectrometry are indicated (C and D) post translational 
modifications from (A and B) are summarised in table form.  
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6.3.6 Generation and testing of antibodies generated against XNP and ADD1 
I generated polyclonal antibodies against the longest isoforms of ADD1 and XNP to 
enable polyclonal recognition of the entire proteins. One rabbit was immunised with 
150µg ADD1-RA purified protein, given four boosts with a further 150µg ADD1-RA 
purified protein over a 90-day period, taking bleeds one week after each boost of 
antigen (see methods section 3.6.14), resulting in four bleeds including a pre-bleed. 
Pre-immune serum was compared to bleed one serum at day 32 and bleed two 
serum at day 60 (Figure 6–8). The XNP immunisation schedule, was started at a 
later date, and was terminated early due to closure of the company providing the 
immunisation schedule. Pre-immune serum was compared to bleed one serum and 
at the timing of the company’s closure the rabbit was exsanguinated at the time 
point of taking bleed two.  
 
To test the specificity of the antibodies in the rabbit bleed sera, western blots were 
performed. Extracts from ADD1 wild type, knock down and S2 cells transfected with 
pAc5.1-ADX-a-V5296 to overexpress V5-ADD1 were run on SDS-PAGE followed by 
western blot and probed with anti-V5 antibody or anti-ADD1 bleed sera. A band of 
approximately 190kDA corresponding to the size of ADD1 was detected by both the 
anti-V5 antibody and the  anti-ADD1 antibody bleed sera (Figure 6–8).  
 
Figure 6–8 Testing of ADD1 serum from rabbit. 
Western blots of cell lysates from wild-type, ADD1 sgRNA knockdown or transiently 
transfected V5-ADD1 S2 cells. Protein was quantified and equal amounts loaded per lane on 
6% SDS-PAGE. Blots were probed with anti-V5 mouse antibody or anti-ADD1 rabbit bleed 
two serum.  
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To assess whether anti-XNP rabbit bleed one serum contained antibodies specific 
for XNP, the pre-immune and bleed sera diluted 1:500 was used in a western blot 
against exogenous FLAG-tagged XNP and wild-type S2 cell lysates (Figure 6–9). 
No protein was detected by probing with pre-immune serum, but the anti-XNP rabbit 
bleed one serum contained antibodies that recognised the same sized band as 
FLAG-XNP expressed from a plasmid. The predicted size of purified XNP is 
~150kDa, but XNP from Drosophila lysate and S2 cells is detected as a band at 
185kDa on western blot139. Antibodies in XNP rabbit bleed one serum can also 




Figure 6–9 Testing of XNP serum from rabbit. 
 (A) Western blots of protein cell lysates from S2 cells either: wild-type (WT) or transiently 
transfected FLAG-XNP (FLAG-XNP). Protein was quantified and equal amounts loaded per 
lane on 8% SDS-PAGE. The blot was cut into 3 strips and probed with either: M2 anti-FLAG 
mouse antibody, anti-ATRX rat serum or anti-XNP rabbit bleed one serum (LHS) (diluted 
1:500).   
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6.4 Summary 
I aimed to characterise the interaction between ADD1, XNP, PIAS and SUMO in 
vitro. Efforts during purification to prevent aggregation and obtain properly folded 
ADD1 and XNP were unsuccessful as assessed by DLS. Therefore it was not 
possible to perform in vitro SUMOylation assays. Post-translational modifications on 
ADD1 and XNP were identified by mass spectrometry (Figure 6–7), confirming the 
presence of a Ubiquitin/SUMO modified XNP at the same site as identified 
previously, K181 (see Introduction 2.8). The misfolded protein was used as a source 
of antigen to generate antibodies. These were tested and found to recognise both 
the native and denatured form of ADD1 and XNP for use in western blot (Figure 6–8 
and Figure 6–9), immunofluorescence (Figure 5–12) and immunoprecipitation 
(Chapter 7) to enhance our understanding of PIAS-XNP, PIAS-ADD1 and ADD1-
XNP complexes, the results of which are discussed in results Chapter 7.  
 
Many techniques including immunofluorescence and immunoprecipitation depend 
on having antibodies that are highly specific and selective for the protein of interest. 
An antibody able to recognise endogenous protein enables analysis of protein 
localisation and interactions in a physiological setting. Tagged proteins in cell lines 
were also used during this PhD study because detection of an epitope tagged 
protein using commercial antibodies provides independent confirmation of results. 
 
6.4.1 Evaluation of the approach  
6.4.1.1 Purified protein approach 
Expression of large proteins is a challenge and was not possible for ADD1 and XNP 
at this stage. Properly folded proteins are essential for in vitro assays because 
protein conformation and structure influences protein function. ADD1 shows some 
salt sensitivity and increasing the salt concentration improved behaviour.  
Nevertheless, as the results indicated that both ADD1 and XNP aggregate, in vitro 
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Notably, ADD1 protein does not run at its predicted molecular weight on SDS-
PAGE. MALDI-TOF analysis, knock-down and overexpression of ADD1-V5 allows 
me to conclude that the protein produced in vitro is ADD1.  
 
The next step with the ADD1 and XNP protein purification would be to co-purify both 
proteins together from co-infected cells. It is possible that both proteins may need to 
be expressed simultaneously to stabilise each other and form a complex. If 
unsuccessful, truncation mutants of XNP could be expressed, focusing on the N-
terminal sequence of XNP 1-223, only found in the long isoform of XNP and 
required for XNP localisation to heterochromatin294 and would confirm the interaction 
observed in Lopez et al., 2014296.  
 
Interestingly, ubiqutination/SUMOylation on XNP at site K181 was identified on 
protein expressed in Sf9 cells. This is in agreement with a previous finding 
investigating an N-terminal fragment of XNP (Heun lab unpublished) using a 
bacterial SUMOylation assay. A QQTGG(K) site was identified in exon 4 of ADD-
RA, indicative of SUMOylation of ADD1 at site K164.  
 
6.4.1.2 Testing antibodies  
Due to early termination of the XNP immunisation programme of the rabbit, the 
affinity and titre of XNP antibodies may have been compromised, however, XNP 
rabbit bleed one serum was able to recognise endogenous XNP, demonstrating the 
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Chapter 7 Exploring the XNP-ADD1 interaction 
and their interaction with PIAS  
 
7.1 Objective 
In this chapter I used the XNP and ADD1 antibodies (generated as part of this PhD 
study, see section 6.3.6) for immunoprecipitation of XNP and ADD1 from S2 cells to 
identify whether ADD1, XNP, PIAS and SMT3 co-immunoprecipitate at endogenous 
protein levels.  
 
7.2 Aims 
• To identify endogenous XNP and ADD1 interactors   
• To identify whether XNP and ADD1 interact with PIAS  
• To identify common interactors between XNP and ADD1 in conditions where 
SUMOylation has been maintained 
• To determine whether ADD1 is SUMOylated  
 
7.3 Results  
7.3.1 Detecting XNP SUMOylation  
Immunoprecipitations were performed from S2 cell nuclear extracts using XNP 
rabbit Bleed 2 serum or pre-immune serum (IgG) coupled Protein G Dynabeads™ in 
the presence and absence of NEM. NEM prevents the removal of ubiquitin-like 
protein modifications (UBLs). If ubiquitin and SMT3 are covalently conjugated to 
XNP a size shift of approximately 9 kDa or 10 kDa respectively should be visible on 
western blot by probing with anti-XNP antibodies. XNP has been identified as a 
SUMOylated protein in Drosophila embryos in a mass spectrometry screen171, but 
direct in vivo evidence is still lacking. A cell line expressing an endogenous tag on 
XNP would be ideal, however, attempts at generating an endogenously-tagged XNP 
S2 cell line were unsuccessful. Therefore, an S2 cell line with a stably retained 
pMT_ATRX_FLAG (Heun lab old nomenclature - ATRX refers to XNP) plasmid was 
used as a control to determine the specificity of my antibody against endogenous 
XNP. XNP can be inducibly expressed by the addition of copper sulphate from the 
pMT_ATRX_FLAG plasmid. 
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A low level of expression was induced from the pMT_ATRX_FLAG plasmid for 3 
days prior to harvesting the cells for immunoprecipitation using the rabbit anti-XNP 
antibody. Immunoprecipitated material was run on SDS-PAGE and detected on 





Figure 7–1 Immunoprecipitation of modified XNP 
Nuclear extracts were made from wild-type S2 cells in buffers with or without NEM. Input 
(IN), IP with pre-immune serum (IgG) and XNP rabbit Bleed 2 serum (XNP IP) after washes 
with IP wash buffer containing 0.5M NaCl. were separated on 6% SDS-PAGE followed by 
western blot probed with anti-XNP rabbit (Rb) Bleed 2 serum (top panel), M2 anti-FLAG 
mouse antibody (middle panel) and Drosophila anti-ATRX rat (Rt) antibody (bottom panel). 
IP was carried out in the absence (-) or presence (+) or NEM detecting an extra band (green 
arrow) in the presence of NEM. The black arrow marks the expected size of the long isoform 
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Rat and rabbit anti-XNP antibodies had different specificities and limits of detection. 
All antibodies recognise the long isoform of XNP, but the rabbit antibody also 
detects a slower migrating band, seen at a slightly higher molecular weight above 
the long isoform of XNP on a western blot, which was not detected with the anti-
ATRX rat antibody (Figure 7–1). This additional band is visible for endogenous and 
FLAG-XNP extracts made in the presence of NEM (labelled XNP modified in Figure 
7–1). Therefore it appears that XNP is post-translationally modified in S2 cells. 
Attempts to verify the identity of this larger band were unsuccessful, as it is difficult 
to detect endogenous UBLs on substrate proteins, as at any one time only a small 
proportion of the total protein is modified and the SMT3 and ubiquitin antibodies 
were not sensitive enough to detect any protein from this immunoprecipitated 
material. 
 
7.3.2 Mass spectrometry of affinity purified XNP-associated complexes from 
S2 cells  
The IP efficiency of XNP rabbit Bleed 2 serum was not optimal. Despite this, an IP-
western blot using XNP rabbit Bleed 2 serum and probed with HP1a antibody (an 
interaction partner of XNP139,299) confirmed that this serum is able to co-
immunoprecipitate HP1a-XNP-complexes (Figure 7–4). Bands absent from IgG 
control lanes were visible on SDS-PAGE silver stain (Appendix Figure 8–3).  
 
To identify proteins that interact with XNP and modified XNP, in the absence and 
presence of NEM respectively, immunoprecipitation followed by mass spectrometry 
(IP-MS) was performed. Volcano plots were generated using Perseus to visualise 
the result of a Student’s T-test comparing interactors identified in XNP-IP and IgG-IP 
in the absence and presence of NEM, after filtering for proteins identified in at least 
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Figure 7–2 Volcano plot of XNP protein interactors in S2 cells in the absence and presence of NEM 
Immunoprecipitation (IP) using Drosophila anti-XNP rabbit Bleed 2 serum (XNP) or rabbit pre-immune serum (Control) IgG coupled to Protein A 
Dynabeads™ was performed from S2 cell lines. IP samples were prepared as described in methods and analysed by mass spectrometry. XNP 
interactors in conditions without NEM (A) and with NEM (B) are plotted. Each dot represents one protein. To determine the XNP interactome, a 
MaxQuant label-free quantitation pipeline was used. Student’s T-test was performed on log2 transformed LFQ values from three control and three XNP 
IPs after filtering for proteins identified by two or more peptides and found in at least two of three replicates. T-test difference ratios (x-axis) were plotted 
against the negative logarithmic p-value of the T-test (y-axis). Named proteins in red are proteins of interest to this PhD study including XNP, H3.3 and 
PIAS. Proteins in purple are linked to RNAi silencing pathways. Proteins in black are consistent XNP interactors. SMT3 is in green. Proteins in yellow 
are 40S and 60S ribosomal proteins, which are likely to be non-specific interactors. The confidence line was generated using a permutation-based FDR 
value of 0.05 and a minimal fold change value of 0.1.  
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124 proteins were significant enriched in -NEM conditions and 608 proteins were 
significantly enriched in +NEM conditions (Figure 7–2). In the XNP IP without NEM 
the histone variant H3.3 is not significantly enriched, whereas other histone proteins 
are some of the most significant interactors (Figure 7–2). However, in the presence 
of NEM, H3.3 is more than four-fold enriched and has a higher -log10 significance 
value compared to other histone proteins (Figure 7–2). woc and row were identified 
by 20 or more peptides in XNP IP-MS (Figure 7–2) and were also found in in the 
PIAS IP-MS from S2 cells (Figure 4–16).  
 
Published interactions of XNP were found in this study, these include the Exocyst 
complex component 3, Sec6338 (identified by 4 peptides) and components of the 
Facilitates Chromatin Transcription (FACT) complex: Ssrp (identified by 4 peptides) 
and dre4 (identified by more than 20 peptides). However DNA replication-related 
element factor339 (Dref), which is involved in insulator function, chromatin 
remodelling, and telomere maintenance, was not detected. Also, ADD1 was not 
identified in either the presence or absence of NEM.  
 
A comparison of the XNP interactome in conditions with and without NEM found 
Tudor-SN, Fmr1 and Su(var)3-9 were only present in + NEM conditions (Figure 7–
3). HP1a, woc, row and Ssrp were detected by LFQ values that differed less than 
two-fold in the absence and presence of NEM. HP1a was detected at higher levels 
in XNP IP in conditions without NEM (Figure 7–3).  
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Figure 7–3 Scatter plot comparing XNP protein interactors in S2 cells in the absence 
and presence of NEM 
Mean log2 transformed LFQ values calculated from three biological replicates, normalised to 
XNP, from XNP IP in +NEM and -NEM conditions. Each dot represents one protein. The top 
plot shows all proteins and the bottom plot shows proteins found only in both conditions. 
Named proteins in red are proteins of interest to this PhD study including PIAS, XNP and 
H3.3. Proteins in purple are linked to RNAi silencing pathways. Proteins in black are 
consistent XNP interactors. SMT3 is in green. Yellow dots are ribosomal proteins which are 
likely to be non-specific interactors. Diagonal lines mark two log2 fold change from zero. 
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7.3.3 XNP-ADD1 interaction with PIAS  
Lopez Falcon 2014296 identified an interaction between XNP and ADD1 and mapped 
this interaction to the first 266 amino acids of XNP (only present in the long isoform 
of XNP). I performed IP of endogenous XNP using anti-XNP rabbit bleed serum and 
IP of endogenous ADD1 using anti-ADD1 rabbit bleed 3 serum. The samples were 
analysed on SDS-PAGE followed by western blot. This showed PIAS and HP1a co-
immunoprecipitate with ADD1 and XNP in the presence of NEM (lanes 6 and 13 of 
Figure 7–4). This is a weak interaction (identified by running 1% input and 100% IP). 
Although the anti-XNP rabbit antibody is more sensitive, the anti-ATRX rat antibody 
was used for co-probing blots with LICOR antibodies so all immunoprecipitated 
material could be loaded.  
 
Figure 7–4 Co-immunoprecipitation of endogenous ADD1 and XNP 
Nuclear extracts made from wild-type Schneider S2 cells in the absence and presence of 
NEM. The input (IN) and Immunoprecipitation (IP) using rabbit pre-immune serum (C), anti-
ADD1 rabbit Bleed 3 serum (ADD1 IP) or anti-XNP rabbit Bleed 2 serum (XNP IP) coupled 
to Protein A Dynabeads™ were run on 4-20% SDS-PAGE and analysed by western blot. 
The western blot was cut and probed with anti-ADD1 rabbit bleed 3 serum (top panel), anti-
ATRX rat antibody (second panel), anti-PIAS sheep antibody (third panel) or anti-HP1a 
mouse antibody (bottom panel). L=ladder  
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For independent validation of the interaction between ADD1 and XNP being 
dependent on SUMOylation, wild type and HA-ADD1 S2 cell lines (generated in this 
study, Appendix Figure 8–11) were both transfected with the pMT_FLAG_ATRX 
plasmid (from which XNP can be inducibly expressed when copper sulphate is 
added). S2 cell lines were generated with this plasmid and maintained under 
hygromycin selection, resulting in stable HA-ADD1; FLAG-XNP S2 cells and FLAG-
XNP S2 cells. When XNP is expressed from an inducible promoter a larger pool is 
available in the soluble fraction. Cell lysate from wild-type, HA-ADD1 FLAG-XNP S2 
cells and FLAG-XNP S2 cells were subject to FLAG pulldown using M2 resin. HA-
ADD1 co-immunoprecipitated with FLAG-XNP only in the presence of NEM (Figure 
7–5).  
 
Figure 7–5 XNP co-immunoprecipitates with ADD1 in the presence of NEM. 
HA-ADD1 S2 cells and wild-type S2 cells that maintain the pMT_FLAG_ATRX plasmid under 
hygromycin selection were generated, resulting in stable FLAG-XNP HA-ADD1 and stable 
FLAG-XNP cell lines. Expression of FLAG-XNP was induced from the pMT_FLAG_ATRX 
plasmid by addition of 200µM CuSO4 for 3 days prior to harvesting. Nuclear extracts were 
made and subjected to FLAG pulldown using anti-FLAG M2 resin. HA-ADD1 S2 cells lysate 
was used as a negative control. The inputs (IN) and immunoprecipitations (IP) were 
analysed on 6% SDS-PAGE followed by western blot probed with anti-FLAG rabbit antibody 
(top panel) or anti-HA rat antibody (bottom panel). IP was carried out in the absence (-) or 
presence (+) or NEM detecting co-immunoprecipitation of ADD1 with XNP (lane 11, filled 
arrow) in the presence of NEM, but not in the absence of NEM (lane 4, hollow arrow). 
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7.3.4 Mass spectrometry of affinity purified ADD1-associated complexes 
from S2 cells  
I immunoprecipitated endogenous ADD1 with the aim of identifying protein 
interactors in common with XNP in the presence and absence of NEM. Using affinity 
capture mass spectrometry, Alekseyenko et al., 2014299 identified: CG14438, HP1b, 
Su(var)205 (HP1a), Su(var)2-HP2, Eggless, CG3680, CG6791, CG1910, bon and 
mod(mdg4) as interactors of ADD1, but not XNP299. However this was performed 
without NEM. Therefore if an interaction occurs through maintenance of UBL PTMs, 
it will not be detected. The same conditions as used for XNP IP-MS were used for 
ADD1 IP-MS, to address the possibility that ADD1 and XNP interactions partners 
change in the presence of NEM. IP efficiency and specificity using anti-ADD1 rabbit 
bleed 3 serum compared to pre-immune serum was confirmed by silver stain 
(Appendix Figure 8–3). 
 
Volcano plots were generated using Perseus to visualise the results of a Student’s 
T-test comparing proteins identified in IP using anti-ADD1 rabbit bleed 3 serum to 
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Figure 7–6 Volcano plot of ADD1 protein interactors in S2 cells in the absence and presence of NEM 
Immunoprecipitation (IP) using Drosophila anti-ADD1 rabbit Bleed 3 serum (XNP) or rabbit pre-immune serum (Control) IgG coupled to Protein A 
Dynabeads™ was performed from S2 cell lines. IP samples were prepared as described in methods and analysed by mass spectrometry. ADD1 
interactors in conditions without NEM (A) and with NEM (B) are plotted. Each dot represents one protein. To determine the ADD1 interactome, a 
MaxQuant label-free quantitation pipeline was used. Student’s T-test was performed on log2 transformed LFQ values from three control and three ADD1 
IPs after filtering for proteins identified by two or more peptides and found in at least two of three replicates. T-test difference ratios (x-axis) were plotted 
against the negative logarithmic p-value of the T-test (y-axis). Named proteins in red are proteins of interest to this PhD study including PIAS, ADD1 
and XNP. Proteins in purple are linked to RNAi silencing pathways. Proteins in black are consistent ADD1 interactors. Proteins in blue are transcription 
activation proteins (Tafs). SMT3 is in green. The confidence line was generated using a permutation-based FDR value of 0.05 and a minimal fold 
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The E3 ubiquitin ligase hyd, SANT domain protein SMRTER (Smr) and Bifunctional 
lysine-specific demethylase and histidyl-hydroxylase NO66 (CG2982) were 
identified as interactors in both the absence and presence of NEM (Figure 7–6). In 
both conditions ADD1 co-immunoprecipitated with HP1a, bon and Tafs (Figure 7–6). 
 
A comparison of the ADD1 interactome in conditions with and without NEM 
recovered an additional 755 proteins in the presence of NEM (Figure 7–7). 
Interactors identified in ADD1 IP-MS in both conditions, such as woc and row, were 
detected by higher LFQ values in NEM conditions, suggesting SUMOylation 
influences ADD1’s interaction partners or interaction strength. Transcriptional 
activator proteins (Tafs), hyd and HP1a were detected by LFQ values that differed 
less than two-fold in the absence and presence of NEM. This supports that their 
interaction with ADD1 does not change in the presence and absence of 
SUMOylation (Figure 7–7).  
 
XNP was detected only in the presence of NEM suggesting SUMOylation of either 
XNP, ADD1 or intermediate interaction partners is needed for ADD1 and XNP to 
interact. Other interactors only present in NEM IP conditions include PIAS, Tudor-
SN and Fmr1 (Figure 7–7).  
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Figure 7–7 Scatter plot comparing ADD1 protein interactors in S2 cells in the absence 
and presence of NEM 
Mean log2 transformed LFQ values calculated from three biological replicates, normalised to 
ADD1, from ADD1 IP in +NEM and -NEM conditions. Each dot represents one protein. The 
top plot shows all proteins and the bottom plot shows proteins found only in both conditions. 
Proteins in red are proteins of interest to this PhD study including PIAS, ADD1 and XNP. 
Proteins in purple are linked to RNAi silencing pathways. Proteins in black are consistent 
ADD1 interactors. Proteins in blue are transcription activation proteins (Tafs). SMT3  is in 
green. Diagonal lines mark two log2 fold change from zero.  
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7.3.5 Interactors in common between ADD1 and XNP IP-MS lists 
In IP-MS analysis, the following criteria were applied to identify shared interactors:  
• proteins immunoprecipitated by ADD1 and XNP in the presence of NEM 
• identified by two or more peptides  
• in at least two out of three replicates  
• not identified by two or more peptides in pre-immune serum controls. 
These are shown in Table 16. The abundance of the different interactors cannot be 
directly compared due to differential recovery from different IP targets.  
 
Shared interactors of ADD1 and XNP were used to query the protein interaction 
database IntAct (https://www.ebi.ac.uk/intact/ ) to build a network of interactors, with 
the aim of identifying proteins with common roles in particular cellular processes. 
The software Cytoscape was used to visualise the network as a node and edge 
diagram. The information in this database is derived from literature curation. Of the 
48 proteins, only 25 appeared in the IntAct database. Fundamentally, XNP, ADD1 
and PIAS could not be linked to interactors. However, useful information could still 
be obtained, most notably that rhea, Rbcn-3A, cora and Pescadillo homologs are all 
enriched in the nervous system, where human ATRX mutations cause a mental 
retardation phenotype. Identification of these proteins supports a role for the ADD1 
and XNP proteins acting in common and conserved pathways. PIAS is found as a 
co-interactor of both ADD1 and XNP only when SUMOylation is maintained in the 
presence of NEM. This indicates that SUMOylation of these proteins and this 
complex may be essential for their role and mechanism in ATRX’s mental 
retardation phenotype.  
 
14 out of the 48 common interactors are involved in chromosome organisation: 
Brahma and Mi-2 are both involved in ATP-dependent chromatin remodelling and 
Brahma in H3K27 acetylation; Ebi is involved in histone deacetylation; Maleless is 
involved in DNA duplex unwinding and heterochromatin assembly; JIL-1 is involved 
in histone phosphorylation; Cap-G, PIAS and Mi-2 are involved in chromosome 
condensation. In Drosophila Rif1 is involved in maintenance of chromatin silencing 
at the telomere. In addition to Rif1, mre11 and JIL-1 have roles in telomere 
maintenance. 
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Table 16 Proteins in common in ADD1 and XNP IP-MS in the presence of NEM 
Proteins identified in two out of three replicates by two or more peptides and not identified in the pre-immune serum negative controls by more than one 
peptide are listed.  
Majority 







A0A0B4KHR8  Ankyrin repeat and KH domain-containing protein mask  scaffolding 17 37 
Q9VSL8  Rhea, isoform G  adaptor  11 30 
M9PB68  Protein purity of essence  E3 ubiquitin ligase 6 30 
A0A0B4LFW6  Receptor mediated endocytosis 8, isoform A  heat shock 5 22 
A0A0B4KEY4  Patronin, isoform I scaffolding 15 21 
P51592  Hyperplastic discs, isoform B  E3 ubiquitin ligase 20 18 
Q9W425  Rabconnectin-3A  Notch signalling  10 18 
A0A0B4LHR3  Transcriptional regulator ATRX homolog  chromatin remodelling  4 18 
A0A0B4K7T7  Rho guanine nucleotide exchange factor 2, isoform D  enzyme 8 16 
Q9VVA4  Uncharacterized protein enzyme 8 16 
P25439  Brahma, isoform E  chromatin remodelling  12 13 
Q9V8R9  Coracle, isoform F  scaffolding 7 13 
X2JBC1  Regulator of nonsense transcripts 1 homolog  mRNA NMD 6 13 
A0A0B4LEK8  Sec24AB ortholog, isoform A  transport 9 12 
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Q9W543  Rabconnectin-3B, isoform A  Notch signalling  8 12 
M9PBG5  Enhancer of bithorax (Ebi) chromatin remodelling  12 11 
Q9V466  Nuclear pore complex protein Nup107  DSBR 11 11 
Q7KVD1  Trio, isoform A  scaffolding 10 11 
Q8SWR8  Ataxin-2, isoform D  miRNA pathways 6 10 
M9PIA6  Chromodomain-helicase-DNA-binding protein Mi-2 homolog chromatin remodelling  10 9 
Q9VP27  Golgi complex-localized glycoprotein 1, isoform B  enzyme 7 9 
Q7KQM6  GIGYF family protein CG11148  autophagy 6 9 
Q86BR6  Autophagy-related autophagy 4 9 
Q9VCN1  DNA polymerase epsilon catalytic subunit  DNA replication 11 8 
Q9VHI1  Hyrax  signalling  9 8 
A1Z987  Chromosome associated protein G, isoform G (Cap-G)  condensin I complex  8 8 
Q961C3  Uncharacterized protein N/A 6 8 
Q9VJH2  Aspartyl-tRNA synthetase, mitochondrial, isoform A  enzyme 12 7 
Q9XZ34  Telomere-associated protein RIF1  DNA replication 10 7 
A0A0C4DHA1  Chondrocyte-derived ezrin-like domain containing protein, isoform E  scaffolding 7 7 
Q7K0D8  Nuclear pore complex protein Nup50  scaffolding 6 7 
M9PGQ6  Puff-specific protein Bx42  Notch signalling  6 7 
Q9W0M7  Splicing factor 3B subunit 3  mRNA processing 5 7 
Q95RJ9  F-box-like/WD repeat-containing protein ebi  Notch signalling 5 7 
O18413  26S proteasome regulatory subunit 8  protein degradation 5 7 
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Q9VTE6  IP14658p  ribosome biogenesis 4 7 
O46048  Enhanced adult sensory chromosome associated 12 6 
M9PI05  Chromosomal serine/threonine-protein kinase JIL-1  chromatin structure 11 6 
Q9XYZ4  Double-strand break repair protein (mre11) DSBR 6 6 
Q9VWD9  LD38919p  protein degradation 5 6 
Q9VIW7  tRNA-splicing ligase RtcB homolog  mRNA processing 4 6 
P24785  Dosage compensation regulator, maleless chromatin associated 9 5 
Q9VWK5  GH15225p/Ulp1 protein deSUMOylation 9 5 
A1Z7P7  Suppressor of variegation 2-10, isoform M  SUMO E3 ligase 7 5 
Q9VL96  Pescadillo homolog  ribosome biogenesis 5 5 
Q9VBQ5  LD38433p  enzyme 5 5 
M9NDW1  DIS JNK pathway 6 4 
A0A0B4LG05  Maternal protein tudor  Piwi-RNA pathway 5 4 
  XNP-ADD1 
  205 
 
7.3.6 SUMOylation modifications on ADD1 and XNP 
Algorithms have been developed to predict where post translational modifications 
(PTMs) are likely to occur on proteins. Putative SUMOylation sites were determined 
by searching the full-length amino acid sequence of ADD1-RA (A1Z8R2) and XNP-
RA (Q9GQN5) with three different PTM prediction tools: SUMOplot 
(http://www.abgent.com/sumoplot), GPS-SUMO (http://sumosp.biocuckoo.org/) and 
JASSA (http://www.jassa.fr). For ADD1-RA, two lysine residues were predicted as 
SUMOylation sites by GPS-SUMO whereas in SUMOplot 21 sites were identified. 
For XNP-RA, three SUMOylation sites were identified in GPS-SUMO and 12 in 
SUMOplot. There was no overlap in the predictions, with predicted SUMO and SIM 
sites not predicted to be in consensus sites.  
 
Unlike XNP that has been identified as a SUMO substrate171, it was not known 
whether ADD1 itself is SUMOylated. A higher molecular weight smear is visible 
above the main HA-ADD1 bands, characteristic of modified forms of ADD1 (Figure 
7–8). ADD1 co-immunoprecipitates with SUMOylated species when NEM is present 
(Figure 7–8).  
 
Figure 7–8 ADD1 co-immunoprecipitates with SUMOylated species. 
Nuclear extracts were made from wild-type (WT) or HA-ADD1 S2 cells. The input (IN) and IP 
with anti-HA resin (IP) were run on 8% SDS-PAGE and analysed by western blot probing 
with anti-HA mouse antibody or anti-SMT3 rabbit antibody. SUMOylated species are marked 
by an asterisk in the longer exposure western blot. 
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A large number of in vivo validated SUMOylation sites do not occur on consensus 
sequences176. To determine where XNP and ADD1 are post-translationally modified 
when expressed at endogenous levels, I searched the MS/MS spectra from S2 cell 
and embryo IP-MS for SUMOylation sites. Despite having high overall peptide 
counts, many peptides that mapped to ADD1 and XNP had the same sequence. 
One QQTGG (K) site was identified in ADD1, mapping to exon 4 at the same site 
found in Sf9 expressed protein. The mass spectrum is shown for this peptide 




Figure 7–9 MS/MS spectrum of an ADD1 peptide modified by QQTGG(K) 
Tandem mass spectrometry (MS/MS) spectrum of a QQTGG (K) site on a peptide identified 
in XNP IP-MS indicating SUMOylation of ADD1 lysine-146. The b and y ions are marked. 
This modification was identified once.  
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7.4 Summary 
In this chapter I have demonstrated that the ADD1 and XNP antibodies could detect  
modified forms of ADD1 (Figure 7–8) and XNP (Figure 7–1) in the presence of NEM 
in S2 cells. Probing the immunoprecipitated material with anti-SMT3 antibodies 
could not confirm that SMT3 was covalently attached to XNP nor ADD1. We 
hypothesised that the interaction between ADD1 and XNP might be mediated by 
SUMOylation of XNP, promoted by PIAS. Mass spectrometry approaches to identify 
post-translational modifications on XNP and ADD1 had limited success due to low 
peptide coverage of the proteins. However, one SUMO site was identified on ADD1 
at K-146 (Figure 7–9). Together, with previous data, this supports the likelihood of 
SUMO-related functions. 
 
The XNP-HP1a interaction shown by Emelyanov et al., 2010139 and ADD1-HP1a by 
Alekseyenko et al., 2014299 most likely occurred in conditions where post-
translational modifications had been lost. I hypothesise that ADD1 might only 
interact with modified XNP which is not very abundant in the cell. My IP-MS 
datasets comparing conditions where SUMOylation has been maintained opens up 
new interaction partners to explore. 
 
7.4.1 XNP interactors  
In mouse cells, recruitment of SSRP1 (a FACT complex component) to 
heterochromatin is dependent on ATRX273, with which it can interact directly340. 
SSRP1 can be modified by ubiquitin-like modifications that have been identified 
through exogenous expression of SUMO in mouse cells305. FACT is an 
evolutionarily conserved histone chaperone that recognises the nucleosome and 
destabilises the interactions between H2A-H2B dimers and the H3-H4 tetramer341. 
H3.3 was also enriched in PIAS +NEM conditions. Dref, a published XNP interactor 
involved in chromatin organisation339, was not detected in my XNP IP-MS. ADD1 
was also not identified (Figure 7–2). This could be due to the conditions used for IP. 
As the anti-XNP antibody was extracted from an early serum (antibody production 
stopped at bleed 2 and rabbit was terminated due to closure of the company making 
it), it may only weakly recognise XNP, which may affect capture of low abundance 
interactors. In addition, washes in IP wash buffer containing 0.5M NaCl may have 
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caused loss of some XNP-complexes and/or interactors during the 
immunoprecipitation procedure potentially due to a weakly binding antibody.  
 
7.4.2 An interaction between ADD1, XNP, HP1 and PIAS 
It is possible that the ADD1 and XNP interaction is indirect or requires the proteins 
to be in a particular post-translationally modified state. This would explain why 
ADD1 and XNP interaction is only found in some experimental settings and not 
others296.342, including the presence of NEM (Figure 7–6). HP1a is a possible 
intermediate binding partner. ADD1 interacts with HP1a299 and XNP interacts with 
HP1a299 and both were identified in ADD1 IP-MS (Figure 7–6) and XNP IP-MS 
(Figure 7–2) in this study and in a HP1a IP-MS299. However, whether ADD1 and 
XNP bind directly needs further clarification. ADD1, XNP and HP1a localise to 
telomeric repeat sequence, where PIAS is also present322. Alternatively, my IP-MS 
shows that PIAS interacts with XNP and ADD1. As PIAS is an E3 SUMO ligase, it is 
possible that PIAS can SUMOylate HP1a, ADD1 and/or XNP, affecting their 
recruitment to chromatin, maintenance at chromatin or the stability of interaction 
partners.  
 
The ADD1-XNP interaction could be context and/or cell cycle dependent, meaning 
that to capture it, as a rare event, is challenging. Understanding the dynamics of 
XNP SUMOylation would help identify a time and/or cell type in which to explore this 
interaction further. There are no other SUMO E3 ligases enriched as interactors of 
XNP and ADD1 (Table 16). 
 
7.4.3 ADD1 interactors  
Endogenous ADD1 IP-MS identified the E3 ubiquitin ligase hyd, the SANT domain 
protein SMRTER (Smr) and the bifunctional lysine-specific demethylase and 
histidyl-hydroxylase NO66 (CG2982) (Figure 7–6). CG2982 demethylates H3K4me3 
and H3K36me, possibly controlling the balance between heterochromatin and 
euchromatin.  
 
Interestingly, ADD1 remains associated with chromatin at mitotic chromosomes 
after HP1a disassociation303 and is found at the boundaries of heterochromatin and 
euchromatin303. Through interaction with other proteins and protein complexes 
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ADD1 could control the balance between heterochromatin and euchromatin. PIAS is 
also weakly enriched at pericentromeric heterochromatin and sub-telomeric regions 
in mitosis143. I hypothesise that PIAS mediated SUMOylation of ADD1 at the G2/M 
transition could influence HP1a re-association with chromatin after mitosis. 
 
7.4.4 Evaluation of the approach  
7.4.4.1 Sensitivity and performance of ADD1 and XNP antibodies in detecting 
post-translationally modified forms of ADD1 and XNP 
The anti-XNP rabbit antibody generated in this study is more sensitive in its ability to 
detect denatured protein on western blot than the anti-ATRX rat antibody (Figure 7–
1). Both XNP and ADD1 rabbit antibodies generated in this study enrich for their 
target protein from a complex protein lysate (Figure 7–4). 
 
7.4.4.2 IP-MS with ADD1 and XNP serum  
For non-affinity purified antibodies, the XNP and ADD1 IP-MS experiments worked 
remarkably well, isolating ADD1 and XNP-associated complexes with enrichment 
above background levels and isolation of known and predicted targets (Figure 7–6 
and Figure 7–2). 
 
7.4.4.3 Overexpression of XNP as a soluble source of modified XNP 
XNP can interact with ADD1 in the presence of NEM (Figure 7–4). This, together 
with Figure 7–5, presents the question of what is different between +NEM and -NEM 
conditions. Perhaps both ADD1 and XNP need to be modified to interact or to 
interact with an intermediate that is preserved in +NEM conditions, which facilitates 
interaction or recruitment of the proteins to form part of a larger complex. To confirm 
that the ADD1-XNP interaction is mediated by SUMOylation, and is not itself direct, 
ADD1 and XNP would need to be produced recombinantly and used in direct 
binding assays in vitro, without the presence of other proteins or PTMs. This was 
not possible during this body of work due to not producing stable ADD1 and XNP in 
vitro. This was the subject of chapter 7 of this thesis. I would also hypothesize that 
modification or absence of modification results in different stabilities of XNP. 
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7.4.4.4 Identification of post-translational modifications 
A SUMOylation site motif on ADD1 was identified by analysis of MS/MS spectra for 
this post-translational modification. However, SUMOylation is not motif specific and 
SMT3 can bind at different protein sites. Confirming SUMOylation at lysine-146 of 
ADD1 would require mutation of the SMT3 C-terminus to generate a T86K site (see 
section 2.3.8.1), which can be digested by trypsin, leaving a small peptide chain 
attached to ADD1 that can be detected by mass spectrometry. This approach could 
also confirm the location of SUMOylation sites on ADD1, XNP and other detected 
proteins.  
 
The standard approach for identifying the function of SUMOylation on a target 
protein is to map the bona fide SUMO target sites on the substrate protein and 
generate SUMOylation-deficient mutants by site-directed mutagenesis. The QQTGG 
(K) SUMOylation site identified in exon 4 of ADD1-RA is novel (Figure 7–9) and was 
found on both Sf9 expressed protein and in IP-MS from endogenous S2 cells. This 
is on a non-canonical sequence that was not identified by prediction based software. 
However, E3 ligases can enable modification of non-consensus sites176. Although 
SUMOylation may be added at alternative sites, the combination of data to support 
modification of K-146 on ADD1 provides a starting point for addressing the role of 
ADD1 SUMOylation in a system with reduced ADD1 SUMOylation by mutating the 
SUMO site.  
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Chapter 8 Conclusions, Perspective and 
Future Direction 
 
In this thesis I identified interaction partners of endogenous Drosophila PIAS in S2 
cells and embryos. I have identified the general and developmental-specific 
interactions, to discover PIAS interactors that may be involved in heterochromatin 
formation. A number of exciting new interactions were discovered. These include 
proteins in RNA processing pathways and the Piwi-piRNA pathway and the histone 
methyltransferase Eggless, that is responsible for heterochromatin formation.   
 
I attempted to purify full length XNP-RA and ADD1-RA protein to characterise their 
direct interaction, which is possibly mediated by SUMOylation. Although 
unsuccessful, this allowed generation of antibodies for further study. These 
antibodies allowed immunoprecipitation of XNP and ADD1 to identify interaction 
partners with and without retention of SUMOylation. This demonstrated that PIAS, 
HP1, ADD1 and XNP co-immunoprecipitate under conditions where SUMOylation is 
maintained (Figure 7–4). 
 
8.1 PIAS self-oligomerises, but does not reside in PIAS bodies in S2 cells at 
endogenous levels 
In the nucleus, only a small percentage of proteins are SUMOylated at any given 
time. In the presence of NEM, where SUMO conjugation to substrates is 
maintained, PIAS is present in SDS resistant structures (consistent with covalent 
modifications) visible on western blot (Figure 4–8 and Figure 4–10), but the 
functional relevance is not known. In 2001 Kumar Hari speculated that PIAS forms 
interactions with chromatin and that these may be stabilised by PIAS self-
association and/or interactions with other scaffolding proteins. A secondary 
consequence of this might be to establish nuclear domains containing a high 
concentration of silencing protein143. Excess PIAS, when overexpressed, forms 
nuclear bodies through SUMO-SIM interactions144 probably indicating loss of the 
normal equilibrium.  
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I hypothesise that PIAS, when SUMOylated, could form or bind insoluble structures 
in the nucleus through its scaffold attachment domain147. Alternatively SUMOylation 
and PIAS may aid phase separation to create local concentrations of target proteins. 
Formation of local concentrations through either phase separation (as seen with 
PIAS bodies in PIAS-V5-PE overexpression) or scaffolding could be important to 
PIAS’s role at euchromatin-heterochromatin boundaries.  
 
8.2 PIAS interacts with boundary elements and RNA Pol II transcription 
components  
PIAS interacts with the boundary element associated factor (BEAF-32) (Figure 4–
18) and both proteins share similar genome localisation patterns in the embryonic 
Drosophila melanogaster cell line Kc16757. PIAS is categorised as binding 
euchromatin, which has a high density of regulatory complexes, and localises to 
gene start sites57.  
 
PIAS interacts with transcription associated factors (Tafs) of the TFIID complex 
irrespective of NEM (Figure 4–17), indicating a SUMO-independent interaction. 
TFIID complex components are important for RNA Pol II transcription initiation. It is 
possible that PIAS-mediated SUMOylation of factors required to localise to TFIID is 
important for transcription regulation. Consistent with these observations, human 
PIAS is also involved in transcription and directly interacts with TATA binding protein 
(TBP)310, suggesting that a role in transcription may be evolutionarily conserved. 
 
8.3 PIAS interacts with nucleic acid binding proteins  
Given that SUMO is involved in a large number of cellular processes (see sections 
2.3.6-2.3.13), it is unsurprising that many proteins were found to interact with PIAS. 
Biochemical (salt fractionation and size exclusion chromatography) experiments 
demonstrated that PIAS is present in multiple complexes (Figure 4–2 and Figure 4–
9). It is likely that PIAS isoforms and post-translational modifications on PIAS 
regulate its ability to self-associate (Figure 4–8) and form part of such complexes. 
PIAS interacting proteins that are also SUMOylation targets may be transient, 
occurring only at a specific point in the cell cycle or during development. 357 
proteins were found to interact with PIAS in all conditions presented in this thesis 
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(Figure 5–7B) in the presence of NEM, indicating that these are constitutive binding 
proteins (not stage/condition specific).  
  
PIAS interacts with proteins involved in: transcription, processing and transport of 
RNA and translation- indicating a regulatory role in all stages of gene expression. 
This has been identified qualitatively at the single protein level (Table 6) and in 
probabilistic models by gene ontology analysis (Table 5, Table 9, Table 10). This 
agrees with previous data that PIAS is essential for interphase chromosome 
organisation, chromosome structure, chromosome inheritance and gene 
expression141. 
 
In light of the recent data linking PIAS and Piwi-piRNA guided chromatin silencing163 
(an RNAi-guided mechanisms), it is of particular interest that members of the RNAi 
machinery were identified in PIAS IP-MS. Although, RNAi components have been 
classified as common mass spectrometry contaminants343, this does not seem to be 
the case here. This is due to: large coverage of the pathway; the abundance of the 
factors following IP; and IgG controls with no detection of RNAi family proteins. 
Biologically, you would also expect RNA mediated transcriptional silencing 
complexes to be abundant, where it is important to protect from transposon activity. 
 
Overlap of proteins identified in interactome studies is often limited. However, two 
independent mass spectrometry studies (discussed below), using HP1a and 
telomeric regions as bait, identified similar proteins as found in my mass 
spectrometry experiments. In my data, using both antibodies against endogenous 
PIAS and tagged versions of PIAS, there was a large overlap in equivalent 
conditions (Figure 4–22).  
 
Published telomere-associated proteins include PIAS, SMT3, XNP and ADD1322. 
Many other proteins were also identified in this study and these overlap with PIAS 
interactors including HP1a, BEAF-32, Mi-2, and Caf1322. This overlap, combined 
with IF staining indicating localisation of PIAS to telomeres143 and deficits in 
telomere clustering and telomere-lamina associations in Su(var)2-101 and Su(var)2-
102  mutants demonstrates a role for PIAS in telomere function and nuclear 
organisation141.   
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I confirmed an interaction between PIAS and HP1a (Figure 4–4) that had previously 
been found in HP1a IP-MS299. In mammals, SUMOylation of HP1ɑ affects 
heterochromatin structure, increases HP1ɑ chromatin binding affinity and enables 
targeting of HP1ɑ to chromatin in the absence of H3K9me3. In a screen of HP1a 
interactors in Drosophila S2 cells, ADD1 was identified as the top hit of over 400 
interactors, appearing in every condition tested303. SMT3 was also identified in 4/6 of 
their replicate studies303. XNP was not identified303. This study supports the 
presence of an HP1a-ADD1 and a HP1-SMT3 (SUMO) complex. It is also possible 
that ADD1 and SMT3 are part of a larger complex with HP1a, with SMT3 addition 
aided by PIAS as these proteins co-immunoprecipitate in the presence of NEM 
(Figure 7–5).  
 
The transcription factors, without children (woc) and relative of woc (row) are 
consistently identified in this study to interact with PIAS, XNP and ADD1 (Figure 4–
15, Figure 4–16, Figure 5–1, Figure 5–2, Figure 7–2 and Figure 7–6). Woc and row 
also co-immunoprecipitate with the boundary and insulator element BEAF-32311. 
Woc and row localise to developmental gene promotors with HP1c311 and regulate 
telomere function344,345.  
 
8.4 The PIAS interactome changes during Drosophila development.  
PIAS is present in high concentrations in the early embryo142 where it localises to 
the DAPI dense regions of pre-blastoderm nuclei during heterochromatin 
establishment at nuclear cycles 10-14144. Kumar Hari observed PIAS localisation 
changing depending on the cell cycle stage141 (Figure 2–4) and as having an inter-
chromosomal thread-like localisation in S2 cells141.  
 
Different PIAS interactors were enriched from Drosophila embryos at different 
stages in development (Figure 5–4, Figure 5–5 and Figure 5–6), identifying unique 
PIAS interactors (Table 11, Table 13 and Table 15). During early development, 
PIAS interacts with pathways previously identified as regulators of heterochromatin 
formation including the Piwi-piRNA pathway and Eggless (Figure 5–1 and Table 11). 
These interactions are restricted to a specific developmental timepoint, suggesting 
changes in PIAS’s interaction partners over time have an effect on PIAS’s function. 
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Mass Spectroscopy data cannot be used to determine function of target proteins. It 
only provides information on the interactome of the protein or complexes it is 
involved in. From this, function can be inferred or suggested but must be followed 
up by phenotypic or functional analysis. 
 
8.5 XNP interacts with PIAS 
Previous experiments in the Heun lab suggested a close relationship between XNP 
and PIAS, as they co-localise in PIAS bodies in S2 cells. The lab therefore 
hypothesised PIAS could SUMOylate XNP because XNP can be SUMOylated171. 
We further hypothesised that failure to SUMOylate XNP due to loss of PIAS, could 
be responsible for the Su(var)2-101/Su(var)2-102 phenotype, and of interest in alpha 
thalassemia x-linked mental retardation syndrome as a novel role for ATRX. 
However, interaction between XNP and PIAS was only observed at endogenous 
levels by immunoprecipitation of PIAS in the presence of NEM and not in reverse by 
immunoprecipitation of XNP. This is consistent with a role of SUMOylation of XNP 
by PIAS. In Drosophila tissues, PIAS co-localises with XNP at polytene inter-bands 
and at a repetitive region of the genome near heterochromatin on the X 
chromosome (at the TAGA repeat)144. However this interaction, compared with the 
many others identified in the PIAS interactome could be described as weak. A 
SUMO deficient mutant of XNP would be required to confirm whether the XNP-PIAS 
relationship was responsible for the Su(var)2-101/Su(var)2-102  mutant phenotype.  
 
8.6 ADD1 interacts with PIAS and is SUMOylated  
IP-MS of PIAS interactors identified a novel interaction between PIAS and ADD1, 
which is independent of SUMOylation, indicating a non-SUMO dependent 
interaction (Figure 4–17). This was confirmed by IP-MS of ADD1, which identified 
PIAS. I also identified a SUMOylation site at K-146 on ADD1 (Figure 7–9). 
 
8.7 ADD1 and XNP interact in the presence of SUMOylation 
ADD1 is the Drosophila homologue of the N-terminal half of mammalian ATRX and 
XNP is the Drosophila homologue of the C-terminal half of mammalian ATRX296. In 
this study XNP and ADD1 only co-immunoprecipitate in the presence of NEM 
(Figure 7–5), suggesting that their interaction may be SUMO mediated or be part of 
a complex requiring SUMO. This allows a degree of protein regulation not present in 
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mammals, if we presume XNP and ADD1 fulfil the same function as mammalian 
ATRX when associated. PIAS, ADD1, XNP and HP1a co-immunoprecipitate when 
using any one of them as bait (Figure 7–4, Figure 4–4, Figure 4–13 and Figure 4–
18A). This indicates that they might be part of a larger SUMO-dependent complex.  
 
It is hypothesised that ADD1 localisation may maintain the border between 
heterochromatin and euchromatin domains303 because during mitosis all HP1a 
interacting proteins except ADD1 are removed from chromatin303 and during 
interphase ADD1 localises at the heterochromatin boundary and has weak, broad 
heterochromatin enrichment303. I have shown that ADD1 localises to DAPI-dense 
regions of pre-blastoderm nuclei where heterochromatin establishment takes place 
in the early Drosophila embryo (Figure 5–12). Although this does not prove that 
ADD1 marks areas for heterochromatin establishment during development, it 
indicates this is worthy of further study to determine if this is a novel and exciting 
role for ADD1 during development.  
 
Similarly to ADD1, XNP localises to heterochromatin in narrow and focal 
subdomains in S2 cells303. However, unlike ADD1, XNP is removed during mitosis. 
My hypothesis is that ADD1 acts as the seed to recruit HP1 and XNP to sites of 
heterochromatin establishment, which is possibly aided by PIAS mediated 
SUMOylation. Therefore a PIAS, ADD1, XNP, HP1a interaction will only be present 
at specific points in development or in the cell cycle.  
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8.8 Speculative Models 
In Su(var)2-101/Su(var)2-102  trans-heterozygous mutants, interphase chromatin is 
decondensed141. My data indicates a number of novel interactions between PIAS 
and proteins involved in chromatin organisation, that could be required for 
establishing and/or maintaining properly folded chromatin. PIAS proteins potentially 
bind the nuclear lamina/matrix through their SAP domain147. Once at chromatin, 
PIAS may co-ordinate SUMOylation within a given chromatin domain either 
specifically or through a “SUMO spray” mechanism. Through this, PIAS may be 
essential to SUMOylate chromatin factors, ensuring their recruitment to form 
repressive chromatin complexes or to regulate transcription through SUMOylation of 
transcription factors346. In the presence of NEM, an increased number of protein-
protein interactions were identified, indicating that SUMO promotes interactions 
between proteins. This may be particularly important during transition phases, such 
as during development, differentiation and diseases arising from defects in gene 
silencing, where chromatin must be restructured. 
 
The first speculative model (Figure 9-1) is adapted from multiple sources and data 
gathered in this thesis. The original published figures copied without amendment are 
in Appendix 6. My model places PIAS in the context of its role in interphase 
heterochromatin organisation. A reduction in PIAS causes chromatin de-
condensation in interphase nuclei141. PIAS localisation is similar to BEAF-32 (a 
boundary associated protein) and is associated with bordering regions of active 
transcription57. This indicates it could be found at the base of loops where 
transcription takes place. My IP-MS data identified many protein interactors of PIAS, 
and consistently identified proteins with roles related to RNA Pol II transcription. A 
long standing hypothesis of Peter Cook is that proteins involved in similar processes 
are clustered in “factories” to ensure efficient interaction347-349.  
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In my model I have placed PIAS at the base of chromatin loops close to RNA Pol II 
transcription factories, where it could function in several related pathways or play 
dual roles as both an activator or repressor based on chromatin context. My data 
demonstrates that PIAS interacts with a larger number of proteins in the presence of 
NEM. This indicates SUMO reliant (SUMO-SIM) interactions (sometimes referred to 
as “glue”), known to bind proteins into large networks (see Appendix model 8)350. 
PIAS mediated SUMOylation presents a theoretically efficient method to “glue” 
proteins in SUMO-SIM networks350 (at the base of loops) thereby causing locally 
increased factor concentrations required for chromatin establishment and formation. 
In short, localisation of PIAS at the base of loops may limit PIAS’ SUMO conjugation 
capacity to target chromatin proteins within its immediate environment, “gluing” them 
at sites of active transcription, generating a high local concentration required for 
establishing chromatin domains, determining which areas of the genome are 
actively transcribed or silenced. 
 
An outstanding question in the SUMOylation field is why are only a small sub-
fraction of proteins SUMOylated. This model could explain why only a subset of 
proteins are SUMOylated, as only those in PIAS’s immediate vicinity and required at 
the time become SUMOylated. 
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Figure 8–1 Regulation of Insulator Function by PIAS-mediated SUMOylation 
(A) Chromatin is organised within domains in the nucleus. (B) A topologically associated 
domain made up of chromatin (black) in open and closed formats with interspersed SUMO 
(green), and PIAS (blue) bound to euchromatin, particularly at the base of loops. Areas of 
functionally differential chromatin are illustrated by coloured ovals; HP1 (GREEN), Active 
(YELLOW/RED), Polycomb (BLUE) or Repressive (BLACK). (Bi) Inset 1 from B showing a 
repressive domain (Bii) Inset 2 from B showing a Polycomb/Bivalent loop in transition to 
repressive, with chromatin (black) forming a loop with PIAS (blue) at the base and a high 
local concentration of SUMO (green) which recruits and maintains a high local concentration 
of chromatin factors (purple) required for remodelling from Polycomb/Bivalent to repressive 
chromatin. (Biii) Inset 3 from B showing an active gene with chromatin (black) forming a loop 
with PIAS (blue) at the base with a low local concentration of SUMO (green), an open gene 
(yellow) with promotor (red circle) is available for transcription. (C) Biii showing gene 
transcription followed by silencing. (Ci) PIAS sits at the base of active chromatin loops and 
helps recruit RNA polymerase to a transcription factory (TXN factory). The gene of interest 
and promoter sit in open chromatin within the loop. (Cii) The gene promoter is recruited to 
the RNA polymerase complex. (Ciii) The gene is pulled through the RNA polymerase 
complex, producing transcript. (Civ) The transcript is released and chromatin binding 
proteins (histones and insulators proteins) are SUMOylated, parting the loop, causing a 
more open chromatin conformation. (Cv) Proteins involved in forming repressive complexes 
can be recruited by SUMO, the promoter is no longer accessible and transcription from the 
gene is prevented through isolation of the loop.  
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Though the model above is based upon published literature there are a number of 
outstanding questions: 
• how chromatin factors are initially recruited to chromatin to seed 
heterochromatin formation in Drosophila 
• how decisions are made as to which factors to recruit  
• how heterochromatin is nucleated and maintained.  
 
Although my interactome data only implies relationships without functional 
confirmation, from it and with support from the literature I can form a working 
hypothesis for heterochromatin formation in the early Drosophila embryo.  
 
Models for heterochromatin establishment are discussed in sections 1.11 and 
2.3.13. Heterochromatin is defined at the molecular level by the presence of the 
histone modification H3K9me3 and HP1. HP1 proteins can be recruited to form 
heterochromatin by multiple mechanisms and HP1 binding is enhanced in a positive 
feedback loop to form heterochromatin domains. 
 
In S. pombe heterochromatin is established through RNA interference (RNAi) based 
mechanisms, using transcripts transcribed from heterochromatic regions. These 
transcripts target histone methyltransferases to deposit methyl marks on histone 3 
lysine 9 (Figure 1-2)351 to form heterochromatin. In Drosophila PIAS and XNP are 
required for transcription of pericentric repeats144 that could act in RNAi-based 
mechanisms to maintain heterochromatin. Furthermore, PIAS interacts with Piwi, a 
Piwi-piRNA component known to promote heterochromatin assembly (Figure 1–3). 
Piwi-piRNA were identified in PIAS IP-MS only at the earliest embryo timepoints 
(Figure 5–1) and RNAi proteins were identified in all PIAS IP-MS conditions.  
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PIAS IP-MS in timepoint 1 embryos (nuclear cycles 7-10) also identified the histone 
methyltransferase Eggless, which Seller et al., 2019123 propose to seed the 
formation of heterochromatin by depositing methyl marks at H3K9. The mechanism 
of Eggless recruitment to chromatin is currently unknown. Seller et al., 2019123 
propose interaction of Eggless with small RNAs could guide Eggless to chromatin. 
Given the novel interaction presented in this thesis between PIAS and Eggless 
(Table 11), it is possible that PIAS-mediated SUMOylation of Eggless could 
enhance its association with chromatin. This would require further confirmation. In 
support of this hypothesis, similar mechanisms have been identified. A SUMO 
dependent mechanism for de novo recruitment of HP1α to heterochromatin in 
mouse ESCs was identified by Maison et al., 2011244, which also requires pericentric 
long non-coding RNAs that correspond to major satellite repeats. Subsequently, the 
same researchers found the histone methyltransferase Su39h1 can exhibit novel E3 
SUMO ligase activity to provide this SUMOylation247.   
 
In Drosophila, although HP1a binding partners have been identified, none are E3 
SUMO ligases299. An argument for PIAS’s involvement in heterochromatin formation 
in Drosophila is that it interacts with proteins required for heterochromatin 
establishment at the timepoints when SUMOylated versions of the protein are 
required for recruitment to or function of at chromatin. Eggless interacts with 
HP1a299 and ADD1299. ADD1, which can directly bind DNA, may provide an 
alternative means of HP1a recruitment and act to nucleate heterochromatin 
formation in a mechanism analogous to mammalian ATRX, which has been shown 
to interact with HP1α352. A combination of redundant mechanisms may act to initiate 
formation of and stabilisation of heterochromatin domains.  
 
Below I outline a hypothetical model for how ADD1, PIAS, XNP and H3.3 are 
involved in incorporation of H3.3 at chromatin (Figure 8–2).  
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Figure 8–2 Hypothetical working model of PIAS, ADD1 and XNP at the equivalent of 
DAXX/ATRX-dependent H3.3 enriched regions of heterochromatin in Drosophila. 
(A) PIAS localises to recognition elements in DNA (RE). ADD1 can directly bind DNA and 
interact with PIAS independently of its SUMOylation status (Table 6). ADD1 binding is 
reinforced by binding of the ADD domain to a combination of histone tail modifications (as for 
human ATRX258). Both PIAS and ADD1 interact with components of the TFIID complex 
(Figure 4–15 and Figure 7–6) and are likely to be involved in mediating transcription close to 
their binding sites in the genome. For example, ADD1 prevents expression of TART 
retroelements in the telomeric HTT array295. PIAS is able to autoSUMOylate144 and 
SUMOylate factors that come into proximity with it in a “SUMO spray” type mechanism225. In 
collaboration with this, RNA may act as scaffolding or target sequences in RNAi pathways to 
both structurally and specifically direct chromatin remodelling. Together, RNA and 
SUMOylation based mechanisms could help provide an open chromatin configuration, 
enabling recruitment of chromatin remodellers, as is the case for SUMOylation of histone 
4234,235. (B) Proteins that are SUMOylated or contain SIM domains can form multivalent 
interactions with each other and are retained at chromatin. XNP can be SUMOylated171 and 
when SUMOylated binds to ADD1 (Figure 7–6). (C) XNP is involved in the deposition of 
histone H3.3 in nucleosomes through interaction with DAXX-like protein (DLP)115 at 
pericentric and telomeric repeats to maintain an open conformation of DNA353. (D) The 
histone methyltransferase Eggless (SETBD1 homolog) is recruited and tri-methylates H3K9. 
Eggless can be modified by SUMO354, interacts with PIAS (Table 11) and ADD1299. Koch et 
al., 2009 propose that SUMOylated Eggless can recruit chromatin regulators and form 
repressive chromatin complexes354. (E) H3K9me3 and ADD1 recruit HP1a independent of 
Eggless355 and ADD1 is required for HP1a recruitment to telomeres295 (in mammals there is 
cross-talk between DNA methylation and histone methylation, de novo DNA 
methyltransferases can interact with histone methyltransferases356 to cooperate for the 
repression of gene expression357). BON could be responsible for HP1a hinge domain 
phosphorylation in Drosophila, as mammalian homologs perform this function249. (F) HP1a’s 
hinge domain is important for its DNA binding properties in Drosophila358. In mammals, 
phosphorylation of this region alters HP1α DNA binding stability and interaction partners 359. 
The mouse HP1α hinge domain has also been shown to be SUMOylated244. It is possible 
that SUMO-phosphorylation cross-talk happens in the hinge region of HP1 in a cell cycle or 
cell stage dependent manner352 to strengthen and reinforce HP1 domains in feedback 
loops124. HP1 forms and defines heterochromatin domains.  
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8.9 Future experiments  
8.9.1 To understand the global role of PIAS at chromatin 
In principle, with tagged versions of PIAS and endogenous antibodies that can 
immunoprecipitate PIAS from different cell types and tissues, the following 
experiments would provide support for a global role of PIAS at chromatin. 
 
8.9.1.1 Mapping PIAS genomic binding sites  
PIAS DamID, which maps protein binding sites in the genome, has been performed 
in the embryonic Drosophila Kc167 cell line57. This revealed that PIAS binds to 
euchromatic regions57. PIAS binding profiles could be explored to identify genomic 
features of PIAS binding sites. If this identified G4 structures and transcription start 
sites, it would along with my interactome data (which identified Tafs and 
transcription factors), builds a case of PIAS mediated transcription regulation in 
Drosophila. PIAS DamID or ChIP-seq could be performed from Drosophila embryos 
to identify changes in PIAS binding sites through development. This localisation 
data could aid study of the function of PIAS in establishing chromatin domains (e.g. 
at heterochromatin) before PIAS dissipates and binds to euchromatin (as observed 
in tissue culture cell lines).  
 
8.9.1.2 Identifying sites of PIAS binding on RNA   
In light of the data identifying interactions between PIAS and RNA binding proteins 
(Figure 5–11), it would be interesting to investigate whether PIAS associates directly 
with RNA. To identify how PIAS is involved in RNA processing, PIAS cross-linking 
and analysis of cDNAs (CRAC) or RNA immunoprecipitation sequencing (RIPseq) 
could be performed. This would allow identification of the RNA bound component of 
PIAS complexes and identify if there is a consensus sequence on mRNAs where 
PIAS binds. This would allow identification and classification of the RNAs that bind 
PIAS and importantly it would allow a comparison to the RNAs identified by HP1a 
CRAC299 to determine whether there are specific RNAs acting at heterochromatin 
regions of the genome.  
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8.9.1.3 Identifying dynamic changes in PIAS localisation during development 
Antibodies used in immunofluorescence on fixed embryos can be used as a starting 
point to identify the timing of localisation, nucleation sites and how heterochromatin 
domains expand by comparison to HP1a domain formations. However, given the 
current perspective of heterochromatin organisation into domains based on the 
biophysical properties of chromatin factors and associated proteins, only by looking 
in Drosophila embryos during development over a time course can we being to 
understand the functional importance of PIAS proteins in organisation of the 
genome. Phase separation of heterochromatin plays a critical role in nuclear 
organisation through dynamic changes and building local concentrations of 
chromatin factors124. PIAS could be fluorescently tagged in the Drosophila genome 
to allow live-imaging of Drosophila embryos to track and dissect the role of PIAS in 
these processes. CRISPR/Cas9 targeting in S2 cells provided a proof-of-principle 
that PIAS can be tagged at the endogenous Su(var)2-10 locus. Using the same 
targeting strategy to generate a Drosophila line would allow study of PIAS 
localisation using high-resolution light microscopy without overexpression of PIAS. 
 
8.9.2 To understand the role of PIAS complexes 
Investigations of PIAS complexes could be pursued. PIAS elutes from gel filtration 
columns over a wide volume, indicating its involvement in complexes of various 
sizes. IP-MS from these different PIAS fractions could inform on the composition of 
PIAS subcomplexes. 
 
8.9.3 To study PIAS function by knockout/knockdown  
PIAS KO is lethal (Heun lab unpublished). Therefore, transient knockdown studies 
to assay the phenotype of PIAS reduction are required. This would probably require 
a rapid, acute depletion strategy. This is an ongoing effort in the Heun lab.  
 
8.9.4 To study PIAS function in genome organisation 
Hi-C experiments on a PIAS inducible knockout or a PIAS E3 ligase deficient mutant 
would allow investigation of the role of PIAS in chromatin structural organisation to 
aid understanding in the context of chromatin loop formation by PIAS and PIAS 
mediated SUMOylation. This would be helpful towards determining a role for PIAS 
and PIAS’s enzymatic activity in establishing chromatin domains.  
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Domain deletion mapping could be used to assess the importance of PIAS 
functional domains and map sites of interaction with HP1a and ADD1 within PIAS.  
 
8.9.5 To understand the role of SUMOylation of XNP and ADD1 
Deciphering the mechanism of action of XNP-SUMOylation is important for 
understanding SUMO regulation of XNP function. XNP and ADD1 may confer 
Su(var) phenotypes in the ln(1)wm4 PEV assay through their interaction with 
components of the SUMOylation machinery. Mass Spectrometry identification of 
SUMOylation sites on ADD1 and XNP allows future targeting of sites to generate 
ADD1 and XNP SUMOylation mutants. This would be required to address the 
function of the SUMO-mediated ADD1 and XNP interaction at both the protein and 
chromatin levels.  
 
8.9.6 To identify an ADD1-XNP complex 
Study of ADD1, XNP and SMT3 in Drosophila melanogaster has both advantages 
and disadvantages. The main advantage of Drosophila, as opposed to mammalian 
cell culture, is the simpler SUMO machinery and fewer redundancies in proteins and 
mechanisms so multiple knockouts are not required. However, in Drosophila the 
functions of ADD1 and XNP as opposed to the single ATRX must be addressed 
separately. Overall Drosophila allows more precise manipulation but has important 
molecular differences to human cells and it is not clear how far these extend at a 
functional level. Using genome editing, ADD1 and XNP could be fused or 
mammalian ATRX could be expressed in Drosophila to compare the function of 
ADD1 and XNP to ATRX and explore the differences in regulation that may have 
arisen as a result of the gene split.  
 
It is possible that ADD1 and XNP act in distinct but overlapping pathways in 
Drosophila compared to vertebrate ATRX proteins. It would be interesting to explore 
whether ADD1 is responsible for “bookmarking” heterochromatin, possibly through 
mechanisms analogous to de novo DNMTs.   
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8.10 Thesis Summary 
I began with four key aims: 
1. to develop tools for identifying PIAS, ADD1 and XNP interactomes at 
endogenous protein levels 
2. to understand whether the previously identified PIAS interaction with XNP 
occurs under physiological conditions 
3. to characterise the interaction between ADD1 and XNP with PIAS  
4. to identify other PIAS interactors that may have an effect at heterochromatin. 
 
Tools for investigating the PIAS, ADD1 and XNP interactomes at endogenous levels 
were successfully developed, these allowed me to confirm the previously identified 
PIAS-XNP interaction and identify an interaction between PIAS and ADD1. It was 
also found that ADD1 and XNP co-immunoprecipitate only in the presence of NEM, 
suggesting that their interaction is mediated by SUMOylation. Finally the 
interactomes of PIAS, ADD1 and XNP were identified along with a large number of 
novel interactors.  
 
The major findings of this thesis are:  
• XNP interacts with PIAS at endogenous expression levels but only in the 
presence of SUMOylation.  
• ADD1 is SUMOylated and localises to areas of heterochromatinization in the 
early embryo. 
• GO terms analysis indicates large numbers of PIAS interactors involved in 
DNA, RNA binding and transcription. This matches previous data indicating 
SUMOylation is essential to all stages of gene regulation.  
• PIAS is a potential novel regulator of heterochromatin establishment through 
interaction with the developmental/germline specific piRNA pathway.  
• PIAS interacts with Eggless. The mechanism of Eggless targeting to 
heterochromatin is currently unknown. SUMOylation is known to target 
proteins to specific localities and is an exciting potential mechanism for the 
function of Eggless.  
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8.11 General conclusion 
Establishment and maintenance of heterochromatin is vital to cellular function and 
cellular viability. Dysregulation of chromatin factors, such as ATRX, results in 
diseases such as Alpha-Thalassemia X-linked mental retardation syndrome and 
cancers. SUMOylation of heterochromatin-associated proteins has been identified 
as an initiation step in seeding heterochromatin formation, potentially by aiding 
localisation to heterochromatin. In this thesis a number of novel interactors of the 
SUMO E3 ligase PIAS have been identified, including ADD1 and XNP (Human 
ATRX homologs) and other chromatin factors. I suggest that the interactome of 
PIAS indicates that it may be a key factor to control and recruit proteins involved in 
multiple mechanisms of chromatin silencing and remodelling. These mechanisms 
are involved in genome packaging, which regulates gene expression, and is often 
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Appendix 1: Mass Spectrometry Optimisation and Quality Control (QC)  
 
 
Figure 8–3 4-20% SDS-PAGE silver stained gels for PIAS, XNP and ADD1 IP 
IgG and PIAS immunoprecipitations in triplicate from WT S2 cells for mass spectrometry 
carried out in the absence of N-ethylmaleimide (NEM). XNP IP using pre-immune serum or 
XNP bleed serum in the absence and presence of NEM. ADD1 immunoprecipitates in the 
ADD1 ProtA lane but is absent from other lanes. IP samples used for Mass Spectrometry of 
the PIAS, XNP and ADD1-associated complexes. Bands at 50 and 20 kDa correspond to the 
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Figure 8–4 Multi-scatter plot of pairwise comparisons of protein abundance (LFQ) 
detected in each PIAS IP-MS sample from S2 cells 
PIAS (P) or IgG (C) immunoprecipitation from wild-type S2 cell nuclear extracts followed by 
mass spectrometry were performed in the absence (-) or presence (+) of NEM in triplicate. 
Each IP-MS sample is represented along each axis. Each dot represents one protein plotted 
by its log2 transformed label-free quantification (LFQ) value on an axis spanning values of 20 
to 30. Larger boxes in black along the diagonal show groupings of replicates paired against 
each other. Pearson correlation values are shown in the top left-hand corner of each box 





Figure 8–5 Principle Components analysis of PIAS IP-MS samples from S2 cells 
(A and B) showing separation of samples from controls (C) samples with or without NEM 
and (D) samples with or without NEM separating from controls Key: PIAS IPs in NEM 
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Appendix 2: PIAS, ADD1 and XNP Expression Levels and Limits of Detection 
 
Figure 8–6 Protein expression levels of PIAS, XNP and ADD1 
from a quantitative proteomics study of Drosophila embryos at different stages in 
development142 downloaded from FlyBase 04-04-2019. Protein expression levels are in 
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Figure 8–7 Total protein extract from 50 Drosophila embryos  
Western blot probed with antibodies recognising ADD1, XNP, PIAS and tubulin. Embryos 
were prepared by manual puncture and boiling in 2X LB, at the specified time points.  
 
 
Figure 8–8 Detection limit of XNP and ADD1 in lysate from Drosophila embryos 
Nuclear extract from wild-type S2 cells serially diluted and run on 6% SDS-PAGE for 
western blot probed with anti-ADD1 rabbit bleed 3 serum (in red) and anti-ATRX rat serum 








20ug  10ug    5ug     2ug
180KDa
150KDa
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Appendix 3: Generation of Plasmids for ADD1 and XNP Protein Expression  
 
Figure 8–9 ScaI restriction digest of pFastBac-HIS3C-LIC_XNP_RA to confirm plasmid construct 
(A) Plasmid maps of pFastBac-HIS3C-LIC and pFastBac-HIS3C-LIC_XNP_RA marked with restriction sites used in this study. Two Zra1 sites are 
present in pFastBac-HIS3C-LIC which can be used to excise the GFP fragment for use in LIC cloning of other DNA fragments into this region of the 
vector. Two ScaI sites are present in pFastBac-HIS3C-LIC and pFastBac-HIS3C-LIC_XNP_RA. (B) Restriction digest of pFastBac-HIS3C-LIC results in 
two bands on agarose gel electrophoresis: 1519 and 3361 or 4090bp depending on whether the GFP fragments has been excised with zra1 prior to 
digestion with ScaI. Restriction digest of pFastBac-HIS3C-LIC_XNP_RA results in two bands on agarose gel electrophoresis: 1519 and 7303bp. The 
molecular weight size marker is not shown as this is part of a larger screening gel. (C) Sanger Sequencing reads aligned to the DNA sequence of XNP-
RA confirming insertion of XNP-RA sequence into the pFastBac vector.  
 
Figure 8–10 Kpn1 restriction digest of pFL-GST_ADD1-RA_LIC to confirm plasmid construct 
(A) Plasmid maps of pFL-GST and pFL-GST_ADD1-RA_LIC marked with restriction sites used in this study. Two Kpn1 sites are present in pFL-GST 
and three Kpn1 sites are present in pFL-GST_ADD1-RA_LIC. (B) Restriction digest of pFL-GST_ADD1-RA_LIC results in three bands on agarose gel 
electrophoresis: 342, 2360 and 7088bp seen in minipreps 1 and 2. Restriction digest of pFL-GST results in two bands on agarose gel electrophoresis: 
342 and 5854bp seen in the final lane. Half the restriction digest was run on a 2% agarose gel and the other half on a 0.5% agarose gel to visualise the 
resolution of the bands against the molecular weight size marker (Thermo Fisher Scientific™ GeneRuler™ 1kb DNA Ladder). (C) Sanger Sequencing 
reads aligned to the DNA sequence of ADD1-RA confirming insertion of the correct sequence of ADD1-RA sequence into the pFL vector.  
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Appendix 4: Generation of an HA-ADD1 S2 Cell Line 
To provide an alternative approach for isolating ADD1 complexes for validation of 
ADD1 interactors, ADD1 HA-tagged S2 cell lines were generated, screened and 
validated. The HA tag was inserted in ADD1 exon 1 (Figure 8–11A) to tag all three 
isoforms of ADD1. A schematic of the CRISPR/Cas9 strategy used for insertion of 
the tag is shown in Figure 8–11B and the homology directed repair template design 
in Figure 8–11C. 
 
Of the screen of S2 cell clones for insertion of the tag, clone 1 has the HA-tag 
integrated in all four copies of the genome at the N-terminus (Figure 8–11D). Clone 
2 contains at least one tagged allele and 3 contains no tagged alleles. HA-ADD1 S2 
cell clones were also screened for HA expression by detection of the HA epitope 
using HA antibodies able to be detected by immunofluorescence (Figure 8–11E). 
This revealed that clone 2 is a mixed population as only some cells express HA and 
that clone 3, in agreement with the PCR, expresses no HA.  
 
Western blot probed with an anti-HA antibody recognised protein bands of the 
expected size in protein lysate generated from HA-ADD1 cell line 1 that were not 
observed in protein extracts from wild-type S2 cells (Figure 8–11F). Therefore clone 
1 was used for further study. Protein extract from HA-ADD1 cell line 1 was subject 
to immunoprecipitation with anti-HA-resin, but with high background (Figure 8–11G) 
in NEM conditions, shown by probing the bottom half of the membrane with 
Drosophila anti-PIAS sheep antibody, as PIAS should co-immunoprecipitate with 
ADD1 in the HA-ADD1 cell line 1. PIAS should not be observed in the wild-type 
(WT) lane, as this represents non-specific binding to the anti-HA resin as no HA 
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Figure 8–11 Generation of HA-ADD1 S2 cell line 
(A) Schematic of the three ADD1 isoforms, ADD1-RA, ADD1-RB- and ADD1-RE in 
Drosophila S2 cells. Exons are in black. The location of the sgRNA recognition site and tag 
are marked (B) Schematic of CRISPR/Cas9 insertion of an HA tag into the coding sequence 
of first exon of ADD1 (C) Design of the repair construct, 500bp IDT fragment designed for 
cloning to generate the repair template for integration of the HA tag. The length of the 
homology arms are shown. Marked in purple are the sites of primer binding. Restriction sites 
engineered for cloning and the site of sgRNA1 recognition are marked (lines in arrow show 
mutations to recognition sequence). (D) Clones were screened to confirm tag insertion at the 
ADD1 genomic locus by PCR using primers binding within the tagged region 
(HA_cloning_REV) and outside of the repair construct (gextFOR) resulting in a band of 
438bp. If the repair construct didn’t integrate, no DNA was amplified, and no band was 
detected. A second PCR using ADD1_cloningdG_FOR and ADD1_gREV was performed to 
confirm all four alleles of ADD1 were tagged by amplifying across the locus containing the 
insertion, resulting in two bands: without the tag (354bp) and with insertion (495bp). PCR 
products were run on 3% agarose and visualised by SybrSafe stain. (E) 
Immunofluorescence on settled S2 cells using an anti-HA mouse antibody recognising 
integration of the HA tag detected with anti-mouse AF 488. (F) HA-ADD1 cell line 1 S2 cells 
and wild-type (WT) S2 cells analysed by SDS-PAGE followed by western blot probing with 
anti-HA antibody, corresponding to tagged ADD1. Ponceau stain shows equal protein 
loading. (G) Immunoprecipitation of ADD1 from nuclear extracts generated from HA-ADD1 
cell line 1 S2 cells and wild-type (WT) S2 cells analysed by SDS-PAGE followed by western 
blot probing with anti-HA antibody. IP washes were performed in 0.3M NaCl containing IP 
wash buffer. The membrane was cut at the 100kDa marker and the 100kDa to 50kDa region 
was probed with Drosophila anti-PIAS sheep antibody.
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Name QQTGG (K) 
Description SUMO-2/3 Q87R 
Composition H(29) C(18) N(7) O(8) 
Position Not C-term 
Type Standard 
New terminus N-term 
Date last modified 14/10/2010 
Specificities 
[K,DP,b2-QQ,QQ,H(16) C(10) N(4) O(4),DP,b3-QQT,QQT,H(23) C(14) 
N(5) O(6),DP,b4-QQTG,QQTG,H(26) C(16) N(6) O(7),DP,b5-
QQTGG,QQTGG,H(29) C(18) N(7) O(8),DP,b2-QQ-H2O,QQ-H2O,H(14) 
C(10) N(4) O(3),DP,b3-QQT-H2O,QQT-H2O,H(21) C(14) N(5) O(5),DP,b4-
QQTG-H2O,QQTG-H2O,H(24) C(16) N(6) O(6),DP,H(27) C(18) N(7) 




Name Short name Composition Neutral mass M + H+ 
b2-QQ QQ H(16) C(10) N(4) O(4) 256.117155 257.1244315 
b3-QQT QQT H(23) C(14) N(5) O(6) 357.1648335 358.17211 
b4-QQTG QQTG H(26) C(16) N(6) O(7) 414.1862972 415.1935737 
b5-QQTGG QQTGG H(29) C(18) N(7) O(8) 471.2077609 472.2150374 
b2-QQ-H2O QQ-H2O H(14) C(10) N(4) O(3) 238.1065903 239.1138668 
b3-QQT-H2O QQT-H2O H(21) C(14) N(5) O(5) 339.1542688 340.1615453 
b4-QQTG-H2O QQTG-H2O H(24) C(16) N(6) O(6) 396.1757325 397.183009 
H(27) C(18) N(7) O(7) H27 C18 N7 O7 H(27) C(18) N(7) O(7) 453.1971963 454.2044727 
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Appendix 6: Published models influential to building the speculative models 
presented in Chapter 8.   
 
Model 1 Five types of chromatin in Drosophila57 
 
Systematic protein location mapping reveals five principal chromatin types in 
Drosophila cells  
Guillaume J. Filion1,$, Joke G. van Bemmel1,$, Ulrich Braunschweig1,$, Wendy 
Talhout1, Jop Kind1, Lucas D. Ward2,3,4, Wim Brugman5, Ines de Castro Genebra 







Figure S3: Chromatin Types Differ Widely in Their Total Protein Occupancy 
(A) Sample plot of the total occupancy (out of 53 mapped proteins) on a 1 Mb segment of 
chromosome 2L. The height of each vertical line indicates the number of proteins bound to a 
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Model 2 Drosophila chromatin compartment organisation14 
 
Chromatin Architecture in the Fly: Living without CTCF/Cohesin Loop 
Extrusion? Alternating Chromatin States Provide a Basis for Domain 
Architecture in Drosophila 




Figure 1. Domain topologies in mammals and Drosophila. a,b) In mammals many domains 
have a loop topology with the specific interaction of convergent CTCF-binding sites (blue 
arrows). a) Blue triangles indicate domains of enhanced interaction with an interaction 
“hotspot” at the apex and black dotted arrows indicate loop anchor interactions. b) Loop 
domain anchored by the CTCF/cohesin complex (red oval). c,d) In Drosophila, “inactive” 
domains (blue bar) are flanked by “active” domains (yellow bars). Black arrows in (c) indicate 
interaction between active domains, generating a “crown” of enhanced interaction above the 
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Figure 4. A compartments are enriched in insulator-binding proteins and housekeeping 
genes. Expanded view of the subregion from Figure 3a (chrom2L: 10 000 000–10 500 000). 
Red bar indicates the extent of the A compartment probe set visualized by in situ 
hybridization in Figure 6. This figure also illustrates different TAD hierarchies; the large TAD 
on the right, comprising an A compartment region, is further subdivided into minidomains 
(see Section 3.4 and Figure 5), whilst the large TAD on the left shows at least three levels of 
progressively larger domains, encompassing both A and B compartment regions. Hi-C from 
Kc167 cells,[32] A compartments from Kc167 cells,[21] BEAF-32 ChIP from Kc167 cells 
(ModENCODE GSM1535963), housekeeping genes from El-Sharnouby et al.[19] and the 
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Model 3 RNA Polymerase II transcription factories are clustered347-349 
 
Hypotheses of Peter Cook 
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Figure 4: Model for the organization of the chromatin fibre in a HeLa nucleus. DNA is wound 
into a nucleosome, and then a zig-zagging string of nucleosomes is tied to a factory through 
a cluster of transcription factors (diamond) or an active polymerase (oval). Components of 
the factory exchange with the soluble pool, and attachments to the factory are made and 
broken as factors dissociate and transcription terminates. 10-20 loops (only three are shown) 
of 5-200 kbp form a cloud around the transcription factory; long, static, loops are likely to 
become heterochromatic and attached to the lamina. 50-100 clouds then form a 
chromosome territory. Modified, with permission, from Wiley-Liss, Inc., a subsidiary of John 
Wiley & Sons, Inc. (Cook, 2001). 
 
Figure 5: A transcription cycle. A chromatin fiber is tied in loops (only one is shown) to a 
factory. The promoter (small circle) binds to one of the polymerases in the factory, and the 
transcript is generated as the template slides (open arrows) through the polymerase; at 
termination, the template detaches so the cycle can repeat. This model can be extended to 
explain how an inactive gene at the tip of a long heterochromatic loop could be activated (not 
shown). First, a transcription unit near the factory attaches, creating subloops. Then, the 
resulting transcription reels in the loop, “remodeling” and “opening” its chromatin. Now, other 
enhancers and transcription units attach, creating successively smaller loops until the 
inactive gene is brought sufficiently close to the factory to bind. Such transcription cycles can 
be incorporated into dynamic models for the way genomes are organized in prokaryotes and 
eukaryotes and for how chromosomes might pair during meiosis (51,52). 
 
Figure 2: A process driving the spontaneous clustering of multivalent factors (a.k.a., the 
‘bridging-induced attraction’). (A) Overview of one Brownian-dynamics simulation. Red and 
green ‘factors’ (colored spheres) bind reversibly to ‘chromatin’ (a string of beads); red factors 
bind only to pink beads, green factors only to light-green ones (non-binding beads shown as 
black dots). Bound factors spontaneously cluster—red with red and green with green—
despite any specified interactions between proteins or between beads. (B) Explanation. 
Local concentrations create positive-feedback loops driving growth of nascent clusters; 
bound factors and binding beads rarely escape, and additional factors/beads are caught as 
they diffuse by. Red and green clusters are inevitably separate in 3D space because their 
cognate binding sites are separate in 1D sequence space. Cluster growth is limited by 
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Model 4 Models of the fine-scale chromatin folding360 
 
Resolving the 3D landscape of transcription-linked mammalian chromatin 
folding 
Tsung-Han S. Hsieh, Elena Slobodyanyuk,  Anders S. Hansen, 





Fig. 6. (D) Schematics of the new layer of chromatin organization revealed by Micro-C. The 
fine-scale chromatin structures such microTADs, E-P/P-P links, and repressive bundle 
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Model 5 SUMOylation of insulator elements (in Drosophila) in large-scale chromatin 
structure in interphase226 
 




Fig. 2. Insulator activity can be regulated by ubiquitination and sumoylation of insulator 
proteins. (A) Two active insulators coming together at an insulator body. dTopors is present 
at the insulator sites, Rm62/Lip is not present, Su(Hw) is ubiquitinated, Mod(mdg4)2.2 and 
CP190 are not sumoylated and dTopors serves as a bridge to the lamina. (B) Two inactive 
insulators that cannot be part of an insulator body. dTopors is absent and Su(Hw) is not 
ubiquitinated, whereas Mod(mdg4)2.2 and CP190 are sumoylated. Rm62/Lip is present and 
bound to RNA. Under these conditions, the two insulator sites cannot interact and form 
insulator bodies. Absence of dTopors also precludes interactions with the lamina. 
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Model 6 “SUMO spray” 225 
 
Stefan Jentsch model 
 
 
Graphical abstract: Protein modification by SUMO affects a wide range of protein substrates. 
Surprisingly, although SUMO pathway mutants display strong phenotypes, the function of 
individual SUMO modifications is often enigmatic, and SUMOylation-defective mutants 
commonly lack notable phenotypes. Here, we use DNA double-strand break repair as an 
example and show that DNA damage triggers a SUMOylation wave, leading to simultaneous 
multisite modifications of several repair proteins of the same pathway. Catalyzed by a DNA-
bound SUMO ligase and triggered by single-stranded DNA, SUMOylation stabilizes physical 
interactions between the proteins. Notably, only wholesale elimination of SUMOylation of 
several repair proteins significantly affects the homologous recombination pathway by 
considerably slowing down DNA repair. Thus, SUMO acts synergistically on several 
proteins, and individual modifications only add up to efficient repair. We propose that 
SUMOylation may thus often target a protein group rather than individual proteins, whereas 
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Model 7 SUMOylation of a protein that contains a SAP domain regulating 
transcription and pre-mRNA splicing361: 
 
Jeffrey Parvin paper 
 
Early steps of gene expression are a composite of promoter recognition, promoter 
activation, RNA synthesis and RNA processing, and it is known that SUMOylation, a 
post-translational modification, is involved in transcription regulation. We previously 
found that SUMO-1 marks chromatin at the proximal promoter regions of some of 
the most active housekeeping genes during interphase in human cells, but the 
SUMOylated targets on the chromatin remained unclear. In this study, we found that 
SUMO-1 marks the promoters of ribosomal protein genes via modification of 
the Scaffold Associated Factor B (SAFB) protein, and the SUMOylated SAFB 
stimulated both the binding of RNA polymerase to promoters and pre-mRNA 
splicing. Depletion of SAFB decreased RNA polymerase II binding to promoters 
and nuclear processing of the mRNA, though mRNA stability was not affected. This 
study reveals an unexpected role of SUMO-1 and SAFB in the stimulatory coupling 
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Model 8: SUMO: The Glue that Binds350  






Covalent SUMO Modification and Noncovalent Interactions with SUMO through 
SUMO-Binding Motifs Mediate the Assembly of PML-NBs and the Dynamic 
Distribution of Proteins between PML-NBs and the Nucleoplasm 
(A) PML forms a homodimer, with each subunit containing multiple SUMO 
modification sites (green lines) and a single SUMO-binding motif (notch). 
Intermolecular interactions, mediated by SUMO and SUMO-binding motifs, nucleate 
the formation of a PML network that is able to recruit an assortment of other SUMO-
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Appendix 6: Materials  
 
Stock solutions  
All water except where stated was Milli-Q (MQ). All stock solutions were autoclaved or filter 
sterilized where appropriate. 
 
Ammonium bicarbonate (ABC): 50mM in water 
 
Acetonitrile (ACN) 50mM in water 
 
Ammonium persulphate (APS) prepared as 10% w/v solution in water, stored at 4ºC for 2 
weeks or at -20ºC longer term 
 
Antibiotics- 1000x solutions were prepared by dissolving the antibiotics listed in Table 17 in 
water. Aliquots were stored at -20ºC, with a working stock kept at 4ºC for a maximum of 2 
weeks. 
 
Table 17 Antibiotic stocks 
Antibiotic Powdered stock  Stock solution 
Kanamycin kanamycin monosulphate 50 mg/ml 
Tetracycline tetracycline hydrochloride 10 mg/ml 
Ampicillin  ampicillin sodium salt 100 mg/ml 
Carbenacillin carbenicillin disodium  100 mg/ml 
Gentamycin gentamicin sulfate 10 µg/ml 
 
Blasticidin (for S2 cell culture) 500mg/mL solution in water 
 
Hygromycin B (for S2 cell culture) 100mg/mL solution in water  
 
CHCA MALDI matrix saturated solution of 10mg a-cyano-4-hydroxycinnamic acid (CHCA), 
400μL nuclease-free water, 100μL 1% (v/v) TFA and 500μL acetonitrile 
 
Coomassie Coomassie brilliant blue 0.1% (w/v) in 50% (v/v) methanol, 10% (v/v) acetic acid 
in water. 
 
Copper Sulfate (CuSO4):  2mM solution in water 
Appendices 
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dNTPs 100mM dATP, dCTP, dGTP and dTTP (Fermentas) were mixed in equal ratios to 
obtain a 25mM stock of all four amino acids. 
 
DAPI solution 4’,6-diaminidino-2-phenylindole dissolved to a final concentration of 5µg/mL 
in 0.1% Triton X-100/PBS 
 
Dithiothreitol (DTT) dissolved to final concentration 1.0M in water and stored in aliquots at -
20°C 
 
DNA loading buffer 5x TBE, 30% glycerol, 0.2% bromophenol blue in nuclease-free water 
(Ambicon) 
 
DNA molecular weight marker Generuler 1 kb (Thermo Fisher Scientific) or 100 bp ladder 
(NEB) was dissolved at 500μg/mL in 1x DNA Loading Buffer.  
500ng – 1μg was normally loaded per lane.  
 
EDTA dissolved at 0.5M in water and adjusted to pH8.0 with NaOH 
 
EGTA dissolved at 0.1M in water and adjusted to pH8.0 with NaOH 
 
Glycerol 50% solution in water  
 
HEPES solution 4-(2-hydroxyethyl)-1-piperazine-1- ethanesulfonic acid dissolved to final 
concentration 1.0M in water and pH adjusted to 8.0 with NaOH  
 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) dissolved to final concentration 1.0M in 
water and stored in aliquots at -20ºC 
 
Iodoacetamide (IAA) 50mM stock, 50mM ABC in water 
 
Lithium chloride (LiCl) 10M solution in water 
 
Magnesium sulfate (MgSO4) 1M stock in water 
 
Nuclease-free water (Ambicon) 
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Poly-Lysine 10% solution in water 
 
Ponceau 0.1% w/w Ponceau S dye, 1% v/v acetic acid in water  
 
Restriction enzymes and associated buffers were purchased from NEB 
 
SDS 10% and 20% w/v stocks prepared in water 
 
Sodium acetate (NaOAc) 0.6% (v/v) glacial acetic acid in 0.2M sodium acetate trihydrate in 
nuclease-free water, pH to 5.0 with 10N NaOH 
 
Sodium chloride 5M stock in water  
 
Trifluroacetic acid (TFA) 0.1% in water 
 
Tris-buffers 2-amino-2(hydroxymethyl)-1,3-propanediol 1.0M solutions in water, pH 
adjusted with HCl or NaOH to make stocks at pH 6.0, 7.5 and 8.0  
 
Triton X-100 10% solution in water 
 
X-gal 5-bromo-4-chloro-3-indolyl b-D-galactopyranoside dissolved to a final concentration of 
20mg/mL in dimethyl sulfoxide (DMSO) and stored in small aliquots at -20ºC (light sensitive, 




Cell lysis buffer 20mM Tris–HCl pH7.5, 20mM NaCl, 2mM MgCl2, 1mM DTT, 1x Roche 
cOmpleteTM EDTA- free Protease Inhibitors (Roche, 5056489001) supplemented with 20mM 
NEM where appropriate 
 
Benzonase buffer 20mM Tris–HCl pH7.5, 20mM NaCl, 2mM MgCl2, 1mM DTT, 1x Roche 
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Chromatin extraction buffer 20mM Tris–HCl pH7.5, 0.35M NaCl, 2mM MgCl2, 1mM DTT, 
1x Roche cOmpleteTM EDTA- free Protease Inhibitors (Roche, 5056489001), 0.1% Triton X-
100 
 
Blocking buffer PBS, Tween20 0.1%, 3% Bovine Serum Albumine (BSA) 
 
Enhancer Solution 11mg Coumaric Acid in 10mL Dimethyl sulfoxide (DMSO) 
 
Embryo extraction buffer 20mM Tris–HCl pH7.5, 20mM NaCl, 2mM MgCl2, 1mM DTT, 1x 
Roche cOmpleteTM EDTA- free Protease Inhibitors (Roche, 5056489001), 0.1% Triton X-100 
 
Embryo wash buffer 0.7% (w/v) NaCl, 0.05% (v/v) Triton X-100 
 
Genomic lysis buffer 150 mM NaCl, 10mM EDTA pH 8.0, 0.5% SDS 
 
GST purification buffer 20mM Tris–HCl pH7.5, 300mM NaCl, 2mM MgCl2, 1mM DTT 
 
GST purification buffer with glutathione 20mM Tris –HCl pH7.5, 300mM NaCl, 2mM 
MgCl2, 1mM DTT, 20mM glutathione (added just before use) and adjusted to pH 8.0 with 
NaOH 
 
High-salt buffer 20mM Tris–HCl pH7.5, 0.5M NaCl, 2mM MgCl2, 1mM DTT, 1x Roche 
cOmpleteTM EDTA- free Protease Inhibitors (Roche, 5056489001), 0.1% Triton X-100 
 
HIS purification buffer (low imidazole) 20mM Tris–HCl pH8.0, 300mM NaCl, 2mM MgCl2, 
0.5mM B-mercaptoethanol, 10mM imidazole. (Note, B-mercaptoethanol was replaced with 
TCEP 1mM for final XNP purification). 
 
HIS purification buffer (high imidazole) 20mM Tris pH8, 300mM NaCl, 2mM MgCl2, 
0.5mM β-Mercaptoethanol, 300mM imidazole (Note, B-mercaptoethanol was replaced with 
TCEP 1mM for final XNP purification). 
 
HIS Wash Buffer 20mM Tris-HCl pH8, 300mM NaCl, 2mM MgCl2, 0.5mM β-
Mercaptoethanol, 30mM Imidazole (Note, B-mercaptoethanol was replaced with TCEP 1mM 
for final XNP purification). 
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Luminol Solution 60mg Luminol, 240mL 0.1M Tris-HCl pH 8.8, 74.4μL 30% H2O2  
 
IF fixative 3.7% formaldehyde solution (Sigma) in 0.1% Triton X-100/PBS 
 
IP buffer 20mM Tris–HCl pH7.5, 0.1M NaCl, 2mM MgCl2, 1mM DTT, 1x Roche cOmpleteTM 
EDTA- free Protease Inhibitors (Roche, 5056489001), 0.1% Triton X-100 
 
IP wash buffer 20mM Tris–HCl pH7.5, 0.1, 0.3 or 0.5M NaCl, 2mM MgCl2, 0.1% Triton X-
100 
 
Phosphate buffered saline (PBS) (prepared by the media kitchen) 137mM NaCl, 2.7mM 
KCl, 2mM KH2PO4, 10mM Na2HPO4 · 2H2O, pH 7.4  
 
PBS-Tween20 0.1% 1X PBS with 0.1% v/v Tween-20 
 
PBS-Triton 0.1% 1xPBS, 0.1% Triton X-100  
 
PBTA 1% (w/v) bovine serum albumin, 0.02% (w/v) sodium azide, 0.05% (v/v) Triton X-100 
in PBS 
 
RIPA buffer 10mM Tris-HCl pH8, 1mM EDTA, 1% Triton, 0.1% sodium deoxycholate, 0.1% 
SDS, 140mM NaCl, 1x Roche cOmpleteTM EDTA- free Protease Inhibitors (Roche, 
5056489001) 
 
TFB1 30mM KAc,100mM RbCl, 10mM CaCl2*2H2O, 50mM MnCl2*4H2O, 15% glycerol, 
(adjusted to pH 5.8 with acetic acid) 
 
TFB2 10mM MOPS, 10mM RbCl, 10mM CaCl2*2H2O, 15% glycerol, (adjusted to pH 6.5 with 
KOH) 
 
Tris-acetate EDTA 1x (TAE) 40mM Tris, 20mM acetic acid, 1mM EDTA, pH 8.0  
 
Tris-borate-EDTA 1x (TBE) 0.1M Tris base, 0.1M boric acid, 2mM EDTA (disodium salt)  
 
Tris-EDTA 1x (TE) 10mM Tris-HCl, 1mM EDTA pH 8.0  
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Trypsin buffer 13ng/μL trypsin (PierceTM Tryspin Protease, MS grade Thermo Fisher 
Scientific), 10mM ABC, 10% ACN 
 
Tris-glycine running buffer 25mM Tris, 250mM glycine, 0.1% SDS  
 
SDS-PAGE transfer buffer 25mM Tris, 192mM glycine, supplemented with 20% methanol 
before use and used cold 
 
6x LB 60mM Tris pH 6.8, 0.6M DTT, 12% (w/v) SDS, 0.06% (w/v) bromophenol blue, 47% 
(v/v) glycerol 
 
2x SDS sample buffer 125 mM Tris-HCl (pH 6.8), 4% (w/v) SDS, 20% (v/v) glycerol, 300 
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Media  
All solutions were prepared by the media kitchen. 
 
Grape juice medium: 50g agar to 1L water and 0.6L grape juice.  
 
Fly food: standard yeast-cornmeal agar medium (Ashburner, 1989362)  
(5g sugar, 60g maize meal, 20g dried yeast, 10g agar and 2.5g Nipagin to IL water). 
 
Luria-Bertani (LB) broth: 10% NaCl, 10% bactotrytone and 5% yeast, sterilised by 
autoclaving and stored at RT 
 
LB-agar: LB supplemented with 1.5% (w/v) agar. For plasmid selection on plates, antibiotics 
were added as required at concentrations listed in Table 17. 
 
SOC 0.5% yeast extract, 2% tryptone, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM 




Bacterial strains  
Stocks of bacterial strains used in this study were made and stored at -80ºC. 
 
10beta was used for routine cloning and propagation of all plasmids 
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Antisera, antibodies, probes and beads 
All primary antibodies used in this study are listed in Table 18 and secondary antibodies in 
Table 19.  
 
Table 18 Primary antibodies used in this study. 
WB- Western blot, IF- immunofluorescence, IP- immunoprecipitation. For IPs use at 3μg 
antibody/30μL Dynabeads™/200μg nuclear extract. 
 
Antibody species Source, catalogue number, 
stock concentration 
Application (dilution) 
dPIAS sheep Ron Hay, Dundee, stock at 
1.2mg/ml, polyclonal 




sheep Bethyl, 1 mg/ml IP 
dSmt3 
(SUMO) 
rabbit Norbert Joswig, polyclonal WB (1:5000), IF (1:1000)  
Ubiquitin mouse P4D1, CST, 3936 monoclonal WB (1:1000) 
ATRX rat Andreas Thomae monoclonal, 
clone 2E10 
WB (1:1000) 
XNP rabbit  ERF (this study), not quantified 
as not affinity purified  
IF (1:500), WB (1:1000), 
IP (30μL serum) 
ADD1 rabbit  ERF (this study) not quantified 
as not affinity purified 
IF (1:1000) WB (1:5000), 
IP (9μL serum) 
BEAF-32 mouse  Developmental Studies 
Hybridoma Bank at the 
University of Iowa (C1A9) 
43ug/ml 
WB (1:500) IP (1:40) 
H3 rabbit - WB (1:1000) 
Cenp-C rabbit Lenhner lab, polyclonal, 
Stephan Heidmann  
WB (1:1000) 
GST rabbit  Sigma WB 1:5000 
Penta HIS mouse Qiagen 34660 WB 1:5000 
FLAG  rabbit Clone D6W58 WB (1:1000) 
FLAG mouse M2 clone  WB (1:1000) 
V5 mouse Invitrogen, R96025  IF (1:100) 
WB (1:1000) 
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HA mouse Clone 12CA5, Simona Saccani 









Table 19 Secondary antibodies used in this study. 
HRP – horseradish peroxidase, WB – Western blot, IF – immunofluorescence.  
 
Antibody species Source, catalogue number, 
stock concentration 
Application (dilution) 
Donkey anti sheep 
HRP 
 - WB (1:10000) 
Mouse IgG HRP 
Linked Whole Ab 
 GE Healthcare, NA931-1ML WB (1:10000) 
Rabbit IgG HRP 
Linked Whole Ab 
 Sigma, GENA934-1ML WB (1:10000) 
Rat IgG, HRP-linked 
whole antibody  
 Sigma, GENA935  
Anti-rabbit 680RD Rabbit  LICOR  WB (1:20000) 
Anti-mouse FW800 mouse LICOR WB (1:20000) 
Anti-rat FW800 rat LICOR WB (1:20000) 
Anti-goat 680RD goat LICOR WB (1:20000) 
Alexa 488 F(ab) 
fragment goat anti-
mouse 
mouse Invitrogen IF (1:100) 
Alexa 488 goat anti-
rabbit 
rabbit Invitrogen IF (1:100) 
Alexa 555 donkey anti-
sheep 
sheep Invitrogen IF (1:100) 
Alexa 647 F(ab) 
fragment goat anti-
mouse 
mouse Invitrogen, A21237 IF (1:100) 
 
His Probe HRP (Pierce 15165, 25 mg/ml, BSA TBS-T, 1:5000)  
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Spodoptera frugiperda 9 (Sf9) cells in Sf-900™ II SFM, Catalog number:  11496015, Thermo 
Fisher Scientific (purchased April 2018) 
 
Drosophila Schneider Line 2 derived L2–4 cell line (S2) 
S2 ADD1HA generated in this study 
S2 ADD1HA PIAS-C-V5 generated in this study 
S2 PIAS-N-V5 generated in this study 
S2 PIAS-C-V5 generated in this study 
 
Plasmids used during this study  
pMT_ATRX_FLAG (Heun lab) 
pMT_Pias9_V5 (Heun lab) 
pBlue (Heun lab) 
pAc5.1-ADX-a-V5 (from Viviana Valadez-Graham296) 
pIB_Cas9_CD4_Blast 
pFL (Cook lab) 
pFastBac (Cook lab) 
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Oligonucleotides 
All primers and gene blocks were synthesized by Integrated DNA Technologies (IDT). Lyophilized Primers were resuspended in 1xTE to a concentration of 
50μM and stored at -20°C as a stock solution. A 1:100 dilution was prepared as a working stock in double-distilled H2O (ddH2O).  
 
Table 20 List of primers 
Purpose Primer Name Primer sequence Tm Date  
To check insertion into the pFL 







Cook lab stock 
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To confirm insertion of a tag at 









To confirm insertion of a tag at 









To confirm insertion of a tag at 

















For amplification of sgRNAs 
from gene blocks containing a 
dU.6 promoter for use in 






55.0 Heun lab stock  
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